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 The xiamycin family of indolosesquiterpenes comprises bioactive 
compounds isolated from several strains of Streptomyces. Several dimeric 
family members have shown strong activity against several strains of 
bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and 
vancomycin-resistant Enterococcus (VRE). These promising initial results, 
coupled with the limited production of these compounds from their natural 
sources, prompted the design of a unified synthetic strategy capable of 
producing several family members from a common synthetic intermediate.  
 Structurally, the xiamycin family members consist of a carbazole 
fused to a trans-decalin ring system. The difference between xiamycin A 
and oridamycin A is a single epimeric stereocenter at C16. It was envisioned 
that a key oxidative radical cyclization could produce both stereochemical 
patterns—with free-radical conditions generating the stereochemistry 
associated with oridamycin A, and chelated radical conditions producing 
the stereochemistry corresponding to xiamycin A.  
 The total synthesis of oridamycins A and B was completed, utilizing a 
free-radical cyclization that correctly set three contiguous stereocenters, 
including two quaternary carbons. The fused carbazole was produced using 
a 6π-electrocyclization/aromatization sequence. Finally, oridamycin B was 
accessed through a palladium-catalyzed, oxime-directed C-H oxidation. 
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Chapter 1. History and Development of Antibiotics 
 
Preface 
 The purpose of this chapter is to outline the events that have informed 
the modern antibiotic drug discovery process, highlighting key insights 
gathered from decades of research. An important theme is that targeting 
bacteria is different than targeting mammalian cells, and effective practices 
for drug development in human disease may not be applicable to infectious 
diseases. Another important message is that simple structural modifications 
of drug molecules can have a profound impact on activity, highlighting the 
role of synthetic organic chemistry in the development of antibiotic medicines. 
  
A. The Foundation of the Antibiotic Era 
There is evidence that humans have been ingesting antibacterial 
compounds for thousands of years, but the modern conception of 
antibiotics has only arisen within the last century.1 Tetracycline (1) has been 
found in skeletal remains dated between 350–550 CE, a discovery explicable 
only if these individuals had ingested tetracycline-containing materials 
(Figure 1.1.a).2 There is speculation, however, that beer was the source, 
casting doubt onto whether the tetracycline was explicitly used to treat 
disease.3 Further evidence of antibiotic use comes from red soils in Jordan, 
which have been traditionally used to treat skin infections. The antibacterial 
cyclic peptides actinomycin C2 (2) and C3 have since been extracted from 
strains of Streptomyces dwelling in these soils, implying that antibiotics 
were intentionally and effectively used in traditional medicines.4  
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In spite of early efforts, treatments for systemic bacterial infections 
were lacking throughout human history. One of the most striking examples 
is the outbreak of the ‘Black Death’ between 1347 and 1351. The infection is 
caused by Yersinia pestis, a Gram-negative bacterium commonly found in 
ground rodents. The outbreak in the 14th century killed between 30-50% of 
the population of Europe in only five years—claiming the lives of over 30 
million people.5 In contrast, between 2010 and 2015 there were 3248 cases 
reported worldwide, 584 of which proved fatal—a dramatic difference of 
over two orders of magnitude between the 14th century and the present.6  
While sanitation has significantly contributed to the disappearance of the 
Black Death, the introduction of modern antibiotic treatments has also 
played a crucial role. Clearly, medicine has advanced significantly in the 
intervening centuries, having nearly eradicated a disease that once wreaked 
havoc on humanity.  
The modern drug discovery process has been a key component in the 
battle against premature human mortality, with its origins in the late 19th 
Figure 1.1.a Molecules implicated in ancient medicine: 1, tetracycline has 
been found in ancient skeletons, possibly coming from ancient beer, and 
2, actinomycin C2 (peptide portions in blue) has been found in traditional 
medicines in Jordan. b Gentian violet (3) is the dye used for Gram 
staining, and inspired Paul Ehrlich to hypothesize the existence of 
chemoreceptors due to its selective action. 
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century. One of the early pioneers was Paul Ehrlich, a German physician 
and scientist. While Paul Ehrlich was a medical student in the early 1870s, 
he observed the selective affinity of dyes for biological tissue, leading him 
to postulate the existence of chemoreceptors on the cells that were 
selectively interacting with the dye molecules.7 Several years later, in 1884, 
Hans Christian Gram discovered that certain bacteria could be selectively 
stained with a dye (gentian violet [3], Figure 1.1.b) in the presence of human 
cells and other types of organisms.8 Using this observation, he invented a 
method to differentiate different types of bacteria, originating the terms 
Gram-positive and Gram-negative bacteria. Ehrlich’s chemoreceptor 
concept coupled with Gram’s dying method led Ehrlich to formulate the 
‘magic bullet’ hypothesis, in which he argued that chemoreceptors on 
microorganisms, parasites, and cancer cells would be suitably differentiated 
from similar structures in host tissues to allow for the selective targeting of 
the infectious agent with a drug molecule. The first modern 
chemotherapeutic agent, Salvarsan (5/6/7, Figure 1.2), arose as a proof of 
this hypothesis.1 In 1904, Paul Ehrlich began a systematic screening program 
to uncover an improved treatment for syphilis. He synthesized hundreds of 
Figure 1.2 Atoxyl (4) was a highly toxic veterinary medicine that inspired 
the early syphilis medication Salvarsan. The originally proposed 
structure of Salvarsan is shown (5), and the 2005 revised structures are 
also depicted (6 & 7). 
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organoarsenic derivatives of the toxic drug Atoxyl (4), eventually 
discovering Salvarsan (5/6/7) in 19099—replaced by the less toxic and more 
soluble Neosalvarsan in 1912.10 Salvarsan and Neosalvarsan were highly 
successful, becoming the most frequently prescribed drugs until they were 
superseded by penicillin in the 1940s.1 Surprisingly, the mechanism of action 
remains a mystery, and the controversy over its structure was only recently 
solved.11 The discovery of Salvarsan gave rise to the modern era of medicinal 
chemistry. Ehrlich’s ‘magic bullet’ concept has survived to this day, as most 
current drugs are effective because they selectively target a specific protein 
while leaving the rest of the proteome largely untouched. The modern drug 
discovery process is also structured in a manner similar to Ehrlich’s 
discovery process in which a lead compound (Atoxyl) displaying desired 
activity is derivatized and systematically screened to produce a safer, more 
effective compound (Salvarsan/Neosalvarsan).  
The systematic screening approach was subsequently applied at 
Bayer in their search for novel antibiotics. Inspired by the selectivity of dyes 
for specific cell types, they began screening azobenzene derivatives for 
activity against infectious agents.12 This screening process eventually 
yielded Prontosil (8), the first of the synthetic sulfa drugs (Figure 1.3). 
Prontosil turned out to be a prodrug for sulfanilamide (9), which had 
Figure 1.3 Early medicines: Prontosil (8) was the first sulfa drug, 
developed by screening azobenzene derived dyes. It was subsequently 
found that prontosil was a prodrug for sulfanilamide (9), the active 
species. Penicillin (10) was the first natural product derived antibiotic. 
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previously been described in the dye industry, and thus was not patentable.1 
Many companies began to mass produce sulfonamide derivatives, leading 
to the rapid development of a new class of antibiotics. In 1937, due to 
exuberance about the sulfa drugs and inconsistent quality control, over 100 
people were poisoned from a poorly formulated drug known as Elixir 
Sulfanilamide.13 This disaster prompted the passage of the 1938 Federal 
Food, Drug, and Cosmetic Act, which ultimately put the Food and Drug 
Administration (FDA) in charge of regulating drug safety in the United 
States.  
The next advance in antibiotics stemmed from the serendipitous 
discovery of penicillin (10) by Alexander Fleming on September 3, 1928 
(Figure 1.3).1 Upon returning from vacation, Fleming noticed a mold colony 
contaminating one of his Petri dishes that had created a 
Staphylococcus-free zone forming a halo encircling the mold colony.14 He 
subsequently developed conditions to produce the antibacterial substance, 
demonstrated its nontoxicity towards animals, and showed its selective 
action against various bacterial strains.14 However, isolation of the pure 
compound eluded him, and he spent the next 12 years unsuccessfully 
attempting to convince chemists to resolve the problems with purification 
and stability.1 Eventually, Florey and Chain disclosed a method for the 
purification of penicillin in 1940, leading to mass production and 
distribution in 1945.15 While several analgesics and antimalarials had 
previously been isolated from plants—salicylic acid, morphine, quinine, 
etc16—penicillin was the first natural product developed as an antibacterial, 
and quickly became the most successful due to its potency and safety.17 It 
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also become the first drug to be produced through fermentation on large 
scale, a practice that continues in modern medicine. 
The early search for antibiotic compounds has had a profound impact 
on the modern drug discovery process. Ehrlich’s ‘magic bullet’ hypothesis 
has survived to this day, and his strategy of systematic screening and 
derivatization is common practice in drug discovery campaigns. Another 
important finding from this era was the discovery that sulfanilamide 
inhibited carboanhydrase.18 Derivatives of sulfanilamide were prepared with 
improved activity against carboanhydrase, leading to highly effective 
diuretics.7 This work revealed that enzymes are excellent drug targets, 
further informing the drug discovery process, and strongly influencing 
future efforts.  
 
B. Humans vs. Microorganisms 
Following the introduction of penicillin in the 1940s, the 
pharmaceutical industry entered the ‘golden age’ of antibiotics, extending 
from the 1940s to the 1970s.19 In these highly productive years, a number of 
novel antibiotics were introduced, improving efficacy and safety. 
Unfortunately, bacteria rapidly began to develop resistance to antibiotics, 
one after another, usually within a few years following widespread use.  The 
continual battle between humans and bacteria, and the role that organic 
synthesis has played, is exemplified through two case studies: 1) the 
β-lactams, and 2) the tetracyclines. In both classes of compounds, bacteria 
have rapidly developed resistance, which has been countered by elucidation 
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of the resistance mechanism followed by structural modifications to the 
drug molecule.  
 To understand bacterial resistance, it is necessary to understand the 
targets of antibiotic compounds, as well as certain key elements of bacterial 
cell structure. As previously mentioned, there are two main classes of 
bacteria: 1) Gram-positive, those that can be stained with gentian violet dye, 
and 2) Gram-negative, those that cannot. Both types of bacteria employ 
protective outer coatings, differing in their composition and organization 
(Figure 1.4.a). Gram-positive bacteria utilize a cell wall composed of a thick 
layer of peptidoglycan, a cross-linked polymer consisting of two alternating 
monosaccharides (N-acetylglucosamine [GlcNAc] and N-acetylmuramic 
acid [MurNAc] with a β-1,4 glycosidic linkage) linked to a short polypeptide  
(4 or 5 amino acids).20-21 In Gram-positive bacteria, the peptidoglycan layer 
protects a single cytoplasmic membrane, and interacts with gentian violet 
dye to produce a positive result in the Gram test.22 In contrast, 
Figure 1.4.a The structural differences between the cell walls of Gram-
positive and Gram-negative bacteria. b The structural similarities 
between the substrate (11) of the transpeptidase enzyme (Enz, also 
known as penicillin binding protein [PBP]) and the structure of penicillin 
(10). 
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Gram-negative bacteria have both inner and outer cytoplasmic membranes 
surrounding a thin layer of peptidoglycan and a periplasmic space. The 
outer cytoplasmic membrane of Gram-negative bacteria prevents gentian 
dye from interacting with the underlying peptidoglycan layer, producing a 
negative result in the Gram test. Both types of bacteria utilize active and 
passive methods (namely, porins) of transportation to migrate molecules 
across their membranes/walls, and both types of transportation are used 
during uptake of antibiotic drugs. In addition, both types of bacteria contain 
membrane-spanning efflux pumps that expunge toxins, defensive surface 
enzymes (including β-lactamases), and complex carbohydrate networks 
that create a protective capsule.23 These numerous defense mechanisms 
pose a considerable challenge when designing antibacterial drugs, 
especially for Gram-negative bacteria, which contain an additional 
membrane relative to their Gram-positive relatives with nearly orthogonal 
permeability properties.24 
 One of the main targets of antibacterial compounds is the cell wall 
biosynthesis pathway. It was first proposed that penicillin was an inhibitor 
of bacterial cell wall biosynthesis in 1956, based on the observation that 
bacteria lost their cell wall upon treatment with penicillin.25-26 Tipper and 
Strominger subsequently proposed that penicillin (10) inhibited a 
transpeptidase (also known as a penicillin-binding protein, or PBP) involved 
in the tail-to-tail crosslinking of peptidoglycan subunits by mimicking the 
acyl-D-Ala-D-Ala motif (11) found in the natural substrate (Figure 1.4.b).27-29 
Further experimentation suggested that the highly strained β-lactam ring 
was opened by the enzyme, forming an irreversible covalent linkage, and 
destroying the catalytic activity.  
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Microorganisms have been battling each other for millennia, and 
β-lactams, such as penicillin, have played an important role. 
Correspondingly, many bacteria developed resistance to β-lactams a billion 
years prior to their use by humans.28 There are four main forms of 
resistance: 1) through the production of β-lactamase enzymes, proteins that 
are capable of hydrolyzing the β-lactam ring, rendering the compound 
inactive, 2) mutation of residues in the active site of the target 
transpeptidase to reduce the affinity of drug molecules (a notable example 
is PBP2a of methicillin resistant Staphylococcus spp.), 3) decreased 
expression of certain transport proteins, preventing entry of the 
antibiotic—especially prevalent among Gram-negative bacteria that are 
able to modulate the expression of passive porin proteins that span the 
outer membrane, and 4) efflux pumps, proteins that span the membrane(s) 
and eject undesired compounds from the interior of the cell.30 In general, 
Gram-negative bacteria are more difficult targets due to decreased 
permeability, and generally higher expression of efflux pumps.30  
To overcome the myriad resistance mechanisms, medicinal chemists 
have modified the structure of antibiotic compounds using the tools of 
organic synthesis. Many antibiotic scaffolds have undergone successive 
structural modifications to overcome resistance, but the cephalosporins 
have undergone one of the most striking transformations.31 The precursor 
to many cephalosporin derivatives is 7-aminocephalosporanic acid (7-ACA, 
13), a semisynthetic compound derived from the natural product 
cephalosporin C (12, Scheme 1.1). Early experiments revealed that acidic 
hydrolysis of cephalosporin C could produce 7-ACA in low yield, but an 
improved procedure from chemists at Eli Lilly produced 7-ACA at a 
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commercial level.31 The two readily modifiable sites on 7-ACA are the C7 
amine and the C3’ oxygen. Modification of these positions produced the 
first generation of cephalosporins, as exemplified by cephalothin (15, Figure 
1.5).32 The second generation of cephalosporins (16, for example) was 
engineered to have increased activity against Gram-negative bacteria due 
to increased cell penetration and reduced binding to β-lactamase 
enzymes.33 The α-methoxyimino substituent in cefuroxime (16) was 
instrumental in sterically shielding the molecule from β-lactamases, 
highlighting the impact a simple chemical modification can have on activity. 
Scheme 1.1 Semisynthetic efforts towards 7-aminocephalosporanic acid 
(7-ACA, 13), a common precursor to cephalosporin antibiotics. 
Figure 1.5 Five generations of cephalosporin antibiotics. 
11 
 
Further refinements produced third generation molecules (17), which 
contained an aminothioazole and several charged moieties, including a 
carboxylate on the oxime, as well as a pyridinium. The charged functionality 
allowed for enhanced penetration through porins, increasing activity 
against Gram-negative bacteria.34 Unsurprisingly, resistance emerged to 
third generation cephalosporins, as well. Several β-lactamases arose that 
were able to break down these molecules, prompting the development of 
fourth generation molecules (18), further improving activity against both 
Gram-positive and Gram-negative bacterial strains.35  
Structural modifications to the cephalosporins transformed an 
antibiotic active against Gram-positive bacteria into a broad-spectrum 
medicine. The inverse has also been achieved with the quinolone family of 
antibiotics. Early quinolones were active against Gram-negative bacteria, 
and were subsequently engineered to have activity against Gram-positive 
organisms, as well.31 The successive chemical modification of the 
cephalosporins and the quinolones demonstrates that a lead compound 
active against only one type of bacteria may be engineered into a 
broad-spectrum agent, broadening the pool of potential lead compounds 
for the development of novel antibiotics. 
The tetracyclines have undergone a similar evolution to produce 
antibiotics with increased activity and efficacy. One of the first 
modifications to the tetracyclines was the reductive removal of the C6 
hydroxyl group of 6-demethyltetracycline (20) to produce sancycline (21), 
improving access to further derivatives by increasing acid and base 
tolerance (Scheme 1.2).36-38 The increased stability enabled nitration of the 
D ring, leading to the synthesis of minocycline (23) after reduction and 
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methylation. Minocycline has a broader spectrum of activity than previous 
tetracyclines, including activity against resistant strains.39-40 Further 
improvements were made in the late 1990s by Wyeth scientists attempting 
to overcome tetracycline resistance. Modification of minocycline at C9 
produced tigecycline (24), which succeeded in improving activity toward 
tetracycline-resistant bacteria by increasing the strength of the binding 
interaction with its target (the small subunit of the bacterial ribosome),41-43 
and by decreasing binding to a common tetracycline efflux pump.44 Simple 
structural modifications at C6, C7, and C9 have significantly altered the 
properties of the tetracyclines, providing safer and more effective drugs. 
Inspired by this, the Myers group set out to develop a scalable, diversifiable, 
fully synthetic route towards the tetracyclines, allowing them to modify the 
scaffold at previously inaccessible positions.45-47 Their synthetic route has 
enabled the preparation of analogues with modifications at C5a48 and C8, 
Scheme 1.2 Modifications to the tetracycline scaffold to produce 
compounds with increased activity. 
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among others (25). Additionally, an orally available tetracycline has been 
advanced to Phase III trials as a result of their endeavors.49  
 Synthetic organic chemistry has enabled the structural modification 
of a variety of antibiotics, improving their properties, and providing an 
indispensable tool in the fight against drug resistant bacteria. Simple 
structural modifications have enabled the creation of Gram-negative 
antibiotics from Gram-positive leads and vice versa. Modifications have 
enabled the creation of medicines that are active against strains of bacteria 
that have developed resistance to compounds of the same structural class—
often due to modification of the binding interaction with the target protein 
or resistance-conferring protein(s) (β-lactamases or efflux pumps, for 
example). While semisynthetic preparations of antibiotics will continue to 
play an important role, total synthesis allows for the introduction of diverse, 
and otherwise inaccessible modifications to the scaffold, allowing scientists 
to probe chemical space more effectively. While it seems prudent to 
develop antibiotics with novel scaffolds and targets, total synthesis also 
enables the preparation of active compounds through structural 
modifications to known scaffolds, helping to stem the tide of infections 
arising from resistant bacterial strains. 
 
C. Lead Discovery 
There are two methods for the discovery of lead compounds, 
1) phenotypic drug discovery, and 2) target-directed drug discovery. In 
phenotypic drug discovery, compounds are screened in live cell assays to 
elicit a specific phenotypic response (in the case of antibiotics, growth 
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inhibition or cell death) without regard for the mechanism of action. In 
target-directed drug discovery, leads are identified from in vitro assays that 
determine the activity of compounds against specific, isolated protein 
targets that have been implicated to be vital for the target organism to 
thrive.  
Early efforts in antibiotic discovery relied on phenotypic drug 
discovery to discover leads for further optimization. The compounds used 
in phenotypic screening can be culled from diverse sources, as exemplified 
by early efforts in antibiotics research. As mentioned above, Salvarsan and 
the sulfa drugs were both discovered by screening synthetic dye 
derivatives, while the β-lactams and the tetracyclines are natural products 
isolated from microorganisms. 
Nearly all current antibiotics are derived from natural products 
isolated between 1940 and 1960, largely discovered through phenotypic 
drug discovery by screening compounds derived from actinomycetes and 
fungi.50-52 Several examples include the penicillins, cephalosporins, 
aminoglycosides, tetracyclines, erythromycin, and vancomycin.52  More 
recently, antibiotic research has shifted from phenotypic drug discovery 
towards target-directed drug discovery. Part of the impetus for this shift 
was the observation that the major classes of antibiotics hit only four 
classical targets: 1) bacterial cell-wall biosynthesis, 2) DNA replication, 
3) bacterial protein synthesis, and 4) folate coenzyme biosynthesis.52 Novel 
targets were sought that would provide new tools in the fight against 
resistant bacteria. Another major factor in the shift towards target-directed 
drug discovery was the introduction of powerful genomics techniques 
beginning in 1995 with the determination of the complete genome sequence 
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of Haemophilus influenza.53 This advance eventually provided the full 
genomes of hundreds of microbial species, allowing for the rapid 
identification of potential targets through genome mining.54 Further 
optimism was derived from the possibility of identifying conserved targets 
that were present in numerous pathogens but absent in higher eukaryotes, 
ideally leading to the development of safe, broad-spectrum compounds. At 
the same time, the move towards target-directed drug discovery inspired a 
shift from screening natural products and towards synthetic molecules, as 
synthetic molecules are more amenable to high-throughput screening 
(HTS) techniques, allowing medicinal chemists to screen a large number of 
compounds in a shorter period of time.52, 55 Furthermore, natural product 
screening became increasing inefficient because previously isolated 
compounds were continuously rediscovered.56 
The modern antibiotic drug discovery efforts using target-directed 
methods and large libraries of synthetic molecules have largely failed. 
Published efforts from GlaxoSmithKline57 and AstraZeneca22 reveal the 
difficulties associated with target-directed drug discovery for antibiotics. 
These reports, along with several others, outline several possible reasons 
for failure. It is widely understood that a major problem is maintaining a 
high drug concentration within the target bacteria. Thus, even if 
compounds demonstrate sufficient biochemical activity, it does not 
translate to antimicrobial activity due to poor permeability through the cell 
wall/membrane and efflux.55, 57 These problems are particularly challenging 
in Gram-negative bacteria, which contain multiple layers of defense. 
Another major difficulty lies in the composition of the libraries used in HTS 
efforts. These libraries are largely composed of molecules that obey 
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Lipinski’s rule of five,58 a set of guidelines developed for orally available 
drugs in areas other than infectious disease. In fact, it has been observed 
that known antibacterial compounds tend to disobey Lipinski’s rules.59 
Furthermore, the majority of compounds in commercial libraries are aimed 
at interacting with G-protein coupled receptors (GPCRs), nuclear 
receptors, voltage-gated ion channels, and ligand-gated ion channels, with 
50% of current drugs focused on these four classes.60 In contrast, antibiotic 
targets for HTS campaigns have primarily been enzymes, which are not 
represented in the protein classes listed above.19  
In summary, the golden age of antibacterial discovery utilized 
phenotypic drug discovery methods with natural products to generate an 
arsenal of life-saving molecules. Modern efforts have focused on 
target-directed drug discovery with synthetic molecules, and have 
encountered significant challenges that must be addressed given the 
increasing prevalence of bacterial resistance. 
 
D. Outlook 
The number of novel antibiotic scaffolds has dropped precipitously 
in recent decades—with every current antibiotic stemming from a scaffold 
discovered before 1984 (Table 1.1).61 Given that resistance is certain to arise 
to all current antibiotics, and that resistance to one molecule within a class 
often leads to resistance of other molecules of the class, this lack of novel 
antibiotic scaffolds is concerning. Additionally, it is financially untenable for 
pharmaceutical companies to continue investing in antibiotic research. 
There are two main reasons for this: 1) treatment courses for antibiotics are 
short, only one or two weeks, and 2) deployment of novel antibiotics must 
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be restricted to slow the development of resistance, thereby maintaining a 
stable of effective antibiotics to treat life-threatening illnesses.44 
Furthermore, recent difficulties in the drug discovery process have further 
disincentivized antibiotic development, as it appears to be  more difficult 
and expensive than previously imagined.22, 57 Accordingly, there have been 
numerous funding proposals to overcome the challenges associated with 
antibiotic discovery, including increased government spending.13, 62-63 
Another discovery mechanism would be through academic labs, although 
this avenue would likely require longer development times. 
Scientifically, there are several aspects of the antibiotic discovery 
process that could be improved. The composition of library compounds 
must be optimized for antibiotic discovery. As previously mentioned, 
current commercial libraries are composed of synthetic molecules 
designed for targets outside of infectious disease (such as GPCRs, etc). 
There is considerable agreement that screening libraries should be made 
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more ‘natural product-like’ by introducing more stereochemical features, 
reducing the number of aromatic rings, increasing molecular weight, and 
increasing polarity.60, 64 In fact, it has been observed that 83% of the core 
ring scaffolds present in natural products are absent in current commercial 
libraries.65 It has been proposed that because natural products are 
structurally akin to metabolites, they are more likely to be able to interact 
with transport systems, increasing the likelihood of successful drug 
delivery.64-65  
Another proposal is to return to phenotypic screening methods, 
which are more likely to identify compounds that are capable of penetrating 
the cell wall/membrane than biochemical binding assays—it has been 
suggested that “it is easier to find the target of an antibacterial compound 
than it is to engineer permeability into an enzyme inhibitor”.57 Even outside 
of antibiotic development there is discussion that HTS and target-directed 
drug discovery are detrimental to the productivity of the pharmaceutical 
industry.66 Between 1999 and 2008 there were more target-directed drug 
discovery efforts than phenotypic drug discovery efforts, but phenotypic 
drug discovery accounted for 37% of first in class molecules, while 
target-directed accounted for 23%.67 Another potential advantage of 
phenotypic drug discovery is that it facilitates the discovery of compounds 
that hit multiple targets because the discovery process does not select for 
binding to a single protein target. It has been proposed that the 
development of resistance may be delayed for molecules with multiple 
targets due to the increased requirements for resistance.19, 55 Using the same 
logic, it has been proposed that a more thorough investigation of 
combination therapies is warranted.55 The success of the combination 
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therapy Augmentin supports this hypothesis, pairing the β-lactam 
amoxicillin with a β-lactamase inhibitor clavulanate. 
In conclusion, while there are many challenges associated with the 
modern antibiotic drug discovery process, there are also many possible 
solutions. Antibiotic resistance is well-documented, and many talented 
scientists are working hard to overcome the obstacles to antibiotic 
development.   
 
E. Relevance to the Xiamycin & Oridamycin Family of Natural Products 
The xiamycin and oridamycin family of natural products were 
extracted from several strains of bacteria and were discovered because of 
their activity in whole cell assays. In other words, they are natural products 
derived from a phenotypic drug discovery platform. They have novel 
molecular scaffolds and promising activity against several resistant strains 
of bacteria, including methicillin resistant staphylococcus aureus (MRSA) and 
vancomycin resistant enterococcus (VRE). Total synthesis of these 
antibacterial compounds could provide structural derivatives, allowing for 
the optimization of their physicochemical properties, and providing 
structurally modified compounds to combat resistance in the future. In light 
of this, a program aimed at the total synthesis of these families was 
undertaken.  
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Chapter 2. Introduction to the Xiamycin and 
Oridamycin Families of Indolosesquiterpenes 
 
Preface 
 This chapter introduces the xiamycin and oridamycin families of 
indolosesquiterpenes, starting with their isolation and biosynthesis and 
moving through previous work on related natural product scaffolds and on 
the family, itself. Finally, a retrosynthesis is outlined that provides a strategy 
to access four monomeric family members.  
 
A. Isolation & Biosynthesis 
The first xiamycin family members to be isolated were oridamycin A 
(26) and oridamycin B (27) in 2010 (Figure 2.1).1 These pentacyclic 
compounds were derived from a soil-dwelling actinomycete, Streptomyces 
sp. strain KS84. Interestingly, they were the first indolosesquiterpenes 
derived from prokaryotes, as all previous indolosesquiterpenes were 
isolated from plants or fungi. The oridamycins were discovered based on 
their activity against Saprolegnia parasitica, a common protozoan that 
infects freshwater fishes, particularly those contained in commercial 
aquacultures. 
Several months later, xiamycin A (28) was isolated along with its 
methyl ester (29) from Streptomyces sp. GT20021503, an endophyte derived 
from the stem of a mangrove tree (Bruguiera gymnorrhiza).2 The related 
family members xiamycin B (32), indosespene (30), and sespenine (33) were 
disclosed soon after, isolated from Streptomyces sp. HKI0595, an endophyte 
28 
 
Figure 2.1 The xiamycin family of indolosesquiterpenes. 
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stemming from another mangrove tree (Kandelia candel).3 During 
heterologous expression of the xia gene cluster in Streptomyces albus, the 
dimeric compounds dixiamycin A (38), dixiamycin B (39), 40 and 41 were 
discovered, further extending the family.4 Another research team was able 
to isolate dixiamycin A (38) and dixiamycin B (39) from the marine-derived 
actinomycete SCSIO 02999, along with two new family members, oxiamycin 
(34) and chloroxiamycin (31).5 Dixiamycin C (42) was soon discovered,6 
followed by three sulfone-bridged dimers, dixiamycins A-C (43-45)—also 
discovered through heterologous expression.7 The final family members to 
be reported were xiamcycins C-E (35-37), which were isolated from a 
topsoil-dwelling acinomycetes, Streptomyces sp. HK18.8  
The xiamycin family members have antibacterial and antiviral 
biological activity (Tables 2.1, 2.2, and 2.3). In general, the antibiotic activity 
is more consequential than the antiviral activity. Interestingly, these 
compounds show minimal cytotoxicity towards mammalian cells, implying 
that they are not DNA intercalators in eukaryotes, and revealing their 
potential as antibiotic lead compounds.9 The monomers are generally less 
active than the dimers, and the sulfone linked dimers are less active than 
the N-N or C-N linked dimers. Interestingly, in both pairs of atropisomeric 
dimers, the M dimer (38 and 40) is slightly more active than the P dimer (39 
and 41). The compounds also show activity against methicillin-resistant 
Compound
saprolegnia parasitica 
(protozoan)
phoma  sp. CCF3818 
(fungus)
saccharomyces 
cerevisiae  (yeast)
oridamycin A ( 26 ) MIC: 3.0 µg/mL MIC: 242 µg/mL MIC: >1000 µg/mL
oridamycin B ( 27 ) MIC: >300 µg/mL N/A N/A
Table 2.2 Biological activity of the oridamycins. 
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Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus 
(VRE), implying that they have a different mechanism of action than 
previous medicines, or that their novel scaffold avoids resistance 
mechanisms developed against previous classes of antibiotics.  
The biosynthesis of these compounds has been independently 
studied by two groups, each of which has used different designations for 
the relevant enzymes and genes. The proteins will be labeled according to 
the designations put forth by the Zhang group10-13, as opposed to those used 
by the Hertweck group.3-4, 6-7 Using the non-mevalonate pathway, the 
xiamycin-producing bacteria generate farnesyl pyrophosphate (46), which 
is then coupled with indole to generate 47 (Scheme 2.1.a). A selective 
epoxidation ensues, catalyzed by the oxidoreductase XiaO, generating 
Table 2.3 Cytotoxic and antiviral activity of the xiamycin family. 
Compound
Cytotoxicity 
(human tumor)
Cytotoxicity 
(monkey)
HIV-1 PEDV HSV-1 HCV
xiamycin A ( 28 ) IC50: >30 µg/mL IC50: 138.12 µg/mL
Moderate 
(CXCR4)
IC50: 20.14 µg/mL Good None
xiamycin A methyl 
ester ( 29 )
IC50: ~10 µg/mL IC50: 103.15 µg/mL None IC50: 5.69 µg/mL N/A N/A
xiamycin C ( 35 ) N/A IC50: 76.9 µg/mL N/A IC50: 11.49 µg/mL N/A N/A
xiamycin D ( 36 ) N/A IC50: 56.03 µg/mL N/A IC50: 0.93 µg/mL N/A N/A
xiamycin E ( 37 ) N/A IC50: 98.74 µg/mL N/A IC50: 2.89 µg/mL N/A N/A
chloroxiamycin ( 31 ) N/A IC50: 162.08 µg/mL N/A IC50: 12.76 µg/mL N/A N/A
sespenine ( 33 ) None None N/A N/A Moderate None
indosespene ( 30 ) None None N/A N/A Moderate None
oridamycin A ( 26 ) None None N/A N/A None None
dixiamycin C ( 42 ) None None N/A N/A Moderate Moderate
32 
 
cyclization precursor 48. The membrane protein XiaH catalyzes the terpene Scheme 2.1 Biosynthesis of the xiamycin family. 
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cyclization precursor 48. The membrane protein XiaH catalyzes the terpene 
cyclization to form the trans-decalin ring system found in 49. XiaM—a P450 
enzyme—selectively oxidizes the equatorial methyl substituent to generate 
indosespene (30). Next, the indole oxygenase XiaI generates 50, which 
undergoes cyclization, followed by elimination and dehydration to produce 
diene 53. This compound spontaneously aromatizes to form xiamycin A (28).  
The dixiamycins are generated from xiamycin A through an oxidation 
catalyzed by the flavoenzyme monooxygenase XiaK (Scheme 2.1.b).13 
Chloroxiamycin (31) is also generated, which is noteworthy given that no 
halogenase enzymes are encoded within the Xia gene cluster. When the 
reaction between XiaK and xiamycin A (28) is conducted in vitro, the dimers 
are not formed, but N-hydroxyxiamycin (54) can be isolated. It seems 
plausible that N-hydroxyxiamycin (54) is a precursor to the dimers, possibly 
through the intermediacy of a nitrogen-centered radical species (for 
further corroboration of this proposed intermediate see the Baran 
synthesis of dixiamycin B below14).  
Sespenine (33) is formed in a similar manner to xiamycin A (Scheme 
2.1.c). The same cationic intermediate 51 is formed, but instead of 
undergoing a base-promoted elimination to produce 52, sespenine (33) is 
generated from an oxindole rearrangement. This pathway was 
hypothesized based on a related, unexpected rearrangement observed 
during the synthesis of hinckdentine A.15 These observations led to a 
biosynthetic proposal for the formation of aspernomine from anominine, 
which was corroborated by quantum chemical calculations.16 Further 
support for this rearrangement comes from the biomimetic synthesis of 
sespenine by the Li group, vide infra (Scheme 2.8.b).17  
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While the biosynthetic pathway for xiamycin A (28) and related 
compounds has been thoroughly studied, no effort towards understanding 
the biogenesis of the oridamycins (26 & 27) has been undertaken. It seems 
possible that the oridamycins arise in an analogous manner to xiamycin A, 
except with a XiaM homolog that oxidizes the axial methyl instead of the 
equatorial methyl of intermediate 49 (Scheme 2.1.d). 
 
B. Synthetic Challenges & Relevant Precedents 
The major synthetic challenges of the xiamycin and oridamycin 
frameworks (57) can be split into two categories: 1) the substituted 
trans-decalin ring system (56, Scheme 2.2.a), and 2) the 2,3-fused carbazole 
(58, Scheme 2.2.b). The trans-decalin system is a common structural motif 
found in terpenoid natural products, resulting in the development of myriad 
Scheme 2.2.a Synthetic approaches towards trans-decalin ring systems 
and b related natural products, one of which harbors a fused carbazole 
nucleus (tubingensin A, 66). 
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methods for its construction. The current discussion will be limited to the 
synthesis of substituted trans-decalins of type 56, in which R1 ≠ H, R2 ≠ H, 
and R3 ≠ H. Examples of fused carbazoles are relatively sparse, and the 
present discussion will be focused on previous synthetic efforts towards 
tubingensin A (66), and the related family member anominine (67).  
 Three of the most common methods to synthesize the trans-decalin 
ring system are: 1) the Robinson annulation, requiring a subsequent enone 
reduction, 2) the Diels–Alder cycloaddition, either intramolecularly or 
through epimerization of a cis-decalin, and 3) polyolefin cyclizations, either 
cationic or radical (Scheme 2.2.a). [NOTE: for the sake of clarity, all 
compounds are drawn in the same orientation with respect to the 
trans-decalin ring system, in certain instances the unnatural enantiomer is 
depicted.] 
Originally reported in 1935, the Robinson annulation was developed 
to construct the carbocyclic core of steroids.18 Nucleophilic attack of the 
enolate derived from a cyclohexanone (59) onto an activated olefin (60) 
generates the first bond, and intramolecular aldol condensation and 
dehydration completes the annulation (Scheme 2.2.a). The resultant enone 
(61) must be stereoselectively reduced to yield the desired trans-decalin 
framework. The Wieland–Miescher ketone (70) is the product of a Robinson 
annulation between 2-methyl-1,3-cyclohexanedione (68) and methyl vinyl 
ketone (69) (Scheme 2.3.a), and it has found widespread use in the synthesis 
of dozens of natural products.19 The proline-catalyzed asymmetric 
synthesis of the Wieland–Miescher ketone significantly improved access to 
useful chiral building blocks, and was one of the first examples of 
organocatalysis (Scheme 2.3.a).20-21 In studies towards clerocidin (73), Markó 
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and coworkers used the Wieland–Miescher ketone to access their key 
intermediate 71 (Scheme 2.3.b).22 They generated the trans-decalin system 
through a dissolving-metal reduction of the enone, trapping the resultant 
enolate with methyl bromoacetate to form 72. A single diastereomer was 
isolated, corresponding to an equatorial alkylation, producing a 
syn-pentane interaction between the two axial methyl substituents. The 
completion of clerocidin (73) using this strategy was never reported. 
Scheme 2.3 Synthetic routes utilizing the Robinson annulation to 
construct trans-decalin ring systems. 
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A Robinson annulation was also used in Masamune’s route towards 
garryine (79) in 1964 (Scheme 2.3.c).23-24 When tricycle 74 was condensed 
with ethyl vinyl ketone, key intermediate 75 was obtained. The trans-ring 
junction was established through a deconjugative alkylation producing 76, 
with subsequent reduction occurring at the less hindered convex face to 
provide the desired stereochemistry. The requisite fused piperidine was 
forged when acyl azide 77 was irradiated with ultraviolet light, releasing N2 
and generating a nitrene intermediate, which inserted into the proximal 
methyl to generate 78. Further elaboration ultimately produced garryine 
(79).  
More recently, Menche et al. utilized a Wieland–Miescher-type 
ketone (71) in their synthesis of dysidavarone A (81, Scheme 2.3.d).25 Using 
the same reduction/alkylation strategy as Markó, they were able to convert 
71 to 80 through alkylation with a functionalized benzylic bromide. They 
observed the same stereoselectivity as Markó, generating the axial methyl 
through an equatorial alkylation. The bicyclic framework of the natural 
product was constructed through a PdII-catalyzed cross coupling between 
the aryl bromide and the ketone enolate, ultimately producing dysidavarone 
A (81).  
The Diels–Alder cycloaddition has also found considerable use in the 
preparation of substituted trans-decalins.26 The most direct method for 
obtaining trans-decalins using the Diels–Alder reaction is through an 
intramolecular Diels–Alder reaction (IMDA). One example comes from the 
synthesis of forskolin (84) by Ikegami and coworkers (Scheme 2.4.a).27 Using 
catalytic thiophenol to equilibrate the diene, they were able to promote a 
thermal IMDA to generate 83 from 82. The observed exo product is 
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hypothesized to arise because an asynchronous transition state is operant. 
The vinylogous enol ether adds to the electrophilic enoate first, so that 
steric interactions play a more important role than electronics. The 
resulting tricyclic product (83) was ultimately elaborated to the target 
natural product (84) in 28 steps. 
Another version of the IMDA is the transannular Diels–Alder, a 
cycloaddition creating multiple smaller rings from a macrocyclic precursor. 
This strategy was used to generate a trans-decalin intermediate 86 en route 
to cassaine (87, Scheme 2.4.b).28 In this case, the cycloaddition produced 
Scheme 2.4 Synthetic routes utilizing the Diels–Alder cycloaddition to 
construct trans-decalin ring systems. 
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both cis- and trans-fused ring junctions in product 86. The cis-junction was 
epimerized after introduction of the C7 ketone to generate the requisite 
trans-junction found in cassaine. The Diels–Alder/epimerization strategy 
was first disclosed by Woodward during his studies on steroids in 1952 
(Scheme 2.4.c).29 He demonstrated that the bicyclic product (89) resulting 
from cycloaddition of butadiene and substituted quinone 88 could be 
equilibrated to the thermodynamically favored trans-isomer when treated 
with base. This strategy was subsequently used by Kametani to rapidly 
construct intermediate 94, which could be elaborated to atisine, veatchine, 
garryine, and gibberellin A15 (Scheme 2.4.d).30 The IMDA was initiated via 
thermolysis of the benzocyclobutane 91 to generate ortho-quinodimethane 
92, which produced the desired tricyclic compound 93. Epimerization was 
realized through oxidation to the benzylic ketone, conversion to the 
α-bromoketone, dehydrobromination to form the enone, and catalytic 
hydrogenation.  
The biomimetic strategy for the construction of trans-decalins is 
through a polyolefin cyclization. The two major mechanistic pathways for 
these types of cyclizations are cationic and radical. Early work by Johnson 
validated the Stork–Eschenmoser hypothesis, using acid to generate the 
symmetric bis-allylic cation from 95, initiating the cascade to form tricyclic 
compound 96 (Scheme 2.5.a).31 The subsequent addition of lithium 
aluminum hydride reduced the resulting trifluoroacetate esters to yield the 
desired alcohols. This strategy was employed by Corey in his synthesis of 
neotripterifordin (99, Scheme 2.5.b).32 The cyclization was initiated through 
Lewis acid promoted epoxide-opening of linear compound 97, generating 
tricycle 98 which was elaborated to the natural product.  
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Another method to initiate cationic polyolefin cyclizations involves 
the formation of a halonium cation. One example comes from Snyder and 
coworkers, who developed a method employing bromodiethylsulfonium 
bromopentachloroantimonate (BDSB), an electrophilic bromine source that 
reacts preferentially with olefins (Scheme 2.5.c).33 They were able to 
construct a variety of natural products using this methodology, including 
peyssonoic acid A (102). Interestingly, they were able to construct both 
cis- and trans-decalins depending on the olefin geometry of the starting 
polyolefin. Furthermore, they successfully extended this technology to 
iodonium and chloronium analogues.  
Radical-based methods for polyolefin cyclizations have also been 
employed, with one of the earliest examples coming from Breslow in 1968.34 
Trans,trans-farnesyl acetate (103) was cyclized to produce substituted 
Scheme 2.5 Synthetic routes utilizing polyolefin cyclizations to construct 
trans-decalin ring systems. 
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trans-decalin 104 (Scheme 2.6.a). CuCl aided in the thermal decomposition 
of benzoyl peroxide to form the desired benzoyl radical, and Cu(OBz)2 
served to terminate the cyclization through oxidation of the resultant 
radical. The cyclization could also be initiated through photosensitization 
of fluorescein to generate the desired benzoyl radical. 
Radical cyclizations can also be initiated using MnIII salts with 
enolizable carbonyl compounds, especially 1,3-dicarbonyls (Scheme 
2.6.b).35-36 The carbonyl compound exists in an equilibrium between the 
neutral carbonyl and the MnIII enolate. Upon formation of the enolate, the 
oxygen-MnIII bond homolytically cleaves to generate the desired α-carbonyl 
radical and a MnII species. Snider and coworkers demonstrated the utility of 
Scheme 2.6 Synthetic routes utilizing radical cyclizations to construct 
trans-decalin ring systems. 
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this technology by synthesizing trans-decalin 106 from β-keto ester 105. 
The axial ester stereochemistry is hypothesized to arise in order to 
minimize steric interactions between the axial substituents in the transition 
state, as methyl esters have smaller A-values (~1.25) than methyl 
substituents (1.74).  
Atom-transfer cyclizations have also been used to construct 
substituted trans-decalins (Scheme 2.6.c). One relevant example comes 
from Yang and coworkers, who were able to generate bicycle 108 using 
Et3B/O2 as the radical initiator.37 The Lewis acid chelated the carbonyl 
substituents to form the trans-decalin containing two axially disposed 
methyl substituents. The yield is low due to the formation of monocyclic 
products arising from premature termination of the cyclization. 
Presumably, the second cyclization is slow due to the congested transition 
state arising from the syn-pentane interaction of the two axial methyl 
substituents.  
Epoxides can also serve as starting materials for radical cyclizations. 
In situ generated TiIII salts can reductively homolyze epoxides to form the 
TiIV alkoxide and an alkyl radical. Cuerva and coworkers used this method 
to construct complex polycycles, avoiding premature termination through 
the strategic introduction of carbonyls along the linear precursors. One 
example is depicted in Scheme 2.6.d, in which a cis-decalin fused to the 
expected trans-decalin is formed (110) due to the modified conformational 
restraints stemming from the unsaturation introduced by the carbonyl 
substituent.  
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Scheme 2.7 Approaches towards related family members. 
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The second challenge in the xiamycin and oridamycin molecules is 
the fused carbazole (Scheme 2.2.b). Relevant precedent for the synthesis of 
this motif comes from tubingensin A (66), which contains a carbazole fused 
to a decalin ring system with the same regiochemistry as the 
xiamycin/oridamycin molecules. The related family member anominine (67) 
bears resemblance to indosespene (30), the biosynthetic precursor of 
xiamycin A, and will also be included in the present discussion.  
Bonjoch reported the first synthesis of these natural products, 
reporting a successful route to anominine in 2010 (Scheme 2.7.a).38 The 
synthesis begins with an organocatalyzed, asymmetric Robinson annulation 
to form Wieland–Miescher-type ketone 111. This substrate was elaborated 
to cis-decalin 112 in five steps, which was converted to exocyclic enone 113 
in nine steps, including a key selenium-oxide mediated allylic oxidation. The 
indole was installed through a Michael addition onto the exocyclic enone, 
and a cross metathesis forged the prenyl olefin. Bonjoch also reported 
progress towards tubingensin A (66), completing a synthesis of the core 
scaffold (Scheme 2.7.b).39 This synthesis began with the Wieland Miescher 
ketone (70), which was elaborated into Michael acceptor 114. To generate 
the fused carbazole, a Michael addition/aldol condensation cascade was 
executed using phase transfer catalysis. The aryl nitro group was reduced, 
and the resulting aniline condensed onto the proximal ketone to produce 
the indole. The carbazole was generated through dehydration followed by 
spontaneous aerobic oxidation.  
Nicolaou and Li reported the synthesis of both anominine and 
tubingensin A from a common synthetic intermediate (120) in 2012 (Scheme 
2.7.c).40 Compound 117 was derived from a Robinson annulation, and was 
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converted to the Stork–Ueno cyclization precursor 118 in three steps.41-42 
After cyclization and functional group manipulation, Grignard addition into 
aldehyde 119 produced common synthetic intermediate 120. To access 
anominine, 120 was deoxygenated via the xanthate, eventually yielding the 
natural product after introduction of the prenyl side chain. To synthesize 
tubingensin A, alcohol 120 was converted to the mesylate and eliminated to 
form triene 121. A 6π-electrocyclization/aromatization sequence furnished 
the desired fused carbazole, ultimately leading to a successful synthesis of 
the natural product. 
The most recent synthesis of tubingensin A comes from the Garg lab 
in 2014 (Scheme 2.7.d).43 Starting from dihydrocarvone they were able to 
produce 122, which was hydroborated and cross coupled with a protected 
carbazole triflate to connect the heterocycle with the aliphatic framework. 
The fused carbazole was generated from a benzyne intermediate, formed 
through elimination of aryl bromide 123 using NaNH2. The benzyne was 
intercepted by the enolate derived from the silyl enol ether to produce the 
fused cis-decalin. Tubingensin A was synthesized after deprotection and 
reduction.  
Three strategies emerge for the construction of fused carbazoles 
based on previous work. Bonjoch used a Michael addition, aldol 
condensation, nitro reduction, amine condensation, aromatization 
sequence on a model system, though this strategy was never successfully 
applied to tubingensin A (Scheme 2.7.b). Nicolaou and Li used a Grignard 
addition, alcohol elimination, 6π-electrocyclization, aromatization strategy 
(Scheme 2.7.c), and Garg used a benzyne annulation (Scheme 2.7.d).  
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C. Previous Syntheses of the Xiamycin and Oridamycin Family Members 
Due to their interesting molecular architecture and promising 
biological activity, the xiamycin family of indolosesquiterpenes has piqued 
the interest of the synthetic community. The first synthetic effort towards 
any of the family members was reported by the Baran lab, disclosing the 
completion of xiamycin A and dixiamycin B (Scheme 2.8.a).14 They accessed 
linear intermediate 125 in eight steps from geraniol, using a Suzuki coupling 
to link the carbazole to the terpenoid portion. Their key step involved 
formation of the trans-decalin ring system 126 through a cationic, 
epoxide-opening cyclization of substrate 125 as promoted by BF3•OEt2. 
After functional group tailoring they were able to produce xiamycin A (28) 
on gram scale. Initial attempts to chemically dimerize xiamycin A to 
dixiamycin A or B (38 or 39) using a variety of oxidants failed. Ultimately, it 
was discovered that dixiamycin B (39) could be generated from an 
electrochemical oxidation, along with bromodixiamycin, which is related to 
the natural product chloroxiamycin (31). The electrochemical dimerization 
likely proceeds through a nitrogen-centered radical, providing support for 
the biosynthetic hypothesis for dixiamycin A and dixiamycin B (Scheme 
2.1.b). Currently, it is unclear why only one atropdiastereomer arises from 
the electrochemical dimerization. 
Sespenine was the next family member to be synthesized (Scheme 
2.8.b).17 Li and coworkers accessed cyclization precursor 128 from geraniol 
(127) in 12 steps, forming desired bicycle 129 through a reductive 
epoxide-opening radical cyclization initiated by in situ generated TiIII.  
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Scheme 2.8 Prior approaches towards xiamycin family members. 
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Oxidation of the resultant secondary alcohol produced an enone, which 
allowed for attachment of C2-methoxycarbonyl indole through a Michael 
addition, eventually producing rearrangement precursor 130. The C2 ester 
substituent was required for the biomimetic rearrangement, as the 
unsubstituted derivative produced only complex mixtures. The indole was 
subsequently oxidized at C3 with Oxone, and the rearrangement was 
promoted with acetic acid at room temperature to produce compound 131. 
Sespenine (33) was constructed after decarboxylation and deprotection. 
Interestingly, only one of the two C3 alcohol epimers underwent the desired 
skeletal rearrangement (see 51, Scheme 2.1.c)—the other epimer primarily 
underwent an aza-Prins cyclization (see 50 to 28, Scheme 2.1.a).  
While the research described in this thesis was underway, Li and 
coworkers published the synthesis of oridamycin A (26), oridamycin B (27), 
xiamycin A (28), indosespene (30), and dixiamycin C (42).44 They disclosed 
two routes to access xiamycin A, both of which used a reductive, 
epoxide-opening radical cyclization analogous to that used for the 
synthesis of sespenine (33). Dixiamycin C (42) was accessed through a 
Buchwald–Hartwig cross coupling between xiamycin A and a brominated 
derivative of xiamycin A. Li and coworkers also disclosed two routes to 
oridamycins A and B. The first route elaborated geranyl acetate (132) to the 
cyclization precursor 133 through a dianion alkylation (Scheme 2.8.c). 
Oxidative radical cyclization produced the desired trans-decalin 134 with 
the axially disposed ester substituent and equatorial methyl. Phenyl sulfone 
protected indole was attached through a Grignard addition, and the 
resulting secondary alcohol was eliminated to form triene 135. The 
carbazole was forged using a 6π-electrocyclization/aromatization 
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sequence to yield 136, which was converted to oridamycin A (26) upon 
reduction and deprotection. Oridamycin B (27) was synthesized using an 
oxime-directed, PdII-catalyzed, C-H oxidation to install the equatorial 
hydroxymethyl. The second route used the same key steps, but the indole 
was appended prior to cyclization, and the carbazole was forged through 
an oxidative Heck cyclization.45 
The Li group’s first route towards the oridamycins is strikingly similar 
to the route outlined in this document, vide infra Chapter 3. All of the key 
steps are the same, including oxidative radical cyclization, Grignard 
addition, 6π-electrocyclization, and oxime-directed C-H oxidation. The 
only significant difference between the strategies is the choice of 
protecting groups.46  
More recently, the Krische group published a synthesis of oridamycin 
A using their direct alcohol C-H functionalization via C-C bond-forming 
transfer hydrogenation methodology (Scheme 2.8.d).47 The first step in their 
synthesis joined 137 with isoprene oxide to form 138 asymmetrically. 
Treatment of silacycle 139 with ZnCl2 generated a cyclic oxocarbenium 
intermediate, which was trapped by an intramolecular Sakurai allylation to 
produce bicycle 140. This fragment was joined to carbazole, and an 
intramolecular Friedel–Crafts cyclization of 141 furnished oridamycin A (26).  
All of the syntheses of the xiamycin family, with the exception of the 
Krische route, utilize a biomimetic cyclization strategy, forming two bonds, 
multiple stereocenters, and the desired trans-decalin ring system in a single 
step. This strategy selection is unsurprising, as there is considerable 
precedent for successful polyolefin cyclization cascades in natural product 
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total synthesis48, with origins in the Stork–Eschenmoser hypothesis put 
forth in 1955.49-50  
 
D. Retrosynthesis 
The goal of this project is to find a solution to both the xiamycin and 
oridamycin scaffolds from a common synthetic intermediate (Scheme 2.9). 
With regards to efficiency, a biomimetic strategy would yield optimal 
results, as it could construct multiple bonds and stereocenters in a single 
operation. With these considerations in mind, a retrosynthesis is presented 
that accesses oridamycin A (26), oridamycin B (27), xiamycin A (28), and 
Scheme 2.9 A unified synthetic approach towards oridamycin A (26) and 
xiamycin A (28) from common synthetic starting material 142. 
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indosespene (30), (Scheme 2.10). The dimeric compounds could be 
addressed upon completion of xiamycin A.  
The key step for all monomers is the oxidative radical cyclization of 
linear β-keto ester 142, forming three consecutive stereocenters, and 
producing the requisite trans-decalin system (Scheme 2.9). The radical 
Scheme 2.10 Retrosynthetic analysis for several members of the xiamycin 
family. 
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cyclization of a β-keto ester was selected for the key step because it 
produces a trans-decalin with an oxidation state similar to that of the 
natural products. Specifically, the C16 substituents will arrive in the correct 
oxidation state, containing an ester and a methyl substituent. Other 
methods provide the C16 gem-dimethyl (see Schemes 2.5.a, 2.5.c, 2.6.a, and 
2.6.d), or other oxidation patterns that would require further manipulation 
(see Scheme 2.5.b). Atom-transfer cyclization was avoided because of the 
extra steps required for the synthesis of the starting α-bromo compounds, 
and for the conversion of the resultant bromide to the desired olefin. The 
MnIII-mediated free radical cyclization, as reported by Snider and 
coworkers, is known to produce a trans-decalin corresponding to the 
oridamycins, in which the methyl group is equatorial and the ester is axial 
(Scheme 2.9, left side).35-36 In order to access the C16 epimeric trans-decalin 
corresponding to indosespene (30), xiamycin A (28), and the dimers, a 
chelated radical cyclization is proposed (Scheme 2.9, right side). Chelated 
radical intermediates stemming from β-keto ester precursors have been 
reported for MnIII-mediated cylclizations51-53, as well as for atom-transfer 
cyclizations, providing promising precedent.37, 54 
Based on previous reports, it seemed likely that the free radical 
cyclization towards the oridamycins (26 & 27) would be more 
straightforward than the chelated radical cyclization towards xiamycin A 
(28) and indosespene (30). Accordingly, the initial focus was on the synthesis 
of oridamycin A and oridamycin B in order to validate the late stage 
transformations before attempting to develop a novel radical cyclization 
methodology. The C16 carboxylic acid of oridamycin A (26) would stem from 
saponification of an appropriate ester precursor, while the secondary 
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alcohol would arise from the ketone of precursor 147 (Scheme 2.10.a). Axial 
hydride delivery is expected, as it would have a lower steric penalty than 
equatorial delivery due to the axial methyl and carboxy substituents. The 
carbazole could arise from a biomimetic cyclization of tetracycle 148 (see 
Scheme 2.1.a), entailing oxidation at the indole C3, aza-Prins cyclization, 
dehydration, and aromatization. Alternatively, a PdII-catalyzed oxidative 
cyclization could be explored45 (after the development of this 
retrosynthesis, Li and coworkers reported the realization of this cyclization 
strategy44). Tetracycle 148 would arise from the key radical cyclization of 
common precursor 149, producing two rings and three consecutive 
stereocenters in a single operation. Based on previous work, it seemed 
probable that the desired trans-decalin would be generated (for further 
discussion, see Chapter 3).35-36, 55-57 A potential difficulty with this 
retrosynthesis is the possibility that the tertiary radical produced after the 
second cyclization could cyclize onto the indole, as these types of radicals 
have been shown to interact with aromatic systems.55, 58 Alternatively, the 
cation that would result from oxidation of this radical could cyclize in a 
Friedel–Crafts fashion. The linear cyclization precursor 149 would be 
derived from indole and allylic bromide 150.59 The allylic bromide 150 would 
be synthesized from the corresponding allylic alcohol, which would be 
derived from oxidized geranyl acetate and the dianion of methyl 2-methyl-
3-oxobutanoate.58, 60-61 To produce the hydroxymethyl substituent of 
oridamycin B (27), a late stage, oxime-directed, PdII-catalyzed C-H oxidation 
was envisioned (Scheme 2.10.b). It was anticipated that coordination to the 
Lewis basic oxime (151) would allow for selective insertion into the 
equatorial methyl via a five-membered palladacycle, with subsequent 
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reductive elimination forming the desired C-O bond and regenerating the 
PdII catalyst.62-63 The requisite oxime 151 could be readily synthesized from 
compound 147, a proposed intermediate in the synthesis of oridamycin A 
(26). 
Xiamycin A (28) was envisioned to arise from pentacyclic ketone 152 
using the same disconnections as the oridamycins (Scheme 2.10.c). 
Pentacyclic ketone 152 would arise from tetracycle 153 using the same 
biomimetic cyclization strategy proposed for the oridamycins (Scheme 
2.10.a). The key step in the synthesis would be the radical cyclization, 
forming the trans-decalin framework in a single step from common linear 
precursor 149. As previously mentioned, the oxidative radical cyclization for 
xiamycin A requires chelation of the two carbonyls during cyclization to 
enforce formation of the trans-decalin bearing an axial methyl substituent 
and equatorial ester (see Scheme 2.9). The product of the desired radical 
cyclization would be readily converted into indosespene (30) through 
reduction and saponification.  
In summary, a retrosynthesis is described that would provide access 
to oridamycin A (26), oridamycin B (27), xiamycin A (28), and indosespene 
(30) from a common synthetic precursor 149. The key step in the 
retrosynthesis involves an oxidative radical cyclization to form the desired 
trans-decalin ring system in a biomimetic polyolefin cyclization. The 
framework associated with the oridamycins would arise from a free radical 
cyclization, while the framework associated with xiamycin A would arise 
from a chelated radical cyclization. 
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Chapter 3. Synthesis of Oridamycin A & Oridamycin B 
 
Preface 
 This chapter outlines the evolution of the synthetic strategy used to 
synthesize both oridamycin A and oridamycin B. The initial retrosynthesis 
was modified multiple times as a result of unexpected results during studies 
towards both natural products. The final sequence utilizes a free-radical 
cyclization to form the trans-decalin ring system, setting three contiguous 
stereocenters in a single operation. The carbazole is constructed using a 
6π-electrocyclization to fuse the trans-decalin to the aromatic system. 
 
A. Initial Efforts 
The first goal was to synthesize a suitable cyclization precursor to 
validate the hypothesis that a trans-decalin harboring the stereochemistry 
associated with the oridamycins could be accessed from a MnIII-mediated 
free-radical cyclization. As previously outlined in Chapter 2, cyclization 
precursor 149 was the initial target for testing this premise. This compound 
was envisioned to arise from indole alkylation of allylic bromide 150, which 
could be accessed from known linear alcohol 154 (Scheme 3.1.a).1-3 This 
compound (154) could be derived from allylic oxidation of geranyl acetate, 
conversion of the resultant allylic alcohol 156 to an allylic bromide, and 
alkylation with the dianion of methyl 2-methyl-3-oxobutanoate (155).  
Implementation of this retrosynthetic analysis began with 
SeO2-mediated allylic oxidation of geranyl acetate (Scheme 3.1.b, 157). 
Mechanistically, the oxidation begins with an ene reaction, in which the  
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Scheme 3.1 Initial studies towards oridamycin A. 
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olefin engages the electrophilic selenium species. This is followed by a 
[2,3]-sigmatropic rearrangement to form the desired oxidized product 
156.4-6  The ene reaction determines the regioselectivity, with the 
electrophilic SeO2 preferentially engaging the more electron rich olefin. 
Oxidized product 156 is selectively produced from geranyl acetate due to 
the deactivation of the other olefin by the allylic acetate. Next, the allylic 
alcohol 156 was converted to allylic bromide 158. Initial attempts using 
Appel conditions (CBr4 and PPh3) were complicated by large amounts of 
P(O)Ph3 byproduct, leading to difficult purifications and loss of product. It 
was found that a one-pot, two-step procedure involving mesylate 
formation followed by Finkelstein reaction provided the desired material in 
significantly higher yield without requiring chromatographic purification 
(Scheme 3.1.b). The necessary acetoacetate derivative was produced 
through alkylation of methyl acetoacetate with methyl iodide to generate 
methyl 2-methyl-3-oxobutanoate (155).7 The dianion of 155 was generated 
using sequential addition of NaH and n-BuLi and was alkylated with allylic 
bromide 158 to produce linear alcohol 154. Presumably, excess dianion (5 
equivalents were used) cleaved the allylic acetate in situ to directly afford 
the linear alcohol 154. A similar process was employed to link indole to the 
linear β-keto ester. Allylic alcohol 154 was converted to the bromide through 
the action of PBr3, and the resultant crude bromide was condensed with 
indole using Zn(OTf)2 to yield the desired cyclization substrate 159.8  
With the desired cyclization precursor 159 in hand, several attempts 
were made to generate the desired trans-decalin 161 using MnIII-mediated 
free-radical conditions (Scheme 3.1.c). Unfortunately, the desired 
trans-decalin 161 was not isolated from these reactions. It was hypothesized 
64 
 
that protection of the indole might be beneficial, and a tosyl-protected 
cyclization precursor 160 was prepared through the dianion of linear indole 
159 (Scheme 3.1.b). The trans-decalin 161 remained elusive when 
tosyl-protected cyclization precursor 160 was used, prompting 
reconsideration of the strategy. It seemed plausible that the transient 
radical and/or cationic intermediates were unproductively interacting with 
the aromatic system, complicating the reaction and producing a mixture of 
unwanted side products. Indeed, previous studies have leveraged the ability 
of intermediate radicals/cations in free-radical cyclizations to engage 
aromatic systems, generating additional rings in cascade reactions.9-10 
These studies further support the hypothesis that the indole may be 
problematic for the free-radical cyclization.  
 
B. Redesign & Completion of Oridamycin A 
To overcome the difficulties encountered when attempting to cyclize 
indole derivatives 159 and 160, it was hypothesized that cyclization prior to 
indole attachment would prove beneficial, eliminating the possibility of 
undesired interactions with the indole. Examination of the literature 
regarding MnIII-mediated free-radical cyclizations revealed that molecules 
related to linear alcohol 154 have been successfully cyclized to produce the 
desired type of trans-decalin ring system.11-12 Gratifyingly, treatment of 
linear alcohol 154 with Mn(OAc)3 and Cu(OAc)2 in AcOH afforded the desired 
trans-decalin 162 in 50% yield as a single diastereomer and as a single olefin 
isomer (Scheme 3.2.a). This cyclization correctly sets three contiguous 
stereocenters present in the target molecule, including two quaternary 
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centers. The remarkable selectivity of this transformation deserves further 
discussion. 
The mechanism of the MnIII-mediated oxidative radical cyclization 
has been studied, and the first step is formation of the MnIII-enolate 
(Scheme 3.2.b).13-14 When the substrate is an α-substituted β-keto ester (such 
Scheme 3.2 Successful oxidative radical cyclization and mechanistic 
rationale. 
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as 154), the formation of the MnIII enolate 163 is the rate-determining step, 
as the enolate rapidly undergoes electron transfer to form a MnII species 
and the free radical 164. Interestingly, when the substrate is an 
α-unsubstituted β-keto ester, formation of the MnIII-enolate is not the 
rate-determining step. In fact, an entirely different mechanism is operant 
with these substrates, in which the alkene acts as a nucleophile to directly 
engage the MnIII-enolate. This hypothesis is based on the observation that 
alkene concentration changes the reaction rate for intermolecular 
additions, and that tether length effects the reaction rate in intramolecular 
cyclizations.13, 15  
Oxidative radical cyclizations mediated by Mn(OAc)3 are thought to 
proceed through free-radical intermediates, as opposed to Mn-complexed 
radicals. Comparisons between atom-transfer cyclizations and oxidative 
radical cyclizations have confirmed that both methods produce the same 
stereochemistry on equivalent substrates.16 Since it is well known that 
atom-transfer radical cyclizations proceed through free-radical 
intermediates,17 it can be postulated that MnIII-mediated oxidative radical 
cyclizations also proceed through free-radical intermediates. Apparently, 
the MnII salt formed after electron transfer does not maintain an interaction 
with the substrate, instead free-radical intermediate 164 undergoes a 6-
endo cyclization onto the proximal olefin to form tertiary radical 165 
(Scheme 3.2.b & 3.2.c). The selectivity of the 6-endo cyclization is predicated 
on the presence of the vinyl methyl substituent on the nucleophilic olefin, 
as 1,2-disubstited olefins form products arising from 5-exo cyclization over 
those arising from 6-endo cyclization.18 One explanation for the observed 
regioselectivity is that the first cyclization is reversible, allowing for the 
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formation of the thermodynamic 6-endo product, which is favored due to 
the increased stability of the resultant tertiary radical 165 and the formation 
of the thermodynamically favored six-membered ring. This hypothesis has 
been put forth to explain observed regioselectivities of other radical 
cyclizations,19 but it seems unlikely in this case. For the first cyclization to 
be reversible the rate of ring-opening (165 to 164, kopen) would have to be 
faster than the second cyclization (165 to 166, kcyc2). The second cyclization 
is faster than oxidation of 165 with Cu(OAc)2 (kox) since no monocyclic 
products are observed (kcyc2 > kox). It has previously been shown that 
oxidation of alkyl radicals with Cu(OAc)2 is faster than six-membered ring-
opening reactions of related β-keto ester substrates (kox > kopen),16 meaning 
that the second cyclization is faster than the ring-opening reaction (by the 
transitive relation, if kcyc2 > kox and kox > kopen, then kcyc2 > kopen). This means 
that the first cyclization is under kinetic control rather than 
thermodynamic control in this system, ruling out the thermodynamic 
explanation predicated on the reversibility of the cyclization. Part of the 
argument is still applicable, however. The relative stability of the resultant 
radicals may have a role in the transition state. Since the secondary radical 
from a 5-exo cyclization is significantly less stable than the tertiary radical 
formed from 6-endo cyclization, the 6-endo transition state may have a 
lower energy barrier than the 5-exo transition state (Scheme 3.2.c). To argue 
that the stability of the product has an impact on a kinetically controlled 
reaction, a late transition state must be operant. In this case, a late 
transition state seems plausible since the initial radical is more stabilized 
than the resultant radical, implying that the process may be endothermic, 
or, at least, not highly exothermic. Another possible explanation for the 
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preference for 6-endo vs. 5-exo is that formation of two vicinal quaternary 
centers is sterically disfavored, bringing several substituents in close 
proximity in the transition state.  
The stereochemistry arising from the first cyclization places the 
ester substituent in the axial position and the methyl substituent in the 
equatorial position (165). There are two explanations for this empirical 
result: 1) the transition state leading to the observed stereochemistry 
minimizes unfavorable dipole interactions,16 and 2) the relative size of the 
methyl group is larger than the methyl ester. To minimize the overall dipole 
of the molecule, the two carbonyl substituents would have to point away 
from each other. In order to do this efficiently, the ester would need to 
occupy an axial position, as observed in trans-decalin 162. Furthermore, the 
methyl ester is less sterically demanding than the methyl group (A-values: 
Me = 1.74 & CO2Me = 1.2-1.3). As the six-membered ring 165 forms, the axial 
C16 substituent and the C12 methyl begin to engage in a syn-pentane 
interaction. Placing the smaller substituent in the axial position at C16 
would incur less of a steric penalty, lowering the energy of the transition 
state. It is certainly possible that both dipole minimization and steric 
interactions play a role in determining the diastereoselectivity of the 
reaction.  
The regioselectivity of the second cyclization (165 to 166) can be 
explained using the same principles outlined for the first 6-endo cyclization. 
In this case, the relative stability of the initial and terminal radicals is almost 
identical, since they are both tertiary alkyl radicals. This makes it more 
difficult to assert that the transition state is late rather than early. Since 
they are of similar energy, it can be posited that the reaction is not highly 
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exothermic, meaning that the stability of the resultant radical will influence 
the product ratio.   
To aid in the oxidative termination of the resultant radical 166, a 
CuII-carboxylate salt is added to the reaction—Cu(OAc)2 reacts 350 times 
faster with secondary radicals than Mn(OAc)3.20-21 The CuII salt interacts with 
the alkyl radical to form a CuIII intermediate 167 that can either form an 
olefin through β-hydride elimination, transfer a ligand through reductive 
elimination, or form a carbocation.22 Interestingly, only one of three 
possible olefin isomers is formed in the cyclization  of linear alcohol 154 to 
bicycle 162. Similar observations have been made on related systems.12 It 
seems likely that intramolecular complexation of the alcohol with the CuIII 
species occurs, producing an intermediate that undergoes β-hydride 
elimination from the methyl group to selectively produce the exocyclic 
methylene 162. In this instance, there are six proximal hydrogen atoms that 
are candidates for β-H elimination. The methyl group is statistically favored 
since there are three equivalent protons fit for elimination. Furthermore, 
for the methine or methylene protons to correctly align in a syn orientation 
with the C–Cu bond, the entire tricyclic ring system would have to twist 
slightly, increasing the strain energy relative to the chair–chair system 167. 
The methyl protons are free to rotate without incurring a twist motion, 
implying that there is less of an energy barrier for β-H elimination from the 
methyl group, explaining the observed selectivity for the exocyclic olefin. 
Furthermore, it is possible that several olefins are produced in the reaction, 
but are equilibrated by the solvent, AcOH, to the exocyclic olefin.   
After successful oxidative radical cyclization, the next challenge was 
to append indole onto bicyclic alcohol 162. Initial experiments were aimed 
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at converting the alcohol into a leaving group, allowing for an alkylation 
using the nucleophilic C3 of indole. Conversion to the bromide was 
unsuccessful using PBr3 and CBr4/PPh3. Mesylate formation followed by 
Finkelstein reaction was also unable to produce the desired bromide, 
though the mesylate was successfully generated. Several attempts using the 
mesylate as the electrophile were also futile.  
 An alternative strategy for indole attachment would be a Grignard 
addition into bicyclic aldehyde 169, readily derived from bicyclic alcohol 162 
through oxidation with the Dess–Martin periodinane (Scheme 3.3.a).23-24 
The product from this reaction would be a secondary alcohol, which would 
require deoxygenation prior to the proposed biomimetic carbazole 
formation en route to oridamycin A/B (see Scheme 2.1.a). Furthermore, the 
deoxygenated product was targeted because the C16 epimeric compound, 
which would be generated from a chelated radical cyclization, would readily 
lead to the natural product indosespene (30) upon deoxygenation. The 
Grignard precursor was prepared in two steps from indole,25 and 
subsequent metal–halogen exchange using EtMgBr generated the desired 
Grignard reagent 170.26 Addition into bicyclic aldehyde 169 proceeded 
smoothly to yield secondary alcohol 171 as a mixture of diastereomers 
(Scheme 3.3.a). The Barton–McCombie deoxygenation method was 
considered, as there was literature precedent for success in related natural 
products,26 but it seemed more expeditious to attempt the reduction of an 
extended iminium species instead (Scheme 3.3.b).27-28 It was anticipated that 
addition of TFA would remove the tert-butyl carbamate protecting group of 
171, increasing the electron density of the indole nitrogen and facilitating 
dehydration to form the extended iminium species 173, which could then be 
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trapped with a silane reductant to form 174. Surprisingly, the addition of 
TFA cleanly afforded the triene product 175, arising from dehydration of the 
Scheme 3.3 Successful synthesis of the pentacyclic scaffold. 
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secondary alcohol (Scheme 3.3.c). None of the deprotected material 172 was 
detected.  
 In light of the unexpected dehydration, a new strategy was adopted 
for the synthesis of oridamycin A. It was envisioned that the triene 175 could 
be induced to undergo a 6π-electrocyclization/aromatization sequence to 
generate the desired carbazole. Previous work on anominine further 
supported this strategy.26 Heating triene 175 in PhMe at 100 oC failed to 
induce electrocyclization, but increasing the temperature to 135 oC 
successfully provided the desired protected carbazole 176 (Scheme 3.3.c). 
The carbamate protecting group was successfully removed using TFA at 
45 oC to produce carbazole 177. At this stage, a one-pot procedure was 
considered to increase the efficiency of the synthesis. The three preceding 
operations seemed primed for adaptation to a telescoped protocol. To start 
the one-pot process, TFA was added to dehydrate secondary alcohol 171, 
forming triene 175 (Scheme 3.3.d). The resultant solution was condensed via 
rotary evaporation, removing both solvent and acid (TFA b.p. = 72.4 oC). After 
condensation, the crude material was dissolved in PhMe, transferred to a 
pressure tube, and heated to 135 oC to affect the desired 
6π-electrocyclization/aromatization. After completion, the solution was 
cooled to 45 oC and TFA was added to remove the tert-butyl carbamate 
protecting group, yielding carbazole 177. This three-step, one-pot 
procedure proved efficient, generating carbazole 177 in 52% yield from 
secondary alcohol 171. 
Only two operations separated carbazole 177 from oridamycin A: 
reduction of the ketone to the secondary alcohol, and saponification of the 
methyl ester to the free acid. Reduction with NaBH4 proceeded 
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uneventfully, successfully delivering hydride from the less hindered face to 
selectively produce desired secondary alcohol 178 (Scheme 3.4.a). All that 
remained was saponification of the methyl ester. Initial attempts using 
standard saponification conditions (LiOH in THF/H2O, KOH in MeOH) 
either returned starting material at low temperature, or decomposed 
starting material at elevated temperature (>100 oC). It seemed likely that 
formation of the requisite tetrahedral intermediate 179 en route to the 
desired acid was disfavored due to the sterically demanding 1,3-diaxial 
Scheme 3.4 Successful synthesis of oridamycin A using a nucleophilic 
ester dealkylation. 
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relationship between the C16 ester–hydroxide adduct 179 and the C12 
methyl group. Similar observations have been made on the structurally 
related derivatives of podocarpic acid 181, dating back to structural 
determination studies conducted in the 1930s (Scheme 3.4.b).29-31 In fact, it 
was reported that the ester was “unaffected by boiling 0.5N-alcoholic 
potassium hydroxide; hydrolysis of methyl O-methylpodocarpate with 
excess of concentrated alcoholic potash at 150o, however, afforded 
O-methylpodocarpic acid.”29 Since potash was unavailable, an alternate 
strategy was considered. If the ester could remain planar throughout the 
saponification process, then the steric requirement of the tetrahedral 
intermediate could be eliminated. It was hypothesized that a nucleophilic 
cleavage protocol would be possible, in which a nucleophile would engage 
the alkyl group on the ester in an SN2 fashion to generate the free acid 
(Scheme 3.4.a, 180). Krapcho decarboxylation conditions were employed for 
this transformation, as the Krapcho decarboxylation is thought to proceed 
through a similar mechanism, except the traditional Krapcho includes an 
anion stabilizing group such that the resultant free acid is lost as CO2. 
Pleasingly, treatment of ester 178 with LiCl in DMF at 160 oC provided 
detectable quantities of oridamycin A. It was then found that NaCN in 
DMSO at 120 oC was a more effective combination, directly providing pure 
oridamycin A in 86% yield (Scheme 3.4.c).  
In conclusion, oridamycin A was accessed in 9 steps from geranyl 
acetate in 4.7% overall yield. The sequence employs a key free-radical 
cyclization of a linear precursor to generate the trans-decalin ring system, 
correctly producing three contiguous stereocenters in a single operation. 
The carbazole was forged through a 6π-electrocyclization/aromatization 
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sequence, fusing the trans-decalin to the aromatic system. Finally, a 
difficult saponification was overcome through nucleophilic dealkylation, 
allowing the carbonyl to remain planar throughout the process. The next 
challenge was to install the hydroxymethyl substituent present in 
oridamycin B. 
 
C. Synthesis of Oridamycin B 
The difference between oridamycin A and oridamycin B is a single 
hydroxyl group. Oridamycin B harbors a hydroxymethyl substituent at C16, 
while oridamycin A contains a methyl at that position. Late-stage 
conversion of oridamycin A to oridamycin B would require a C-H oxidation, 
converting an inert C-H bond into a C-O bond. Thankfully, there is proximal 
functionality available in oridamycin A that could serve to direct a 
transition-metal mediated C-H oxidation. Specifically, it was envisioned 
that the secondary alcohol of 178/183 could serve as a directing group for 
an Ir-catalyzed C-H silylation, producing a silacycle (184/185) that could be 
oxidized using the Tamao method to produce the desired C-O bond 
(Scheme 3.5.a).32 When these conditions were employed on ester 178 or 183, 
the desired silacycles 184/185 were detected by UPLC-MS, but the reaction 
mixture was complicated by side products, and the desired product could 
not be purified and isolated. The protocol for the Ir-catalyzed C-H silylation 
involves the use of a glove box to exclude H2O and O2. Unfortunately, no 
glove box was readily available, so this strategy was abandoned. 
As an alternative, a PdII-catalyzed C-H oxidation was explored. This 
method requires the installation of a strongly Lewis basic oxime to act as a 
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directing group.33-34 O-Methyloximes are often used as directing groups for 
these transformations, but they are difficult to remove, requiring strong 
acidic conditions. With the hope of avoiding these harsh conditions, a 
method reported by Sanford was explored in which an oxime is installed 
and is converted to an O-acetyloxime in situ (Ac2O/AcOH as solvent).35 The 
O-acetyloxime serves as the directing group, and is significantly easier to 
remove than an O-methyloxime.  
Anticipating difficulties conducting the C-H oxidation in the 
presence of the Lewis basic carbazole nitrogen, the tert-butyl carbamate 
protected carbazole 176 was prepared. The three-step, one-pot protocol for 
carbazole formation was modified to a two-step, one-pot protocol by 
Scheme 3.5 Initial attempts to install the hydroxymethyl substituent 
through a directed C-H oxidation. 
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withholding TFA addition at the end of the sequence, directly yielding 
tert-butyl carbamate carbazole 176 from secondary alcohol 171 in 68% yield 
(Scheme 3.5.b). The oxime was installed without difficulty, and the resulting 
oxime 186 was treated with Pd(OAc)2 and PhI(OAc)2 in 1/1 AcOH/Ac2O at 
100 oC. The resultant material was a complex mixture of compounds, but 
the desired compound 187 could be detected by mass via UPLC. The mass 
analysis also revealed that a significant amount of deprotected carbazole 
was present, indicating that AcOH at elevated temperature was sufficient 
to cleave the tert-butyl carbamate. Furthermore, approximately equal 
amounts of oxime and O-acetyloxime were present, indicating that the 
formation of the O-acetyloxime directing group was inefficient under the 
conditions. The resulting complex mixture resisted purification, and the 
desired compound could not be isolated. To avoid complications with the 
protecting group, the C-H oxidation was attempted on the unprotected 
carbazole, but that strategy proved untenable, generating a complex 
mixture.  
To further minimize the number of possible side products, a more 
robust protecting group and a more predictable oxime were used. 
Specifically, the tosyl-protected carbazole harboring an O-methyloxime 
was synthesized (Scheme 3.6.a). Successful installation of the tosyl group 
required deprotonation with NaH and treatment with p-TsCl at 50 oC. 
Introduction of the oxime was straightforward, and the resulting 
O-methyloxime 187 was subjected to the reported C-H oxidation 
conditions.33 Pleasingly, the desired acetoxymethyl 189 was formed, 
presumably via the five-membered palladacycle 188.  
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The promising result on tosyl protected O-methyloxime 187 
prompted reexamination of the tert-butyl carbamate protected compound 
176. The tert-butyl carbamate protecting group is already present earlier in 
the synthesis, eliminating the unnecessary deprotection, re-protection, and 
Scheme 3.6.a Successful C-H oxidation on tosyl-protected model 
compound 187, b completion of oridamycin B (27). 
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deprotection sequence required for the tosyl protected series. 
Furthermore, the deprotection of the tert-butyl carbamate could be 
conducted at the same time as removal of the oxime and acetate protecting 
groups, allowing for a global deprotection protocol using aqueous acid. 
Initial C-H oxidation experiments yielded the desired product 192, but in 
relatively low yield. Lowering the temperature and increasing the reaction 
time increased the yield, presumably by decreasing the formation of 
deprotected carbazole, which likely interferes with the palladium catalyst. 
Ultimately, optimal conditions were found that yield oxidized product 192 
in 69% yield. The final remaining steps to complete oridamycin B include 
global deprotection, reduction of the ketone, and saponification of the 
ester.  
Global deprotection of O-methyloxime 192 was problematic. More 
specifically, removal of the O-methyloxime was difficult—cleavage of the 
carbamate and acetyl groups proceeded under relatively mild conditions. 
As predicted, the harsh conditions required to remove the O-methyloxime 
caused significant loss of material. After extensive experimentation, it was 
found that the desired diol 193 could be obtained through treatment of 
protected O-methyloxime 192 with a mixture of aqueous 1M HCl and 
acetone at 80 oC, which was immediately followed by treatment of the crude 
material with NaBH4 to reduce the ketone. Conversion of diol 193 into 
oridamycin B (27) ensued using the conditions optimized for oridamycin A, 
albeit in lower yield.  
 In conclusion, oridamycin B was accessed in 12 steps from geranyl 
acetate in 0.37% overall yield. The yield is lower for oridamycin B relative to 
oridamycin A because of difficulties with the last steps, including oxime 
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removal. Ultimately, however, this strategy still represents an efficient 
protocol for producing this pentacyclic natural product, accessing 
oridamycin B from common synthetic intermediate 171 in just 6 steps.  
  
81 
 
REFERENCES 
 
[1] Gonzalez, M. A., & Molina-Navarro, S., Attempted synthesis of 
spongidines by a radical cascade terminating onto a pyridine ring. J. 
Org. Chem. 2007, 72, 7462–7465. 
[2] Jenny, L., & Borschberg, H. J., Synthesis of the dolabellane diterpene 
hydrocarbon (±)-δ-araneosene. Helv. Chim. Acta 1995, 78, 715–731. 
[3] Kitagawa, Y., Itoh, A., Hashimoto, S., Yamamoto, H., & Nozaki, H., 
Total synthesis of humulene - Stereoselective approach. J. Am. Chem. 
Soc. 1977, 99, 3864–3867. 
[4] Arigoni, D., Vasella, A., Sharpless, K. B., & Jensen, H. P., Selenium 
dioxide oxidations of olefins. Trapping of the allylic seleninic acid 
intermediate as a seleninolactone. J. Am. Chem. Soc. 1973, 95, 7917–
7919. 
[5] Sharpless, K. B., & Lauer, R. F., Selenium dioxide oxidation of olefins. 
Evidence for the intermediacy of allylseleninic acids. J. Am. Chem. Soc. 
1972, 94, 7154–7155. 
[6] Warpehoski, M. A., Chabaud, B., & Sharpless, K. B., Selenium dioxide 
oxidation of endocyclic olefins. Evidence for a dissociation-
recombination pathway. J. Org. Chem. 1982, 47, 2897–2900. 
[7] Nawrat, C. C., Lewis, W., & Moody, C. J., Synthesis of amino-1,4-
benzoquinones and their use in Diels–Alder approaches to the 
aminonaphthoquinone antibiotics. J. Org. Chem. 2011, 76, 7872–7881. 
[8] Zhu, X., & Ganesan, A., Regioselective synthesis of 3-alkylindoles 
mediated by zinc triflate. J. Org. Chem. 2002, 67, 2705–2708. 
[9] Yang, D., Xu, M., & Bian, M.-Y., Chiral auxiliaries for asymmetric 
radical cyclization reactions:  Application to the enantioselective 
synthesis of (+)-triptocallol. Org. Lett. 2000, 3, 111–114. 
[10] Snider, B. B., Mohan, R., & Kates, S. A., Manganese(III)-based oxidative 
free-radical cyclization. Synthesis of (±)-podocarpic acid. J. Org. 
Chem. 1985, 50, 3659–3661. 
[11] Snider, B. B., Mohan, R., & Kates, S. A., Manganese(III)-based oxidative 
free-radical cyclizations 2. Polycyclization reactions proceeding 
through tertiary cations. Tetrahedron Lett. 1987, 28, 841–844. 
82 
 
[12] Zoretic, P. A., Fang, H. Q., & Ribeiro, A. A., Synthesis of d,l-norlabdane 
oxide and related odorants: An intramolecular radical approach. J. 
Org. Chem. 1998, 63, 4779–4785. 
[13] Snider, B. B., Patricia, J. J., & Kates, S. A., Mechanism of 
manganese(III)-based oxidation of β-keto-esters. J. Org. Chem. 1988, 
53, 2137–2143. 
[14] Snider, B. B., Manganese(III)-based oxidative free-radical 
cyclizations. Chem. Rev. 1996, 96, 339–364. 
[15] Corey, E. J., & Kang, M. C., A new and general synthesis of polycyclic 
γ-lactones by double annulation. J. Am. Chem. Soc. 1984, 106, 5384–
5385. 
[16] Curran, D. P., Morgan, T. M., Schwartz, C. E., Snider, B. B., & 
Dombroski, M. A., Cyclizations of unsaturated •CR(COX)2 radicals. 
Manganese(III) acetate oxidative cyclizations of unsaturated 
acetoacetates and atom-transfer cyclizations of unsaturated 
haloacetoacetates give the same radicals. J. Am. Chem. Soc. 1991, 113, 
6607–6617. 
[17] Curran, D. P., Chen, M. H., & Kim, D., Atom transfer cyclization 
reactions of hex-5-ynyl iodides: Synthetic and mechanistic studies. J. 
Am. Chem. Soc. 1989, 111, 6265–6276. 
[18] Kates, S. A., Dombroski, M. A., & Snider, B. B., Manganese(III)-based 
oxidative free-radical cyclization of unsaturated β-keto esters, 1,3-
diketones, and malonate diesters. J. Org. Chem. 1990, 55, 2427–2436. 
[19] Julia, M., Free-radical cyclizations. Acc. Chem. Res. 1971, 4, 386–392. 
[20] Heiba, E. I., & Dessau, R. M., Oxidation by metal salts. IX. Formation 
of cyclic ketones. J. Am. Chem. Soc. 1972, 94, 2888–2889. 
[21] Heiba, E.-A. I., & Dessau, R. M., Oxidation by metal salts. VII. 
Syntheses based on the selective oxidation of organic free radicals. J. 
Am. Chem. Soc. 1971, 93, 524–527. 
[22] Kochi, J. K., Electron-transfer mechanisms for organometallic 
intermediates in catalytic reactions. Acc. Chem. Res. 1974, 7, 351–360. 
[23] Dess, D. B., & Martin, J. C., A useful 12-I-5 triacetoxyperiodinane (the 
Dess–Martin periodinane) for the selective oxidation of primary or 
83 
 
secondary alcohols and a variety of related 12-I-5 species. J. Am. 
Chem. Soc. 1991, 113, 7277–7287. 
[24] Dess, D. B., & Martin, J. C., Readily accessible 12-I-5 oxidant for the 
conversion of primary and secondary alcohols to aldehydes and 
ketones. J. Org. Chem. 1983, 48, 4155–4156. 
[25] Watson, C. G., & Aggarwal, V. K., Asymmetric synthesis of 1-
heteroaryl-1-arylalkyl tertiary alcohols and 1-pyridyl-1-arylethanes 
by lithiation–borylation Methodology. Org. Lett. 2013, 15, 1346–1349. 
[26] Bian, M., Wang, Z., Xiong, X., Sun, Y., Matera, C., Nicolaou, K. C., & Li, 
A., Total syntheses of anominine and tubingensin A. J. Am. Chem. Soc. 
2012, 134, 8078–8081. 
[27] Bennasar, M. L., Zulaica, E., Jimenez, J. M., & Bosch, J., Studies on the 
synthesis of mavacurine-type indole alkaloids. First total synthesis of 
(±)-2,7-dihydropleiocarpamine. J. Org. Chem. 1993, 58, 7756–7767. 
[28] Mewshaw, R. E., Meagher, K. L., Zhou, P., Zhou, D., Shi, X., Scerni, R., 
Smith, D., Schechter, L. E., & Andree, T. H., Studies toward the 
discovery of the next generation of antidepressants. Part 2: 
Incorporating a 5-HT1A antagonist component into a class of 
serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 307–
310. 
[29] Sherwood, I. R., & Short, W. F., 192. Podocarpic acid. Part I. J. Chem. 
Soc. 1938, 1006–1013. 
[30] Wenkert, E., Afonso, A., Bredenberg, J. B. s., Kaneko, C., & Tahara, A., 
Synthesis of some resin acids. J. Am. Chem. Soc. 1964, 86, 2038–2043. 
[31] Wenkert, E., & Jackson, B. G., Partial degradation and reconstitution 
of podocarpic acid. A novel method of hydrolysis of highly sterically 
hindered esters. J. Am. Chem. Soc. 1958, 80, 217–219. 
[32] Simmons, E. M., & Hartwig, J. F., Catalytic functionalization of 
unactivated primary C-H bonds directed by an alcohol. Nature 2012, 
483, 70–73. 
[33] Desai, L. V., Hull, K. L., & Sanford, M. S., Palladium-catalyzed 
oxygenation of unactivated sp3 C-H bonds. J. Am. Chem. Soc. 2004, 
126, 9542–9543. 
84 
 
[34] Baldwin, J. E., Jones, R. H., Najera, C., & Yus, M., Functionalisation of 
unactivated methyl groups through cyclopalladation reactions. 
Tetrahedron 1985, 41, 699–711. 
[35] Neufeldt, S. R., & Sanford, M. S., O-Acetyl oximes as transformable 
directing groups for Pd-catalyzed C-H bond functionalization. Org. 
Lett. 2010, 12, 532–535. 
 
85 
 
Chapter 4. Progress Towards Xiamycin A 
 
Preface 
 This chapter outlines strategies used towards the trans-decalin 
associated with xiamycin A and the dimeric natural products. The approaches 
were developed through mechanistic considerations and relevant literature 
precedent, with photoredox catalysis proving to be the most promising avenue 
to date. 
 
A. Initial Efforts 
As previously outlined, xiamycin A (28) was envisioned to arise from 
the same linear precursor used to access the oridamycins. Introduction of 
a Lewis acid would produce chelated radical intermediate 194, leading to 
the formation of the C16 epimeric trans-decalin (Scheme 4.1.a, 195). The 
simplest strategy to access the desired intermediate 194 involves addition 
of a Lewis acid to the MnIII-mediated oxidative radical cyclization. There is 
literature precedent that this is a viable option. Yang and coworkers 
Scheme 4.1.a General strategy for chelated cyclization, and b precedent. 
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reported that addition of Yb(OTf)3 to a Mn(OAc)3-mediated cyclization of 
196 yielded the tricyclic compound 197 containing the desired 
stereochemistry (Scheme 4.1.b).1 The yield was low (18%), but these results 
appeared to be a promising lead for further optimization. Unfortunately, 
employing the conditions described by Yang et al. did not provide the 
desired trans-decalin 195 (Table 4.1, Entry 1). Lower temperature and longer 
reaction time failed to improve the results (Entry 2). The allylic alcohol was 
protected as the acetate to minimize potential disruptive interactions with 
the Lewis acid, but this also failed to improve the reaction (Entry 3). The 
co-oxidant Cu(OAc)2 was introduced to assist with termination of the final 
alkyl radical species, but this strategy was unsuccessful (Entries 4-9). 
Interestingly, the cyclization failed without Lewis acid if TFE was used as 
the solvent, even when all other variables were identical to the conditions 
successfully employed for the synthesis of the oridamycins (Entry 6). Using 
Table 4.1 Attempts at a chelated MnIII-mediated oxidative radical 
cyclization. 
Entry
Substrate 
(R) 
Solvent Oxidant (equiv.)
Co-oxidant 
(equiv.)
Lewis acid (equiv.) Temp ( oC) Time Result
1 H TFE Mn(OAc)3 (2.1) — Yb(OTf)3 (1.0) 0 3h decomp.
2 H TFE Mn(OAc)3 (2.1) — Yb(OTf)3 (1.0) -20 36h decomp.
3 Ac TFE Mn(OAc)3 (2.1) — Yb(OTf)3 (1.0) 0 7h complex mixture
4 H TFE Mn(OAc)3 (2.1) Cu(OAc)2 (1.0) Yb(OTf)3 (1.0) -20 36h complex mixture
5 H TFE Mn(OAc)3 (2.2) Cu(OAc)2 (1.0) Yb(OTf)3 (1.0) 0 0.3h decomp.
6 H TFE Mn(OAc)3 (2.0) Cu(OAc)2 (1.0) — 0 12h decomp.
7 H CH2Cl2 Mn(OAc)3 (2.1) Cu(OAc)2 (1.0) Yb(OTf)3 (1.0) -78 to 40 48h complex mixture
8 H THF Mn(OAc)3 (2.2) Cu(OAc)2 (1.0) MgCl2 (5.0) rt 4h decomp.
9 H CH2Cl2 Mn(OAc)3 (2.1) Cu(OAc)2 (1.0) Mg(ClO4)2 (1.0) -78 to 40 48h decomp.
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other solvents (THF, CH2Cl2) and other Lewis acids (MgCl2, Mg(ClO4)2) also 
failed to provide the desired material (Entries 7-9). Ultimately, this avenue 
was abandoned. 
 
B. Mechanistic Considerations & Alternate Strategies 
Before considering alternate strategies for chelated radical 
cyclizations, the mechanism of the chelated MnIII-mediated oxidative 
radical cyclization was examined. For a successful chelated cyclization, the 
first step would involve engagement of the Lewis acid with the β-keto ester 
to form intermediate 199 (Scheme 4.2). Next, the MnIII enolate 200 would 
arise in a process analogous to the unchelated cyclization (see Scheme 
3.2.b). The resultant enolate 200 would undergo electron transfer to 
generate the chelated radical 194 and a MnII species. As previously 
mentioned, the resultant MnII salt does not maintain an interaction with the 
Scheme 4.2 Mechanistic considerations for the chelated MnIII-mediated 
oxidative radical cyclization. 
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substrate after electron transfer.2 To produce chelated radical intermediate 
194, the Lewis acid would need to maintain coordination to the substrate 
throughout this process (199 to 194). It seems unlikely that a free radical 
intermediate would exist long enough to allow for the Lewis acid to 
intercept it prior to cyclization, requiring an intermolecular interaction to 
outcompete the intramolecular cyclization of a highly reactive 
intermediate. Generating a substrate bound to two different transition 
metal complexes while generating a highly reactive radical intermediate 
seemed like a difficult construct to engineer (Scheme 4.2, 200). A simpler 
solution was sought. 
Since the transition state with an equatorial ester and an axial methyl 
group was sought, it seemed possible that increasing the steric bulk of the 
ester substituent so that it became larger than the methyl group could 
provide the desired stereochemical arrangement. Unfortunately, even 
isopropyl esters (~1.2) have a smaller A-value than methyl groups (~1.7), 
presumably because the ester can orient the bulky alkyl substituent away 
from the ring to minimize steric interactions. Furthermore, large chiral 
auxiliaries have been used in MnIII-mediated cyclizations that produce the 
stereochemistry associated with the oridamycins (Scheme 4.3).3 These 
Scheme 4.3 Precedent indicating that increasing the steric bulk of the 
ester will not change the diastereoselectivity. 
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results suggest that ester modification would be a fruitless endeavor 
towards xiamycin A. 
 Another strategy would be to use a covalent linkage instead of a 
dative coordination to hold the two functional groups in the correct 
orientation. The most straightforward example would be acetonide 203 
(Scheme 4.4.a). In fact, this avenue was briefly explored on acetonide 205 
and 5-isoxozolone 206 (Scheme 4.4.b). Several experiments using 
MnIII-based and CeIV-based oxidants failed to produce the desired 
compound. Furthermore, this strategy required de novo synthesis of 
heterocyclic cyclization precursors, a process that abandons the original 
strategy of producing the xiamycin and oridamycin families from a common 
synthetic precursor.  
 
Scheme 4.4 Attempts at using heterocycles to obtain the desired 
stereochemistry. 
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C. Single-Electron Oxidation of Chelated Enolates 
Another strategy would be to introduce the Lewis acid as the 
counterion for enolate 207 and then perform a single-electron transfer 
(SET) oxidation to generate the chelated radical cation 208 (Scheme 4.5.a). 
For the integrity of the counterion-substrate interaction to be maintained 
throughout the process, the SET oxidant must act through an outer sphere 
process, rather than an inner sphere process. An inner sphere process 
occurs when the substrate becomes a ligand for the oxidant, as exemplified 
by the MnIII-mediated oxidation of β-keto esters (199 to 194). An outer 
sphere oxidation occurs without this requirement—the electron can move 
through space between the oxidant and the substrate.4 The outer sphere 
oxidant would not disrupt the interaction between the enolate counterion 
Scheme 4.5 Enolate SET strategy to access chelated radical cations. 
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and the substrate during oxidation, while an inner sphere oxidant would 
likely replace the counterion.  
Relevant precedent includes oxidative radical cyclizations of enolates 
using ferrocenium-based oxidants such as [Cp2Fe]PF6 (Scheme 4.5.b).5-18 
Importantly, cyclizations of β-dicarbonyl compounds such as 209 have been 
demonstrated. Importantly, there is evidence that ferrocenium salts are 
outer sphere oxidants, minimizing disruption of the enolate–counterion 
interaction.19 The majority of these cyclizations employ lithium enolates, but 
sodium, potassium, magnesium, zinc, silicon, and titanium enolates/enol 
ethers have also been cyclized with varying degrees of success.10 Lithium 
enolates were chosen for pilot studies, since they have been reported to be 
the most consistent and straightforward for a wide variety of enolate 
oxidations.20 At the outset, it was unclear if the lithium counterion would 
maintain a chelation interaction with both carbonyl substituents after SET 
oxidation. Optimism was derived from the Masamune–Roush modification 
of the Horner–Wadsworth–Emmons reaction, which employs LiCl to 
chelate β-phosphonate esters, lowering their pKa values to so that they can 
be deprotonated with an amine base.21  
Several substrates were prepared through protection of the allylic 
alcohol to prevent unwanted interactions between the allylic alcohol and 
the chelating counterions (Table 4.2). Lithium enolates were prepared using 
several different bases (LDA, n-BuLi, and LiHMDS) and in several solvents 
(THF, DME, and PhMe). In all cases, the desired trans-decalin 195 failed to 
form upon treatment with [Cp2Fe]PF6. Several reactions produced 
promising crude mixtures, but characterization of the resultant material 
was foiled because the products had the same Rf (these experiments are 
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denoted by ‘inseparable mixture,’ Entries 3-8). Other outer sphere oxidants 
were examined, including Cu(OTf)2 and Fe(phen)3(PF6)3, but these also failed 
to produce the desired bicycle 195. In one instance, trace bicycle 211 was 
detected in the crude NMR (Entry 8, yield not determined).  
Entry
Substrate 
(R) 
Solvent Oxidant (equiv.)
Co-oxidant 
(equiv.)
Base (equiv.) Temp ( oC) Time Result
1 TBS THF [Cp2Fe]PF6 (2.5) —
nBuLi (1.3)/            
i -Pr2NH (1.2)
-78 to 0 1h complex mixture
2 TBS THF [Cp2Fe]PF6 (2.5) —
nBuLi (2.1)/            
i -Pr2NH (2.2)
-78 to 0 1h complex mixture
3 TIPS DME [Cp2Fe]PF6 (2.5) —
nBuLi (1.3)/            
i -Pr2NH (1.2)
-60 to 0 25h inseparable mixture
4 TIPS DME [Cp2Fe]PF6 (2.5) — nBuLi (1.1) -65 to -40 32h inseparable mixture
5 TBS DME [Cp2Fe]PF6 (3.5) — LiHMDS (1.5) -65 to -10 27h inseparable mixture
6 TBS DME [Cp2Fe]PF6 (3.0) — LiHMDS (1.5) 0 to rt 6h inseparable mixture
7 TBS THF [Cp2Fe]PF6 (2.5) — LiHMDS (1.2) 0 2h inseparable mixture
8 TBS PhMe [Cp2Fe]PF6 (2.5) — LiHMDS (1.3) -78 to rt 20h
inseparable mixture 
(contains 211)
9 H THF [Cp2Fe]PF6 (2.5) — LiHMDS (1.1) -78 to 0 2h complex mixture
10 TBS THF [Cp2Fe]PF6 (2.5) Cu(OAc)2 (1.0) LiHMDS (1.2) 0 2.5h complex mixture
11 TBS DME [Cp2Fe]PF6 (3.5) Cu(OTf)2 (1.0) LiHMDS (1.5) -70 to 0 29h decomp.
12 TBS THF Cu(OTf)2 (2.5) — LiHMDS (1.5) -78 to rt 24h no rxn.
13 TBS THF Cu(OTf)2 (3.5) — LiHMDS (1.5) -78 to rt 48h no rxn.
14 TBS THF Fe(phen)3(PF6)3 (2.5) — LiHMDS (1.5) -78 to 0 3h decomp.
Table 4.2 Enolate SET experiments with lithium enolates. 
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Oxidations of zinc enolates were also conducted (Table 4.3). The 
enolates were formed through initial deprotonation with LiHMDS or NaH, 
followed by incubation of the resultant enolate with Zn(OTf)2 at room 
temperature. The oxidation potential of [Cp2Fe]PF6 was too low to initiate 
radical cyclization, so the stronger oxidant Fe(phen)3(PF6)3 was used (Entries 
3-10). Unfortunately, none of the desired trans-decalin 195 was formed.  
Promising precedent exists for the SET oxidation of titanium enolates 
(Scheme 4.6.a).22-24 Specifically, it is known that the radical cation formed 
from titanium enolates derived from Cp2TiCl2 dissociates relatively slowly 
Table 4.3 Enolate SET experiments with zinc enolates. A Syringe pump. 
Entry
Substrate 
(R) 
Solvent
Lewis acid / 
counterion (equiv.)
Oxidant (equiv.)
Co-oxidant 
(equiv.)
Base (equiv.) Temp ( oC) Time Result
1 H THF Zn(OTf)2 (2.0) [Cp2Fe]PF6 (2.5) — LiHMDS (1.1) -78 to rt 1h no rxn.
2 H THF Zn(OTf)2 (2.0) [Cp2Fe]PF6 (2.5)
Cu(OAc)2 
(1.0)
LiHMDS (1.1) -78 to rt 1h no rxn.
3 H THF Zn(OTf)2 (1.5) Fe(phen)3(PF6)3 (2.5) — LiHMDS (1.1) -78 to 0 0.5h no rxn.
4 TBS THF Zn(OTf)2 (1.5) Fe(phen)3(PF6)3 (2.5) — LiHMDS (1.3) -80 to -20 19h decomp.
5 TBS THF Zn(OTf)2 (1.5) Fe(phen)3(PF6)3 (2.5) — LiHMDS (1.3) -78 to rt 21h
complex 
mixture
6 TBS THF Zn(OTf)2 (1.5) Fe(phen)3(PF6)3 (2.5)
A — LiHMDS (1.3) -78 to rt 16h decomp.
7 TBS THF Zn(OTf)2 (1.4) Fe(phen)3(PF6)3 (2.5)
A — NaH (1.2) rt 4h decomp.
8 TBS DME Zn(OTf)2 (1.5) Fe(phen)3(PF6)3 (2.5) — LiHMDS (1.3) -78 to 0 7.5h decomp.
9 TBS MeCN Zn(OTf)2 (1.5) Fe(phen)3(PF6)3 (2.5) — LiHMDS (1.3) -45 to -15 2.5h no rxn.
10 TBS DME Zn(OTf)2 (1.5) Fe(phen)3(PF6)3 (2.5)
Cu(OAc)2 
(1.0)
LiHMDS (1.3) -78 to 0 7.5h decomp.
11 TBS THF Zn(OTf)2 (1.5) Ce(NH4)2(NO3)6 (2.5) — LiHMDS (1.3) -78 3h no rxn.
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(kTi-O = ~3 x 10-2 s-1 in CH2Cl2), allowing for a chelated cyclization to occur 
before radical cation decomposition.25-27 Harran and coworkers 
demonstrated the utility of titanium enolate oxidations in their work 
towards palau’amine, generating dimeric compounds 214 and 215 in good 
yield from titanium enolate 213 (Scheme 4.6.a).28 While Harran et. al. used 
(i-PrCp)2TiCl2 as the counterion and Cu(OTf)2 as the oxidant, the majority of 
studies use Cp2TiCl2 as the counterion and Fe(phen)3(PF6)3 as the oxidant 
(Scheme 4.6.b).22-27 Unfortunately, none of the conditions employed yielded 
the desired trans-decalin 195 (Table 4.4). At low temperature, starting 
Scheme 4.6 Precedent for titanium enolate SET to generate 
electrophilic radical cations. 
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material was returned (Entries 1-3), and at higher temperatures a complex 
mixture of compounds was obtained (Entry 4). Further efforts using 
Ce(NH4)2(NO3)6 and [Cp2Fe]PF6 as oxidants, and Ti(Oi-Pr)4 as the counterion 
were also unsuccessful (Entries 5-8).  
Several other attempts were made to oxidize various metal enolates 
to promote a chelated radical cyclization (Table 4.5). Entry 1 was inspired by 
a recent publication detailing the diradical character of enolates derived 
from TiCl4 (Scheme 4.7).29 Zakarian and coworkers have leveraged this 
property to trap in situ generated •CCl3 to diastereoselctively produce 221 
from oxazolidinone 218. In the present case, it was hypothesized that a 
diradical intermediate could be intramolecularly intercepted by the internal 
Table 4.4 Enolate SET experiments with titanium enolates. A Added with 
syringe pump. 
Entry
Substrate 
(R) 
Solvent
Lewis acid / 
counterion (equiv.)
Oxidant (equiv.) Base (equiv.) Temp ( oC) Time Result
1 TBS THF Cp2TiCl2 (1.1) Fe(phen)3(PF6)3 (2.5) NaH (1.1) -50 5h no rxn.
2 TBS THF Cp2TiCl2 (1.1) Fe(phen)3(PF6)3 (2.5) NaH (1.2) -20 12h mostly sm
3 TBS THF Cp2TiCl2 (1.5) Fe(phen)3(PF6)3 (2.5)
A LiHMDS (1.3) -78 to rt 4h no rxn.
4 TBS PhMe Cp2TiCl2 (1.3) Fe(phen)3(PF6)3 (2.5)
NaH (1.1) / 
K2CO3 (2.5)
0 to 85 24h
complex 
mixture
5 TBS THF Cp2TiCl2 (1.5) Ce(NH4)2(NO3)6 (2.5) LiHMDS (1.3) -78 to rt 14h
complex 
mixture 
6 Ac MeCN Cp2TiCl2 (1.2) Ce(NH4)2(NO3)6 (2.5) LiHMDS (1.1) 0 12h
decomp. 
(mostly sm)
7 TBS THF Ti(Oi -Pr)4 (1.15) Fe(phen)3(PF6)3 (2.5) NaH (1.1) -50 to -10 23h decomp.
8 TBS THF Ti(Oi -Pr)4 (1.4) [Cp2Fe]PF6 (2.5) NaH (1.4) -5 4h
inseparable 
mixture
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olefin to produce the desired bicycle 195, using TiIV as both the oxidant and 
the Lewis acid. The reaction was unsuccessful, but the concept would 
become important in future studies.  
Entry
Substrate 
(R) 
Solvent
Lewis acid / 
counterion (equiv.)
Oxidant (equiv.) Base (equiv.) Temp ( oC) Time Result
1 H CH2Cl2 — TiCl4 (1.1) i -Pr2NEt (1.1) 0 10 min decomp.
2 H AcOH — Ce(NH4)2(NO3)6 (2.5) — rt 23h decomp.
3 TBS THF — [Cp2Fe]PF6 (2.5)
EtMgBr (1.2)/ 
i -Pr2NH (1.3)
-30 to 0 6h no rxn.
4 TBS THF/HMPA — [Cp2Fe]PF6 (2.5)
EtMgBr (1.2)/ 
i -Pr2NH (1.3)
-78 to 0 5.5h mostly sm
5 Ac THF EtAlCl2 (1.1) Ce(NH4)2(NO3)6 (2.5) LiHMDS (1.1) -78 to rt 17.5h no rxn.
6 Ac PhMe Yb(OTf)3 (1.3) Fe(phen)3(PF6)3 (2.5) LiHMDS (1.2) 0 to 50 25h decomp.
Table 4.5 Other enolate SET experiments.  
Scheme 4.7 Precedent for using titanium enolates as both Lewis acids 
and oxidants to generate chelated radical cations. 
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Another avenue that was explored was oxidation of the β-hydroxy 
ester dianion 223 (Scheme 4.8.a). Adding two equivalents of base to the 
substrate could generate the dianion, and subsequent addition of a Lewis 
acid capable of chelating both functional groups would produce cyclic 
enolate intermediate 223. Oxidation could lead to radical cation 224 that 
would maintain a strong metal–substrate coordination through the alkoxy–
metal interaction, potentially leading to a chelated intermediate with a 
longer half-life. Unfortunately, experiments employing Cp2TiCl2 as the 
counterion were unsuccessful (Table 4.6, Entries 1-6). A variation of this 
Scheme 4.8 Enolate SET oxidations with β-hydroxy ester substrates. 
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strategy entails generation of an aluminum chelated radical using AlMe3, in 
which a bond metathesis occurs, releasing methane and generating the 
aluminum alkoxide 228 (Scheme 4.8.b). Subsequent addition of base could 
generate the cyclic aluminate complex 229. Several oxidants were added to 
the presumed aluminate, and none of these experiments produced the 
desired trans-decalin 226 (Entries 8-11). 
 
 
Entry
Substrate 
(R) 
Solvent
Lewis acid / 
counterion (equiv.)
Oxidant (equiv.) Base (equiv.) Temp ( oC) Time Result
1 TBS THF Cp2TiCl2 (1.2) Fe(phen)3(PF6)3 (2.5)
LiHMDS (2.1) / 
Na3PO4 (2.5)
-78 to rt 22.5h no rxn.
2 Ac THF Cp2TiCl2 (2.2) Ce(NH4)2(NO3)6 (2.5)
KHMDS (2.1) / 
K2CO3 (3.0)
-78 to rt 18h
inseparable mix. 
(mostly sm)
3 Ac THF Cp2TiCl2 (1.1) Ce(NH4)2(NO3)6 (2.5)
KHMDS (2.1) / 
K2CO3 (3.0)
-78 to -25 4.5h no rxn.
4 Ac THF Cp2TiCl2 (1.1) Cu(OTf)2 (2.5) LiHMDS (2.1) -78 to rt 20.5h
inseparable mix. 
(mostly sm)
5 TBS PhMe Cp2TiCl2 (1.2) Cu(OTf)2 (2.5)
LiHMDS (2.1) / 
K2CO3 (2.5)
-78 to rt 20h no rxn.
6 TBS THF Cp2TiCl2 (1.2) Cu(OTf)2 (2.5)
LiHMDS (2.1) / 
Na2HPO4 (2.5)
-78 to rt 15h no rxn.
7 Ac THF ClTi(Oi -Pr)3 (1.1) Ce(NH4)2(NO3)6 (2.5) LiHMDS (2.1) -78 to rt 17.5h complex mixture
8 Ac THF AlMe3 (1.1) Ce(NH4)2(NO3)6 (2.5) LiHMDS (1.1) -78 to rt 14h no rxn.
9 Ac PhMe AlMe3 (1.1) V(O)Cl3 (2.5) LiHMDS (1.1) -78 to rt 17h decomp.
10 Ac PhMe AlMe3 (1.1) V(O)Cl2(OTFE) (2.5) LiHMDS (1.1) -78 to 5 16h no rxn.
11 Ac THF AlMe3 (1.1) Ag(pic)2 (2.5) LiHMDS (1.1) -78 to rt 16.5h no rxn.
Table 4.6 Enolate SET oxidations with β-hydroxy ester substrates. 
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D. Dual-Function Vanadium Reagents: Both a Lewis Acid and an Oxidant 
Another strategy for producing the desired chelated radical was to 
use the enolate counterion as both the oxidant and the chelating metal (see 
Table 4.5, Entry 1 for first example). It seemed strange that the MnII species 
formed after electron transfer did not maintain an interaction with the 
substrate in the MnIII-mediated radical cyclization (Scheme 4.9.a, 200 to 
Scheme 4.9 Using vanadium(V) reagents as both oxidants and Lewis 
acids to generate chelated radicals. 
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194). It was hoped that a more Lewis acidic species could be found that 
would maintain a chelating interaction with the substrate after electron 
transfer. This would require an inner sphere oxidant that would form the 
enolate intermediate 199, then undergo electron transfer to form the 
desired chelated radical intermediate 207 (Scheme 4.9.a). The high energy 
radical cation intermediate 208 implicated in the enolate SET oxidation 
strategy could be avoided, and there would be fewer reagents required, 
minimizing the number of possible interacting entities. Literature 
precedent for this type of reactivity was sparse, but there are reports of 
oxo-vanadium complexes that can act as both Lewis acids and oxidants, 
undergoing electron transfer while interacting with the substrate through 
bidentate chelation (Scheme 4.9.b, 231).30-31 Furthermore, oxo-vanadium 
oxidants have been shown to generate electrophilic radicals from β-keto 
esters (234), which can be trapped with nucleophilic olefins, a process 
analogous to the desired cyclization (Scheme 4.9.c).32-33 The oxo-vanadium 
compound developed by Livinghouse was employed, which has been shown 
to be more reactive and selective than the standard alkoxy variants.34 The 
first experiment rapidly decomposed the substrate (Table 4.7, Entry 1). Upon 
consideration of the mechanism, it was clear that HCl was generated upon 
formation of the initial radical, which could promote decomposition. To 
buffer the solution, 2,6-lutidine was added, but the reaction stalled at low 
temperature, and produced a complex mixture of products at higher 
temperature (Entries 3-4). It has previously been observed that addition of 
TMSOTf or AgOTf to oxo-vanadium oxidations increases reactivity.35 There 
is no mechanistic rationale, but this observation coupled with the 
observation that base reduces reactivity has led to a mechanistic 
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hypothesis; perhaps the Brønsted or Lewis acid interacts with the 
oxo-vanadium compound at the oxygen atom, decreasing the electron 
Table 4.7 Attempts at using vanadium(V) reagents as both oxidants and 
Lewis acids to generate chelated radicals. A Added with syringe pump. 
Entry Solvent Oxidant (equiv.)
Additive 
(equiv.)
Base (equiv.) Temp ( oC) Time Result
1 CH2Cl2 V(O)Cl2(OTFE) (3.0) — — 0 2h decomp.
2 CH2Cl2 V(O)Cl2(OTFE) (3.0) — 2,6-lutidine (4.0) -78 10h
complex mixture 
(mostly sm)
3 CH2Cl2 V(O)Cl2(OTFE) (3.0) — 2,6-lutidine (4.0) -40 4h complex mixture
4 CH2Cl2 V(O)Cl2(OTFE) (2.5)
A — 2,6-lutidine (4.0) -70 to -40 23h
inseparable mixture 
(mostly sm)
5 CH2Cl2 V(O)Cl2(OTFE) (3.0)
A CuCl2 (1.2) 2,6-lutidine (4.0) -40 22h
α-chloro 239 (yield 
nd), and sm
6 CH2Cl2 V(O)Cl2(OTFE) (3.0)
A — 2,4,6-tri-t Bupyr. (4.0) -40 to rt 18h
inseparable mixture 
(mostly sm)
7 PhMe V(O)Cl2(OTFE) (3.0)
A — 2,4,6-tri-t Bupyr. (4.0) -40 to rt 18h no rxn.
8 CH2Cl2 V(O)Cl2(OTFE) (3.0)
A TMSCl (1.0) 2,4,6-tri-t Bupyr. (4.0) rt 15h inseparable mixture
9 CH2Cl2 V(O)Cl2(OTFE) (3.0) AgOTf (3.0) 2,4,6-tri-t Bupyr. (4.0) -78 to -20 5.5h no rxn.
10 CH2Cl2 V(O)Cl2(OTFE) (3.0) TMSOTf (3.0) 2,4,6-tri-t Bupyr. (4.0) -40 to -20 13h inseparable mixture
11 PhMe V(O)Cl2(OTFE) (3.0) TMSOTf (3.0) 2,4,6-tri-t Bupyr. (4.0) -78 to rt 22h inseparable mixture
12 PhMe V(O)Cl2(OTFE) (3.0) Cu(OTf)2 (3.0) 2,4,6-tri-t Bupyr. (4.0) -55 to -25 2.5h α-chloro 239 (56%)
13 PhMe V(O)Cl2(OTFE) (2.0) Cu(OTf)2 (1.0) 2,4,6-tri-t Bupyr. (4.0) -55 to -35 4.5h
α-chloro 239 (yield 
nd), and sm
14 PhMe V(O)Cl2(OTFE) (2.0)
Cu(OTf)2 (1.0)/ 
Zn(OTf)2 (1.0)
2,4,6-tri-t Bupyr. (4.0) -65 to -25 6.5h
α-chloro 239 (yield 
nd), and sm
15 PhMe V(O)Cl2(OTFE) (2.0)
AgOTf (4.0)/ 
Cu(OTf)2 (1.0)
2,4,6-tri-t Bupyr. (4.0) -60 to 50 20.5h inseparable mixture
16 PhMe V(O)Cl2(OTFE) (2.0) Cu(OAc)2 (1.0) 2,4,6-tri-t Bupyr. (4.0) -60 to -15 23h α-chloro 239, and sm
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density at vanadium and increasing reactivity in a manner analogous to 
carbonyl activation. An initial foray using TMSCl seemed to improve the 
reaction, yielding a less complex mixture of products. Unfortunately, the 
mixture still resisted purification and characterization (Entry 8). Further 
experiments with TMSOTf yielded similar results (Entries 10-11). Addition of 
AgOTf precipitated a sticky black solid and returned starting material (Entry 
9). Based on the hypothesis that protic or Lewis acids activate the 
oxo-vanadium species, several other Lewis acids were explored (Entries 
12-16). Interestingly, addition of Cu(OTf)2 yielded α-chlorinated product 239 
in 56% yield. Characterization of this material led to its retroactive 
identification in previous crude reaction mixtures (most notably in Entry 5). 
Further experiments failed to yield any of the desired trans-decalin 238.  
 
E. Atom-Transfer Cyclizations 
Difficulties encountered with the enolate SET oxidation strategy 
prompted the exploration of atom transfer cyclizations. Conceptually, 
generation of the desired chelated radical would be similar to the enolate 
SET oxidation (Scheme 4.10.a). First, the Lewis acid would engage the 
substrate to form chelated intermediate 240. Next, the initiator would 
reduce the C-Br bond to form the desired chelated radical 194. Similar to 
the enolate SET oxidation, the electron transfer would not interrupt the 
Lewis acid-substrate interaction. Promising literature precedent exists for 
chelated atom-transfer cyclizations of α-seleno β-keto esters (241) as 
reported by the Yang group (Scheme 4.10.b).36 The relevant substrate was 
prepared and subjected to the reported conditions, but no reaction 
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occurred (Table 4.8, Entry 1). The reaction was slowly allowed to warm from 
–78 oC to rt, but only starting material remained. Eventually, heating the 
reaction to 70 oC consumed the substrate, but the crude NMR revealed that 
the substrate had decomposed. The Yang group also reported a chelated 
atom-transfer cyclization of α-bromo β-keto esters,37 along with a method 
for generating the requisite brominated starting material.38 Using the 
reported conditions for α-bromination provided an intractable mixture. 
Ultimately, treatment of the sodium enolate with NBS successfully yielded 
the desired bromide. At this stage, traditional atom-transfer cyclization 
conditions were employed with the aim of replicating the MnIII-mediated 
result before attempting to introduce a chelating Lewis acid (Entries 2-5). 
Unfortunately, a brief survey was unsuccessful, yielding starting material or 
complex mixtures of products.  
Scheme 4.10 Chelated atom-transfer radical cyclization. 
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 A modification to the atom-transfer cyclization was also explored, 
entailing generation of a chelated β-hydroxy ester followed by initiation of 
the desired radical cyclization. Guindon and coworkers have extensively 
examined the effects of various Lewis acids on β-hydroxy and β-alkoxy 
esters under radical reduction conditions.39-44 They found that 
monodentate Lewis acids lead to the formation of one diastereomer, while 
bidentate Lewis acids produce the opposite diastereomer. AlMe3 is 
commonly employed as the bidentate Lewis acid for β-hydroxy ester 
substrates (such as 247), leading to excellent diastereoselectivity (Scheme 
4.11.a).43 These conditions led to the expected chelation-controlled 
reduction product 250, implying that the aluminum alkoxy effectively 
coordinates to the ester to make cyclic chelated radical 249. In the present 
case, it was anticipated that an atom-transfer cyclization could be induced 
if the reductant was omitted. Further support for this strategy comes from 
the successful allylation of aluminum chelated radicals (Scheme 4.11.b),42 and 
the successful reductive cyclization of aluminum chelated radicals 
Entry
Substrate 
(R 1, R 2)
Solvent
Lewis acid 
(equiv.)
Initiator (equiv.) Temp ( oC) Time Result
1 Ac, SePh THF Mg(ClO4)2 (1.1) Et3B (5.0) /O2 -78 to 70 48h decomp.
2 TBS, Br PhH — AIBN (0.1) 75 4h no rxn.
3 TBS, Br PhH — Bu3SnSnBu3 (0.1)/hν rt 2h inseperable mixture
4 TBS, Br THF — Bu3SnSnBu3 (0.1)/hν rt 4h complex mixture
5 H, Br PhH — Bu3SnSnBu3 (0.1)/hν rt 1.5h no rxn.
Table 4.8 Attempts at using atom-transfer to promote radical 
cyclizations (unchelated). 
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(generated from the α-seleno β-hydroxy ester, not shown).45 Confusingly, 
when α-bromo β-hydroxy ester 253 was subjected to the reported reaction 
conditions without Bu3SnH, no reaction occurred (Table 4.9, Entry 1). Even 
Table 4.9 Atom-transfer cyclizations with α-bromo β-hydroxy esters. 
Scheme 4.11 Atom-transfer cyclizations with α-bromo β-hydroxy esters. 
Entry Solvent
Lewis acid 
(equiv.)
Initiator (equiv.) Base (equiv.)
Temp 
( oC)
Time Result
1 CH2Cl2 AlMe3 (1.1) Et3B (5.0) /O2 — -78 48h
complex mixture 
(mostly sm)
2 CH2Cl2 AlMe3 (1.1) Et3B (10.0) /O2 — rt 19h
complex mixture 
(mostly sm)
3 CH2Cl2 EtAlCl2 (2.0) Et3B (5.0) /O2 — -5 20h
inseparable 
mixture
4 CH2Cl2 AlMe3 (1.1) Ru(bpy)3Cl2•6H2O (5 mol%) — -78 to rt 21h no rxn.
5 THF AlMe3 (1.2) Ru(bpy)3Cl2•6H2O (5 mol%) 2,4,6-tri-t Bupyr. (2.0) rt 3h no rxn.
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elevated temperature failed to consume the starting material (Entry 2). Use 
of the more electrophilic EtAlCl2 instead of AlMe3 induced a reaction, but 
the result was a complex mixture of products (Entry 3). Attempts using the 
photoredox catalyst Ru(bpy)3Cl2•6H2O failed to consume starting material 
(Entries 4-5).  
 
F. Investigation of a Truncated Model System 
Considering the mechanism of the atom-transfer cyclization, it 
seemed possible that the complex mixtures were a result of the many 
possible products under the conditions employed (Figure 4.1). Even a 
successful cyclization could produce a mixture of bromide diastereomers 
(255 & 256), in addition to three possible olefin isomers (257), with further 
complications arising from monocyclic products (258, 259, & 260). It 
seemed prudent to optimize the cyclization on a model system that would 
facilitate analysis. Cutting a prenyl unit out of the original substrate would 
leave allylic acetate 264 as a model system that would accurately model both 
the initiation and termination of the cyclization (Scheme 4.12). The 
substrate was synthesized starting from prenyl alcohol 261, which was 
acetylated. The allylic oxidation catalyzed by SeO2 yielded allylic alcohol 
Figure 4.1 Possible products arising from atom-transfer cyclization. 
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262, albeit in low yield (26%), presumably because the olefin is electron 
deficient due to the acetate (which is the basis for the regioselectivity when 
conducting the same reaction on geranyl acetate). Conversion to the iodide, 
and alkylation using the dianion derived from methyl 2-methyl-3-
oxobutanoate (155) yielded model allylic alcohol 263.   
Model allylic alcohol 263 was subjected to the standard 
MnIII-mediated oxidative radical cyclization conditions in an attempt to 
obtain the free-radical cyclization product as a standard (Table 4.10, Entries 
Table 4.10 Initial cyclization attempts on truncated model system 264. 
Scheme 4.12 Synthesis of a truncated model system. 
Entry
Substrate 
(R) 
Solvent Oxidant (equiv.)
Additive 
(equiv.)
Base (equiv.) Temp ( oC) Time Result
1 Ac AcOH Mn(OAc)3 (2.2) Cu(OAc)2 (1.0) — rt 7.5h complex mixture
2 H AcOH Mn(OAc)3 (2.2) Cu(OAc)2 (1.0) — rt 6.5h complex mixture
3 Ac CH2Cl2 V(O)Cl2(OTFE) (3.0) TMSOTf (3.0) 2,4,6-tri-t Bupyr. (4.5) -78 to -10 7.5h
inseparable mix. 
(mostly sm)
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1-2). Surprisingly, these reactions yielded a complex mixture of products 
that resisted characterization. Model allylic acetate 264 was also treated 
with the oxo-vanadium oxidant in the presence of TMSOTf as an activator, 
but the reaction yielded mostly starting material (Entry 3).  
The model system 265 was also used to probe the aluminum chelated 
radical cyclization strategy. Accordingly, the model α-bromo β-hydroxy 
ester 265 was prepared (Scheme 4.12, 264 to 265). When the presumed 
aluminum complex was treated with Et3B/O2, no reaction occurred (Table 
4.11, Entry 1). Using EtAlCl2 to generate the aluminum complex resulted in 
decomposition of the starting material (Entry 2). To determine if the desired 
radical was being formed, Bu3SnH was added to the reaction to see if 
reduction or reductive cyclization would occur. Interestingly, the reduction 
product 269 was formed in 41% yield, but no cyclization products were 
observed (Entry 3). This indicates that the desired radical was forming, but 
was not cyclizing. It was surprising that an intermolecular process was 
Entry Solvent
Lewis acid / 
counterion (equiv.)
Initiator 
(equiv.)
Additive (equiv.) Temp ( oC) Time Result
1 CH2Cl2 AlMe3 (3.0) Et3B (5.0)
A /O2 — -78 4h no rxn.
2 CH2Cl2 Et2AlCl (2.0) Et3B (5.0)
A /O2 — -5 4h decomp.
3 CH2Cl2 AlMe3 (3.0) Et3B (2.0)
A /O2 Bu3SnH (1.8) -40 4h 269 (41%)
4 CH2Cl2 AlMe3 (3.0) Et3B (1.0)
A /O2 Bu3SnH (1.8) 0 2h
inseparable mixture 
(approx. half sm)
5 PhMe AlMe3 (3.0)
CuI (0.2) / 1,10-
phen (0.4)
— -70 to rt 22h
inseparable mixture 
(mostly sm)
Table 4.11 Cyclization attempts on truncated model system 265. 
A Added with syringe pump. 
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outcompeting an intramolecular process. It is possible that the 
nucleophilicity of the olefin in 265 is significantly attenuated by the acetate, 
preventing cyclization onto the electrophilic radical.  
 
G. Exploration of a Truncated Model System Lacking the Allylic Acetate 
To improve the nucleophilicity of the olefin and more closely model 
the first cyclization, a second model system was devised. The only 
difference between the second model system and the first is the omission 
of the allylic acetate. Synthesis of the second model system 272 was 
relatively straightforward (Scheme 4.13). Commercial trans-2-methyl-2-
butenal (270) was reduced to yield allylic alcohol 271, which was converted 
to the iodide and coupled with the dianion derived from methyl 2-methyl-
3-oxobutanoate (155) to yield model β-keto ester 272. The bromide 273 was 
produced in the usual manner, and subsequent reduction afforded model 
α-bromo β-hydroxy ester 274. The chelated aluminum intermediate was 
generated in the usual way, and fluorinated phenols (3,5-CF3-PhOH and 
F5PhOH) were added to generate a more electrophilic aluminum species, 
Scheme 4.13 Synthesis of a truncated model system lacking the allylic 
acetate. 
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increasing the electrophilicity of the resultant radical and increasing 
reactivity. Reactions conducted in this manner failed to consume starting 
material, whether conducted at –70 oC or room temperature (Table 4.12, 
Entries 1-3). Using ultraviolet light and Bu3SnSnBu3 initiated a reaction, but 
the crude material was a complex mixture of products (Entry 4). Similarly, 
using the photoredox catalyst fac-Ir(ppy)3 consumed starting material, but 
yielded a complex mixture (Entry 5). CuI-mediated radical initiation yielded 
what appeared to be the opposite diastereomer of the starting material, 
though this has not been rigorously determined (Entry 6).  
 
H. Photoredox Catalyzed Radical Cyclization 
Although several previous experiments had employed photoredox 
catalysts, a more thorough investigation seemed warranted. Thankfully, the 
Table 4.12 Atom-transfer experiments on truncated model system 274. 
A Syringe pump. 
Entry Solvent
Lewis acid / 
counterion (equiv.)
Initiator (equiv.) Additive (equiv.)
Temp 
( oC)
Time Result
1 CH2Cl2 AlMe3 (1.1) Et3B (2.0)
A /O2 pentafluorophenol (2.2) -70 2.5h no rxn.
2 CH2Cl2 AlMe3 (1.1) Et3B (1.0)
A /O2 3,5-CF3-PhOH (2.2) -70 3h no rxn.
3 CH2Cl2 AlMe3 (1.1) Et3B (2.0)
A /O2 3,5-CF3-PhOH (2.2) rt 3h
complex mixture 
(mostly sm)
4 CH2Cl2 AlMe3 (1.1) Bu3SnSnBu3 (0.2)/ hν 3,5-CF3-PhOH (2.2) rt 4h complex mixture
5 CH2Cl2 AlMe3 (1.1) fac -Ir(ppy)3 (2.5 mol%)
3,5-CF3-PhOH (2.2) /      
p-MeOPhNPh2 (2.0)
rt 12h complex mixture
6 PhMe AlMe3 (1.1)
CuBr (10 mol%) / 
PMDA (1.0)
3,5-CF3-PhOH (2.2) / 
TBABr (0.5)
rt 22.5h
opposite 
diastereomer
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recent explosion of interest in iridium- and ruthenium-based 
photocatalysts46-49 has extended into intramolecular radical cyclizations of 
α-bromo β-dicarbonyls (Scheme 4.14a–4.14.b).50-52 Prior work has 
demonstrated that three termination modes are possible: 1) reductive 
(Scheme 4.14.a), 2) atom-transfer (Scheme 4.14.b), or 3) oxidative (Scheme 
4.14.c), depending on the substrate and conditions used. At the outset, it was 
unclear which termination pathway would prevail, but it was hoped that the 
tertiary radical would be oxidized to the cation en route to the desired 
exocyclic olefin. Initial experiments were focused on conducting 
cyclizations without the presence of a chelating Lewis acid so that other 
parameters could be optimized before attempting to reverse the 
diastereoselectivity. The first attempt utilized Ru(bpy)3(PF6)2, which did not 
have a reduction potential high enough to cleave the C-Br bond (Table 4.13, 
Scheme 4.14 Precedent for various termination modes for 
photoredox-catalyzed radical cyclizations. 
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Entry 1). Further examination of the literature revealed that tertiary 
bromides such as 273 are difficult substrates for photoredox catalysis, 
typically requiring the strongest reducing catalyst fac-Ir(ppy)3.53 
Gratifyingly, irradiation of fac-Ir(ppy)3 with blue LEDs in the presence of 
Entry Solvent Catalyst (equiv.) Base (equiv.) Time Notes 282
1 CH2Cl2 Ru(bpy)2(PF6)2 (2.5 mol%) 2,6-lutidine (1.1) 24h — 0% (no rxn.)
2 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) 2,6-lutidine (2.0) 1h — 10%
3 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) Et3N (2.0) 2h — 8%
4 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) DBU (2.0) 2h — 0%
5 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) p-MeOPhNPh2 (2.0) 2h — 0%
6 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) (p-BrPh)3N (2.0) 2h — 3%
7 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) DABCO (2.0) 2h — 10%
8 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) DABCO (2.0) 1.5h — 8%
9 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) DABCO (2.0) 1.5h after rxn, added HCl (4.0), 0.5h 17%
10 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) DABCO (2.0) 1.5h freeze-pump-thawed 3x 10%
11 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) Et3N (2.0) 1h after rxn, added HCl (4.0), 18h 17%
12 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) i -Pr2NEt (2.0) 1h after rxn, added HCl (4.0), 18h 15%
13 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) DABCO (2.0) 1h after rxn, added HCl (4.0), 18h 28%
14 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) 4-MeOpyridine (2.0) 1h after rxn, added HCl (4.0), 21h 13%
15 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) DMAP (2.0) 1h after rxn, added HCl (4.0), 21h 12%
16 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) PMDA (2.0) 1h after rxn, added HCl (4.0), 21h 7%
17 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) imidazole (2.0) 1h after rxn, added HCl (4.0), 21h 14%
18 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) piperidine (2.0) 1h after rxn, added HCl (4.0), 21h 9%
19 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) TMEDA (2.0) 1h after rxn, added HCl (4.0), 20h 11%
20 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) t -BuNH2 (2.0) 1h after rxn, added HCl (4.0), 20h 14%
21 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) (EtO)3N (2.0) 1h after rxn, added HCl (4.0), 20h 12%
22 CH2Cl2 fac -Ir(ppy)3 (2.5 mol%) 2-aminopyridine (2.0) 1h after rxn, added HCl (4.0), 20h 17%
Table 4.13 Optimization of photoredox-catalyzed radical cyclization of 
truncated model system 273 to produce lactone 282. 
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model bromide 273 yielded lactone 282 in 10% isolated yield (Entry 2). 
Several bases were surveyed, with DABCO providing the best result as 
determined analysis of the crude NMR (Entry 7, internal standard: 0.02M 
1,3,5-trimethoxybenzene in CDCl3). Before attempting further optimization, 
the mechanism of the reaction was considered (Scheme 4.15.a). First, the 
photoredox catalyst is excited by the visible light from [IrIII] to [IrIII]*. The 
excited catalyst reductively cleaves tertiary bromide 273 to yield free radical 
283, which undergoes a 6-endo cyclization to yield tertiary radical 284. 
During this process, the catalyst is oxidized from [IrIII]* to [IrIV]. The oxidized 
catalyst produces the carbocation 285 from tertiary radical 284. The 
resultant cation can form three possible olefins 286 or lactone 282. 
Alternatively, a radical chain mechanism may be operant, in which the 
initiation is the same, but tertiary radical 284 abstracts bromine from 
tertiary bromide 273 to propagate the chain. The resultant tertiary bromide 
could be readily eliminated to form 286, which could then be converted to 
lactone 282 through the action of the conjugate acid of the base. This 
mechanism seems unlikely in this case because it involves the direct 
interaction of a tertiary radical with a tertiary bromide, a highly congested 
transition state.  
The NMR of the crude product revealed several vinyl protons, 
implying that olefins 286 were forming from the reaction. The mixture of 
olefins could not be separated, so other techniques were sought to better 
determine the cyclization yield. It was anticipated that addition of HCl at 
the end of the reaction could converge the olefins 286 to lactone 282 
(Scheme 4.15.b). Re-protonation of the olefin could regenerate the cation 
285, and then allow for capture by the proximal ester to form lactone 282. 
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Indeed, addition of HCl increased the yield of lactone 282, and allowed for 
a more thorough analysis of the cyclization. A variety of bases were 
screened with the additional HCl step, and it was found that DABCO was 
optimal, yielding 28% of lactone 282 (Entry 13).  
During experiments with model bromide 273, several experiments 
were conducted towards the double cyclization (287 to 288/289, Table 4.14).  
Initial experiments on acetate protected linear precursor 287 were 
unsuccessful with both Ru(bpy)3Cl2•6H2O and fac-Ir(ppy)3 in the presence 
or absence of Lewis acid additives (Entries 1-9). When the linear alcohol 290 
was used instead of its acetate protected congener, the desired cyclization 
to bicycle 162 occurred (Table 4.15, as determined by the crude NMR, 
internal standard: 0.02M 1,3,5-trimethoxybenzene in CDCl3). Initial 
experiments probed the effect of concentration, revealing that more dilute 
reactions increased the yield of 162 (Entries 1-3). This is expected for an 
Scheme 4.15 Proposed mechanism for the photoredox-catalyzed 
cyclization of truncated model system 273. 
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intramolecular process, as increasing dilution decreases the probability of 
destructive intermolecular interactions. Next, equivalents of base were 
varied, revealing that less than one equivalent was detrimental (Entries 4-8). 
Various solvents were explored, with polar solvents retarding the reaction 
rate (Entries 10-17). The solvent appeared to have little impact on yield, so 
MeCN was chosen for future reactions as it was better able to solubilize 
photocatalyst salts. Exploration of photocatalysts revealed that 
Ru(bpy)3(PF6)2 was optimal (Entries 18 to 22). The catalyst loading was 
explored, with the hope that lower catalyst loadings would decrease the 
rate of oxidation of the alkyl radicals, decreasing the amount of premature 
oxidation (Entries 23-27). These experiments were inconclusive. 
Impressively, the reaction proceeded efficiently when 0.01 mol% of catalyst 
was  used  (Entry 27). The  yields  slowly  decreased  over  time,  presumably 
  
Table 4.14 Initial attempts at the photoredox-catalyzed cyclization of 
acetate 287. 
Entry Solvent Lewis acid (equiv.) Catalyst (equiv.) Base (equiv.) Time Result
1 MeCN — Ru(bpy)3Cl2•6H2O (5 mol%) — 0.5h complex mixture
2 MeCN — Ru(bpy)3Cl2•6H2O (5 mol%) 2,4,6-tri-t-Bupyr. (1.2) 0.5h complex mixture
3 MeCN Sc(OTf)3 (1.0) Ru(bpy)3Cl2•6H2O (5 mol%) — 1h decomp.
4 MeCN Sc(OTf)3 (0.1) Ru(bpy)3Cl2•6H2O (5 mol%) 2,4,6-tri-t-Bupyr. (2.0) 24h complex mixture
5 MeCN Yb(OTf)3 (0.1) Ru(bpy)3Cl2•6H2O (5 mol%) 2,4,6-tri-t-Bupyr. (2.0) 24h complex mixture
6 CH2Cl2 — fac -Ir(ppy)3 (2.5 mol%) 2,6-lutidine (2.0) 1h complex mixture
7 CH2Cl2 — fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 0.5h decomp.
8 CH2Cl2 — fac -Ir(ppy)3 (1.5 mol%) DABCO (2.0) 0.5h decomp.
9 CH2Cl2 — fac -Ir(ppy)3 (2.5 mol%) DABCO (2.0) 0.5h decomp.
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Entry Solvent Catalyst (equiv.) Base (equiv.) Time 162 290
1 CH2Cl2 (0.1M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 1.5h 7.4% —
2 CH2Cl2 (0.05M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 1.5h 8.1% —
3 CH2Cl2 (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 1.5h 13.7% —
4 CH2Cl2 (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (0.5) 0.5h 8.0% —
5 CH2Cl2 (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (1.0) 0.5h 12.0% —
6 CH2Cl2 (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 0.5h 11.4% —
7 CH2Cl2 (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (4.0) 0.5h 12.0% —
8 CH2Cl2 (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (8.0) 0.5h 11.6% —
9 CH2Cl2 (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 0.5h 12.0% —
10 PhMe (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 0.5h 4.9% —
11 MeCN (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 0.5h 6.5% 30.0%
12 DMF (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 0.5h 4.2% 43.0%
13 THF (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 0.5h 3.4% 23.0%
14 DMSO (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 0.5h 3.5% 43.0%
15 MeCN (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 3.5h 13.0% —
16 DMF (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 3.5h 8.4% —
17 DMSO (0.02M) fac -Ir(ppy)3 (0.5 mol%) DABCO (2.0) 3.5h 11.4% —
18 MeCN (0.02M) fac -Ir(ppy)3 (1.0 mol%) DABCO (2.0) 0.5h 8.1% —
19 MeCN (0.02M) Ir(ppy)2(dtbpy)PF6 (1.0 mol%) DABCO (2.0) 0.5h 9.9% —
20 MeCN (0.02M) Ir(dF-ppy)3 (1.0 mol%) DABCO (2.0) 0.5h 8.1% —
21 MeCN (0.02M) Ir(dF-ppy)2(dtbpy)PF6 (1.0 mol%) DABCO (2.0) 0.5h 9.9% —
22 MeCN (0.02M) Ru(bpy)3(PF6)2 (1.0 mol%) DABCO (2.0) 0.5h 11.6% —
23 MeCN (0.02M) Ru(bpy)3(PF6)2 (1.0 mol%) DABCO (2.0) 0.5h 12.6% —
24 MeCN (0.02M) Ru(bpy)3(PF6)2 (0.5 mol%) DABCO (2.0) 0.5h 11.5% —
25 MeCN (0.02M) Ru(bpy)3(PF6)2 (0.1 mol%) DABCO (2.0) 0.5h 11.4% —
26 MeCN (0.02M) Ru(bpy)3(PF6)2 (0.05 mol%) DABCO (2.0) 0.5h 7.3% —
27 MeCN (0.02M) Ru(bpy)3(PF6)2 (0.01 mol%) DABCO (2.0) 0.5h 10.4% —
Table 4.15 Photoredox-catalyzed cyclization of 290. 
117 
 
 
Table 4.16 Attempted Photoredox-catalyzed cyclization of 290 in the 
presence of copper co-oxidants (continued on next page). 
Entry Solvent
Catalyst 
(equiv.)
Additive (equiv.) Base (equiv.) Time 162 290 154
1
MeCN 
(0.02M)
fac -Ir(ppy)3 
(0.5 mol%)
CuOAc (20 mol%) DABCO (2.0) 6h — — —
2
MeCN 
(0.02M)
fac -Ir(ppy)3 
(0.5 mol%)
[(MeCN)4Cu]PF6 (20 mol%) DABCO (2.0) 6h — — —
3
MeCN 
(0.02M)
Ru(bpy)3(PF6)2 
(4.0 mol%)
Cu(OTf)2 (1.0) DABCO (2.0) 3.5h — — —
4
MeCN 
(0.02M)
Ru(bpy)3(PF6)2 
(4.0 mol%)
Cu(OAc)2 (1.0) DABCO (2.0) 3.5h — — —
5
MeCN 
(0.02M)
Ru(bpy)3(PF6)2 
(4.0 mol%)
Cu(2-ethylhexanoate)2 (1.0) DABCO (2.0) 3.5h — — —
6
MeCN 
(0.02M)
Ru(bpy)3(PF6)2 
(4.0 mol%)
CuCl2 (1.0) DABCO (2.0) 3.5h — — —
7
MeCN 
(0.02M)
Ru(bpy)3(PF6)2 
(4.0 mol%)
Cu(hfacac)2 (1.0) DABCO (2.0) 3.5h — — —
8
CH2Cl2 
(0.02M)
Ru(bpy)3(PF6)2 
(7.5 mol%)
Cu(2-ethylhexanoate)2 (1.0) DABCO (2.0) 18h — 49.0% —
9
CH2Cl2 
(0.02M)
Ru(bpy)3(PF6)2 
(7.5 mol%)
Cu(2-ethylhexanoate)2 (1.0) / 
2,2'-bpy (1.0)
DABCO (2.0) 18h — 56.0% —
10
CH2Cl2 
(0.02M)
Ru(bpy)3(PF6)2 
(7.5 mol%)
Cu(2-ethylhexanoate)2 (1.0) / 
1,10-phen (1.0)
DABCO (2.0) 18h — 53.0% —
11
CH2Cl2 
(0.02M)
Ru(bpy)3(PF6)2 
(7.5 mol%)
Cu(2-ethylhexanoate)2 (1.0) / 
terpyridine (1.0)
DABCO (2.0) 18h — — —
12
CH2Cl2 
(0.02M)
Ru(bpy)3(PF6)2 
(7.5 mol%)
Cu(2-ethylhexanoate)2 (1.0) / 
3,4,7,8-Mephen (1.0) 
DABCO (2.0) 18h — — —
13
CH2Cl2 
(0.02M)
Ru(bpy)3(PF6)2 
(2.5 mol%)
Cu(2-ethylhexanoate)2 (0.5) DABCO (2.0) 22h — 50.0% —
14
CH2Cl2 
(0.02M)
Ru(bpy)3(PF6)2 
(2.5 mol%)
Cu(2-ethylhexanoate)2 (0.2) DABCO (2.0) 22h — 53.0% —
15
CH2Cl2 
(0.02M)
Ru(bpy)3(PF6)2 
(2.5 mol%)
Cu(2-ethylhexanoate)2 (0.1) DABCO (2.0) 22h — 55.0% —
16
CH2Cl2 
(0.02M)
Ru(bpy)3(PF6)2 
(2.5 mol%)
Cu(2-ethylhexanoate)2 (0.05) DABCO (2.0) 22h — 56.0% —
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because the starting material is sensitive, and was slowly decomposing over 
time.  
Addition of CuI and CuII co-oxidants was explored in an attempt to 
improve the reaction (Table 4.16). These experiments failed to produce any 
of the desired bicycle 162 (except Entry 20, 1% yield). Instead, the copper 
salts significantly retarded the reaction, often returning large amounts of 
Table 4.16 Attempted Photoredox-catalyzed cyclization of 290 in the 
presence of copper co-oxidants. 
Entry Solvent
Catalyst 
(equiv.)
Additive (equiv.) Base (equiv.) Time 162 290 154
17
CH2Cl2 
(0.02M)
Ru(bpy)3(PF6)2 
(2.5 mol%)
Cu(2-ethylhexanoate)2 (0.01) DABCO (2.0) 22h — 45.0% —
18
MeCN/THF 
(0.012M)
Ru(bpy)3(PF6)2 
(2.5 mol%)
Cu(2-ethylhexanoate)2 (0.5) / 
2,2'-bpy (0.5)
DABCO (2.0) 20.5h — — —
19
MeCN/THF 
(0.012M)
Ru(bpy)3(PF6)2 
(2.5 mol%)
Cu(2-ethylhexanoate)2 (0.2) / 
2,2'-bpy (0.2)
DABCO (2.0) 20.5h — — 13.0%
20
MeCN/THF 
(0.012M)
Ru(bpy)3(PF6)2 
(2.5 mol%)
Cu(2-ethylhexanoate)2 (0.1) / 
2,2'-bpy (0.1)
DABCO (2.0) 20.5h 1.0% — 9.0%
21
MeCN/THF 
(0.012M)
Ru(bpy)3(PF6)2 
(2.5 mol%)
Cu(2-ethylhexanoate)2 (0.05) 
/ 2,2'-bpy (0.05)
DABCO (2.0) 20.5h — 9.0% 3.0%
22
MeCN/THF 
(0.012M)
Ru(bpy)3(PF6)2 
(2.5 mol%)
Cu(2-ethylhexanoate)2 (0.01) 
/ 2,2'-bpy (0.01)
DABCO (2.0) 20.5h — 17.0% —
23
DMF 
(0.02M)
Ru(bpy)3(PF6)2 
(1.0 mol%)
CuOAc (20 mol%) K2CO3 (1.1) 19h — — —
24
DMF 
(0.02M)
Ru(bpy)3(PF6)2 
(1.0 mol%)
CuOAc (20 mol%) 2,6-lutidine (1.1) 19h — — —
25
DMF 
(0.02M)
Ru(bpy)3(PF6)2 
(1.0 mol%)
CuOAc (20 mol%) NaH2PO4•2H2O (1.1) 19h — — —
26
DMF 
(0.02M)
Ru(bpy)3(PF6)2 
(1.0 mol%)
CuOAc (20 mol%) Na2HPO4 (1.1) 19h — — —
27
DMF 
(0.02M)
Ru(bpy)3(PF6)2 
(1.0 mol%)
CuOAc (20 mol%) NaOAc (1.1) 19h — — —
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starting 290. Interestingly, loadings as low as 1 mol% of 
Cu(2-ethylhexanoate)2 were sufficient to shut down the reaction (Entries 17 
and 22). Various ligands were explored to modulate reactivity and increase 
solubility, but to no avail.  
Ultimately, time constraints prevented further exploration of 
photoredox catalyzed radical cyclizations, but these initial results seem to 
be a promising avenue for further study. 
 
I. Retrospective Analysis  
Unfortunately, none of the strategies employed were able to produce 
isolable amounts of the desired trans-decalin associated with xiamycin A. 
In retrospect, it would have been helpful to commit more time to the 
isolation and characterization of reaction products. Specifically, more time 
could have been spent analyzing experiments labeled as ‘inseparable 
mixture,’ as they had interesting crude NMR spectra. Standard SiO2-based 
methods were consistently employed, but proved to be insufficient. 
Perhaps normal-phase HPLC techniques would have been more effective.  
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Chapter 5. Future Directions 
 
A. Future Directions for the Xiamycin Family 
 It would be worthwhile to synthesize the ‘dioridamycins’ and 
compare their biological activity to the dixiamycins (Scheme 5.1). The only 
difference would be a single epimeric stereocenter on each monomer, 
leading to a minimal difference in overall structure. It is possible that the 
biological activity could be comparable to the natural dimers.  
 To synthesize ‘dioridamycin A/B’ (291/292) the electrochemical 
dimerization developed by Baran could be employed directly on oridamycin 
A (26) to produce the unnatural N-N linked dimers.1 Baran and coworkers 
observed only one of the two possible atropisomers in their synthesis of 
dixiamycin B (39), so it is possible that only one atropisomer of 
‘dioridamycin’ would be formed under identical conditions. 
 Synthesis of ‘dioridamycin C’ (295) would require a simple 
modification to the previously reported synthesis (Scheme 5.1.b). Namely, a 
Grignard reagent could be employed that would introduce the desired 
functional handle at C6 to allow for late-stage Buchwald–Hartwig C-N cross 
coupling to produce the desired dimeric compound 295. A similar strategy 
was previously employed by Li et al in their synthesis of dixiamycin C (42).2  
 The synthesis of ‘dioridamycin D/E’ (301/302) would require more 
development (Scheme 5.1.c). Hydroboration/oxidation of 296 could 
produce the primary alcohol 297. Elimination of the secondary alcohol and 
oxidation/functionalization of the primary alcohol would generate 298. A 
Friedel–Crafts acylation could produce the desired fused carbazole 299 
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harboring a functional handle at C21. Triflation would precede a C-N cross 
coupling to form ‘dioridamycin D/E’ (301/302).  
 Future experiments could also be directed at producing xiamycin A 
(28, Scheme 5.2). Due to significant difficulties encountered when 
Scheme 5.1 Proposed syntheses of the ‘dioridamycins.’ 
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attempting to generate the chelated radical intermediate, a mechanistically 
distinct strategy was sought. Starting with common synthetic precursor 
303, methylation and transesterification could produce gem-dimethyl 304. 
The ester would be transformed into a photoactivatable substituent, such 
that upon irradiation with visible light in the presence of a photocatalyst 
substrate 304 would undergo a radical decarboxylation, followed by radical 
cyclization to produce gem-dimethyl bicycle 305.3-4 The carbazole 306 
would be produced in the usual manner, and a C-H oxidation would 
produce the desired oxidized product through selective engagement of the 
equatorial methyl to produce 307. Further manipulations would lead to 
xiamycin A (28). 
 
B. Future Directions for Organic Chemistry 
 The current culture surrounding organic chemistry seems to favor 
applied research over basic research. Certainly, many great advances have 
Scheme 5.2 Alternate synthetic strategy for xiamycin A (28). 
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come from applying synthetic organic chemistry to myriad other fields, 
including biology, materials science, medicinal chemistry, and inorganic 
chemistry. That said, it seems as though excitement for basic research on 
organic chemistry has diminished, with proclamations that the era of 
“molecules” is over.5 There is a push to reduce funding for classic organic 
chemistry, but findings in basic research are the fuel for translational 
research—applications of organic chemistry require a strong foundation of 
basic understanding. That is not to say that all funding should be focused 
on basic research rather than translational research. Both areas must push 
forward simultaneously. 
 A stronger emphasis on physical organic chemistry and mechanistic 
understanding is necessary to advance the field. The principles behind 
chemical reactivity must be honed in order to rationally construct complex 
molecules. Otherwise we are groping in the dark. Funding for basic research 
in organic chemistry can be discontinued when every reaction reliably 
produces the desired product.   
 Another promising future direction for organic chemistry is the 
blending of computational and organic chemistry. This collaboration could 
lead to a deeper understanding of the complex interactions at play in 
organic chemistry, aiding in the design and development of complex 
molecules. Furthermore, once a more robust understanding of chemical 
interactions is achieved, computational resources could be directed at 
predicting the outcomes of reactions, which would significantly accelerate 
research progress in organic chemistry and related fields.  
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 Finally, it seems apparent that modularity will play an increasingly 
important role as organic chemistry matures. Nature has repeatedly 
demonstrated the power of modularity through DNA, proteins, and 
oligosaccharides. Presumably, the prevalence of cross coupling in drug 
discovery is due to its modular nature, allowing for high variability within a 
synthetic route. Modular methods are needed that produce a wider range 
of chemical motifs to battle the overwhelming tendency to produce flat, 
sp2-rich compounds. The field must expand the repertoire of ‘click 
chemistry’ to include more methods that generate chiral centers, expanding 
the range of readily accessible chemical space.6  
 Another potential application of modularity could be in catalyst 
design. A catalyst domain that specifically binds to a particular substrate 
could be generated, and then various reactive functional units could be 
attached in a modular fashion to the binding domain. In this way, a target 
substrate could be selectively modified at various positions using catalysts 
readily synthesized from a common binding domain precursor.  
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Appendix I. Experimental Details and Tabulated Data 
 
General Information. All commercial reagents (Aldrich, Alfa-Aesar, Acros 
Organics, Fluka) were used without further purification. All solvents were 
reagent or HPLC grade (Fisher). Anhydrous solvents were purchased from 
Sigma-Aldrich and were used without further purification. All reactions 
were carried out under an argon atmosphere unless otherwise noted. 
Analytical thin-layer chromatography (TLC) was performed using EMD 
Millipore silica gel 60 F254 plates (250 m thickness) and visualized by UV 
fluorescence quenching and KMnO4 staining. Preparative thin-layer 
chromatography (PTLC) separations were performed with EMD Millipore 
silica gel 60 F254 plates (1000 m or 500 m thickness). Flash column 
chromatography was performed using Silicycle silica gel 60 (40-63 µm). 
Yields refer to chromatographically and spectroscopically pure compounds. 
Infrared measurements were performed on a JASCO FT/IR 6100 
spectrometer. 1H NMR and 13C NMR spectra were recorded on a Bruker 
Avance DRX-600 MHz at ambient temperature unless otherwise stated. 
Chemical shifts are reported in parts per million relative to residual solvent 
CDCl3 (1H, 7.26 ppm, 13C, 77.16 ppm) or CD3OD (1H, 3.31 ppm, 13C, 49.00 ppm). 
Multiplicities are reported as follows: s = singlet, d = doublet, dd = doublet 
of doublets, t = triplet, td = triplet of doublets, tt = triplet of triplets, m = 
multiplet, q = quartet, app. = apparent, br. s = broad singlet. Diastereomeric 
ratio (dr) was determined by 1H NMR analysis. High-resolution mass 
spectral analyses were performed by the MSKCC core facility staff.  
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156 
 
 Allylic Alcohol 156. SeO2 (15.5 g, 140 mmol, 0.7 equiv.) was added to a 
solution of geranyl acetate (157, 39.2 g, 200 mmol, 1.0 equiv.) in anhydrous 
EtOH (500 mL) and was heated under a reflux condenser (oil bath = 105 oC) 
for 24 h. After cooling to room temperature, the solution was filtered 
through a celite pad and condensed. The resultant orange oil was dissolved 
in EtOH (100 mL) and Et2O (360 mL) and cooled to 0 oC. Next, solid NaBH4 
(7.6 g, 200 mmol, 1.0 equiv.) was added in three equal portions and the 
solution was allowed to stir for 1 h at 0 oC. More NaBH4 (3.0g, 79 mmol, 
0.39 equiv.) was added, and the solution was allowed to stir 3 h at 0 oC. Upon 
completion, ice cold H2O (300 mL) was slowly added to quench the reaction, 
which was allowed to slowly warm to room temperature and was stirred 
overnight. Saturated aq. NaHCO3 was added, the layers were separated, and 
the aqueous layer was extracted with Et2O (3 x 100 mL). The combined 
organic layers were washed with H2O (2 x 100 mL) and brine (1 x 100 mL), 
dried over MgSO4, filtered, and condensed to yield a yellow oil that was 
distilled (1.0 mbar, product in fraction collected between oil bath 
temperatures 175 oC  205 oC) to yield the allylic alcohol 156 as a pale-yellow 
oil (23.3 g, 55 % yield). 
 
 156: The spectroscopic data matched the literature1; 1H NMR 
(600 MHz, CDCl3) δ 5.38 – 5.26 (m, 2H), 4.56 (d, J = 7.1 Hz, 2H), 3.96 (s, 2H), 
2.18 – 2.11 (m, 2H), 2.09 – 2.04 (m, 2H), 2.03 (s, 3H), 1.68 (s, 2H), 1.64 (s, 3H); 
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13C NMR (150 MHz, CDCl3) δ 171.3, 141.8, 135.4, 125.3, 118.7, 68.9, 61.5, 39.2, 25.8, 
21.1, 16.5, 13.8.  
 
 
158 
 
 Allylic Bromide 158. A solution of allylic alcohol 156 (9.88 g, 46.6 mmol, 
1.0 equiv.) in anhydrous THF (150 mL) was cooled to -40 oC in a dry 
ice/acetone bath. MsCl (4.7 mL, 60.6 mmol, 1.3 equiv.) was added in one 
portion, followed by dropwise addition of Et3N (12.9 mL, 93.2 mmol, 
2.0 equiv.) and the contents were allowed to slowly warm to -20 oC over the 
course of 1 h. Next, a solution of LiBr (16.2g, 186.4 mmol, 4.0 equiv.) in THF 
(50 mL) was slowly added and the solution was slowly allowed to warm to 
0 oC over the course of 1.5 h. After stirring at 0 oC for 1 h, the solution was 
quenched with H2O (100 mL), the aqueous was extracted with Et2O (3 x 
100 mL), the combined organics were washed with sat. aq. NaHCO3 (1 x 
100 mL), brine (1 x 100 mL), dried over MgSO4, filtered, and condensed to 
yield pure allylic bromide 158 as an orange-yellow oil (11.52 g, 90% yield). 
 
 158: Spectroscopic data was in agreement with the literature2; 1H 
NMR (600 MHz, CDCl3) δ 5.55 (t, J = 7.1 Hz, 1H), 5.32 (tq, J = 7.1, 1.3 Hz, 1H), 
4.57 (d, J = 7.1 Hz, 2H), 3.95 (s, 2H), 2.15 (q, J = 7.3 Hz, 2H), 2.07 (t, J = 7.8 Hz, 
2H), 2.04 (s, 3H), 1.74 (s, 3H), 1.69 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 171.2, 
141.4, 132.6, 130.5, 119.0, 61.4, 41.7, 38.7, 26.5, 21.2, 16.5, 14.8. 
 
135 
 
 
155 
 
Methyl 2-Methyl-3-oxobutanoate 155. Methyl acetoacetate (54 mL, 
500 mmol, 1.0 equiv.) and iodomethane (31 mL, 500 mmol, 1.0 equiv.) were 
cooled to 0 oC. Then K2CO3 (104 g, 750 mmol, 1.5 equiv.) was added in four 
equal portions over the course of 30 min. The reaction was vigorously 
stirred for 18 h (vigorous stirring is vital!) and allowed to slowly reach room 
temperature. Then, the contents were diluted with Et2O (~150 mL), filtered, 
the precipitate was washed with Et2O (6 x 100 mL), then the filtrate was 
condensed and distilled (1.0 mbar, 44 oC vapor temperature) to yield methyl 
2-methyl-3-oxobutanoate 155 as a clear oil (54.3 g, 84% yield).  
 
155: Spectroscopic data was in agreement with the literature3; 1H 
NMR (600 MHz, CDCl3) δ 3.74 (s, 3H), 3.52 (q, J = 7.2 Hz, 1H), 2.23 (s, 3H), 1.35 
(d, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 203.7, 171.1, 53.6, 52.6, 28.6, 
12.9. 
 
 
154 
 
 Linear Alcohol 154. NaH (60 wt%/mineral oil, 9.3 g, 234 mmol, 
5.0 equiv.) was added to a flame-dried flask, followed by the addition of 
anhydrous THF (540 mL) and HMPA (15 mL) and the solution was cooled to 
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0 oC. Next, neat 155 (30.3 g, 234 mmol, 5.0 equiv.) was added slowly, causing 
the gas evolution and the grey suspension to thicken. The solution was 
stirred at 0 oC for 30 min. A solution of n-BuLi (2.37M in hexanes, 98 mL, 
234 mmol, 5.0 equiv.) was added dropwise at 0 oC, and the suspension 
became soluble and turned orange. Crude allylic bromide 158 (12.8 g, 
46.7 mmol, 1.0 equiv.) in THF (50 mL) was then added rapidly in one portion. 
The reaction was allowed to slowly warm to room temperature and was 
stirred for 16 h. Upon completion, the reaction was quenched with sat. aq. 
NH4Cl (300 mL), the aqueous layer was extracted with CH2Cl2 (3 x 150 mL), 
dried over MgSO4, filtered, and condensed. The resultant orange oil was 
purified via flash column chromatography (silica gel, gradient of 
hexanes/EtOAc 20/3  4/1  3/1  20/7) to yield linear alcohol 154 as a 
pale orange oil (10.73 g, 82% yield). 
 
 154: Spectroscopic data was in agreement with the literature4; 1H 
NMR (600 MHz, CDCl3) δ 5.38 – 5.26 (m, 2H), 4.56 (d, J = 7.1 Hz, 2H), 3.96 (s, 
2H), 2.18 – 2.11 (m, 2H), 2.09 – 2.04 (m, 2H), 2.03 (s, 3H), 1.68 (s, 2H), 1.64 (s, 
3H); 13C NMR (150 MHz, CDCl3) δ 205.6, 171.2, 139.3, 133.7, 124.7, 123.8, 59.5, 
52.8, 52.5, 40.1, 39.4, 33.2, 26.2, 16.3, 16.2, 12.9.  
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159 
 
 Linear Indole 159. Linear alcohol 154 (1.35 g, 4.79 mmol, 1.0 equiv.) was 
dissolved in 48 mL Et2O and cooled to 0 oC. PBr3 (226 µL, 2.39 mmol, 
0.5 equiv.) was added and the solution was allowed to stir at 0 oC for 25 min. 
Upon completion, the reaction was quenched with ice water, followed by 
cold sat. aqueous NaHCO3 (0 oC). The aqueous layer was extracted 2x with 
EtOAc, and the combined organic layers were washed with sat. aqueous 
NaHCO3, brine, dried over MgSO4, filtered, and condensed. The resultant 
material was used directly in the next step without further purification. A 
suspension of Zn(OTf)2 (2.1 g, 5.75 mmol, 1.2 equiv.), TBAI (1.77 g, 4.79 mmol, 
1.0 equiv.), indole (1.12 g, 9.58 mmol, 2.0 equiv.), and i-Pr2NEt (1.8 mL, 
10.54 mmol, 2.2 equiv.) in 28 mL of PhMe was created, to which crude 
bromide 158 was added as a solution in PhMe. The resultant suspension was 
stirred at room temperature for 1 h, and was quenched with sat. aqueous 
NH4Cl. The aqueous layer was extracted 3x with EtOAc, and the combined 
organic layers were washed with H2O, dried over MgSO4, filtered, and 
condensed. The resultant material was purified via flash column 
chromatography (silica gel, 20% Et2O/hexanes) to produce linear indole 159 
as a yellow oil (1.28 g, 70% yield). 
 
159: Rf = 0.27 (silica gel, 20% acetone/hexanes); IR (film): max 3404, 
2984, 2912, 1739, 1710, 1454, 1433, 1336, 1203, 1089, 740 cm-1; 1H NMR 
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(600 MHz, CDCl3) δ 8.05 (s, 1H), 7.59 (d, J = 7.7 Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 
7.21 – 7.16 (m, 1H), 7.13 – 7.06 (m, 1H), 6.97 – 6.90 (m, 1H), 5.45 (t, J = 7.1 Hz, 
1H), 5.13 (d, J = 6.7 Hz, 1H), 3.72 (s, 3H), 3.52 (q, J = 7.2 Hz, 1H), 3.47 (d, J = 
7.2 Hz, 2H), 2.66 – 2.50 (m, 2H), 2.24 (t, J = 7.7 Hz, 2H), 2.13 (q, J = 7.2 Hz, 2H), 
2.10 – 2.05 (m, 2H), 1.75 (s, 3H), 1.59 (s, 3H), 1.32 (d, J = 7.2 Hz, 4H); 13C NMR 
(150 MHz, CDCl3) δ 205.7, 171.3, 136.6, 135.4, 133.5, 127.6, 125.1, 123.3, 122.0, 
121.4, 119.2, 119.1, 116.2, 111.2, 52.8, 52.6, 40.3, 39.6, 33.4, 26.5, 24.1, 16.3, 16.1, 
13.0; HRMS (ESI, m/z) calcd for C24H32NO3 [M+H]+ 382.2382, found 382.2367. 
 
 
160 
 
 Linear Tosyl-Indole 160. A suspension of NaH (60% dispersion in 
mineral oil, 52 mg, 1.31 mmol, 1.0 equiv.) in 13 mL THF was prepared at room 
temperature, and subsequently cooled to 0 oC. A solution of linear indole 
159 (500 mg, 1.31 mmol, 1.0 equiv.) in THF was added and stirred for 20 min, 
followed by slow addition of n-BuLi (2.04M/hexanes, 640 µL, 1.31 mmol, 
1.0 equiv.). The solution was stirred for an additional 20 min at 0 oC, and 
p-TsCl (274 mg, 1.44 mmol, 1.1 equiv.) was added. The reaction was stirred at 
for 1 h at 0 oC, and was quenched with sat. aqueous NH4Cl. The aqueous 
layer was extracted 3x with CH2Cl2, and the combined organic layers were 
dried over MgSO4, filtered, and condensed. The resultant material was 
purified via flash column chromatography (silica gel, 5% acetone, 45% 
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PhMe, 50% hexanes) to produce linear tosyl-indole 160 as a yellow oil (375 
mg, 53% yield). 
160: Rf = 0.28 (silica gel, 20% acetone/hexanes); IR (film): max 3431, 
2928, 1716, 1446, 1368, 1173, 1120, 973, 744, 670, 578 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 7.96 (d, J = 8.3 Hz, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 7.6 Hz, 1H), 
7.32 – 7.28 (m, 1H), 7.27 – 7.26 (m, 1H), 7.23 – 7.18 (m, 3H), 5.35 (t, J = 7.1 Hz, 
1H), 5.12 (t, J = 6.9 Hz, 1H), 3.72 (s, 3H), 3.54 (q, J = 7.2 Hz, 1H), 3.34 (d, J = 
7.0 Hz, 2H), 2.69 – 2.52 (m, 2H), 2.33 (s, 3H), 2.25 (t, J = 7.6 Hz, 2H), 2.12 (q, J = 
7.2 Hz, 2H), 2.09 – 2.03 (m, 2H), 1.71 (s, 3H), 1.60 (s, 3H), 1.33 (d, J = 7.2 Hz, 3H); 
13C NMR (150 MHz, CDCl3) δ 205.7, 171.2, 144.8, 137.3, 135.6, 135.5, 133.7, 131.2, 
129.9, 126.9, 124.9, 124.7, 123.1, 122.9, 122.8, 121.0, 119.7, 113.9, 52.8, 52.6, 40.3, 
39.6, 33.4, 26.6, 24.0, 21.7, 16.4, 16.3, 13.0; HRMS (ESI, m/z) calcd for 
C31H37NO5NaS [M+Na]+ 558.2290, found 558.2277. 
 
 
162 
 
Bicyclic Alcohol 162. Linear alcohol 154 (2.82 g, 10.0 mmol, 1.0 equiv.)  
was dissolved in PhMe (~100 mL) and trace water was removed via 
azeotropic distillation, then it was dissolved in acetic acid (110 mL) and 
degassed with two freeze-pump-thaw cycles (Note: as has been previously 
noted for related transformations, it was vital to thoroughly degass the 
solution prior to cyclization to obtain reasonable yields).5 Next, 
Mn(OAc)3•2H2O (5.9 g, 22 mmol, 2.2 equiv.) and Cu(OAc)2•H2O (2.0 g, 
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10 mmol, 1.0 equiv.) were added simultaneously, and the dark brown 
suspension was stirred at room temperature under an Argon atmosphere 
for 16 h. The suspension was condensed, then taken up in EtOAc (~100 mL), 
to which H2O (~100 mL) and sat. NaHSO3 (~100 mL) were added. The phases 
were separated and the aqueous layer was extracted with EtOAc (2 x 50 mL). 
The combined organic layers were washed brine (2 x 50 mL), then dried over 
Na2SO4, filtered, and condensed. The orange oil was purified via flash 
column chromatography (silica gel, hexanes/Et2O 3/7) to yield bicyclic 
alcohol 162 as a crystalline white solid (1.41 g, 50% yield).  
 
162: Rf = 0.67 (silica gel, Et2O); IR (film): max 3444, 2951, 1711, 1457, 1223, 
1024, 891 cm-1; 1H NMR (600 MHz, CDCl3) δ 5.04 (s, 1H), 4.73 (s, 1H), 3.85 (d, 
J = 6.7 Hz, 2H), 3.66 (s, 3H), 2.95 (td, J = 14.8, 6.3 Hz, 1H), 2.52 – 2.43 (m, 2H), 
2.09 (ddd, J = 13.3, 6.4, 2.7 Hz, 1H), 2.03 – 1.91 (m, 4H), 1.67 (td, J = 14.1, 4.3 Hz, 
1H), 1.63 – 1.54 (m, 1H), 1.43 (d, J = 5.8 Hz, 1H), 1.37 (s, 3H), 0.85 (s, 3H); 13C NMR 
(150 MHz, CDCl3) δ 208.2, 173.9, 146.1, 107.9, 58.9, 57.6, 57.3, 52.3, 39.1, 38.8, 
37.8, 37.1, 26.0, 21.4, 13.4; HRMS (ESI, m/z) calcd for C16H24O4Na [M+Na]+ 
303.1572, found 303.1572. 
 
 
A1 
 
 Mesylate A1. Bicyclic alcohol 162 (26 mg, 92 µmol, 1.0 equiv.) was 
dissolved in 1 mL CH2Cl2 and cooled to -78 oC. Et3N (25 µL, 184 µmol, 
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2.0 equiv.) was added and the solution was stirred for 10 min. MsCl (10 µL, 
120 µmol, 1.3 equiv.) was added, and the solution was removed from the cold 
bath and stirred for 25 min before being quenched with sat. aqueous 
NaHCO3. The solution was further diluted with Et2O and H2O, the aqueous 
layer was extracted 3x with Et2O, and the combined organic layers were 
washed with sat. aqueous NaHCO3, 2x with H2O, 2x with sat. aqueous NH4Cl, 
and brine, dried over MgSO4, filtered, and condensed. The resultant 
material was used (and characterized) without further purification, yielding 
mesylate A1 as a yellow oil (28 mg, 85% yield).  
 
A1: Rf = 0.31 (silica gel, 40% ethyl acetate/hexanes); IR (film): max 3350, 
2939, 1712, 1354, 1225, 1173, 951, 733 cm-1; 1H NMR (600 MHz, CDCl3) δ 5.01 (s, 
1H), 4.70 (s, 1H), 4.47 (dd, J = 10.2, 4.1 Hz, 1H), 4.40 (dd, J = 10.2, 8.3 Hz, 1H), 
3.66 (s, 3H), 3.00 (s, 3H), 2.95 (td, J = 14.8, 6.2 Hz, 1H), 2.54 – 2.45 (m, 2H), 2.16 
(dd, J = 8.3, 4.0 Hz, 1H), 2.11 (ddd, J = 13.3, 6.2, 2.7 Hz, 1H), 2.04 – 1.88 (m, 3H), 
1.71 (td, J = 14.1, 4.6 Hz, 1H), 1.61 (dd, J = 10.5, 4.7 Hz, 1H), 1.37 (s, 3H), 0.89 (s, 
3H); 13C NMR (150 MHz, CDCl3) δ 207.6, 173.6, 144.1, 109.2, 77.4, 77.2, 77.0, 65.9, 
57.6, 57.0, 53.7, 52.3, 39.3, 38.7, 37.8, 37.4, 36.9, 25.7, 21.4, 13.3; HRMS (ESI, 
m/z) calcd for C17H27O6S [M+H]+ 359.1528, found 359.1528. 
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169 
 
Bicyclic Aldehyde 169. Bicyclic alcohol 162 (1.31 g, 4.7 mmol, 1.0 equiv.) 
was dissolved in anhydrous CH2Cl2 (50 mL) and cooled to 0 oC. Dess–Martin 
periodinane6-7 (3.97 g, 9.4 mmol, 2.0 equiv.) was added and the cloudy white 
suspension was stirred at 0 oC for 30 min. The reaction was quenched with 
1:1 sat. aqueous NaHCO3: sat. aqueous Na2S2O3 (~50 mL) at 0 oC, then 
removed from the ice bath and allowed to stir at room temperature until 
both layers were transparent. The aqueous layer was extracted with CH2Cl2 
(3 x 25 mL), and the combined organic layers were washed with 1:1 sat. 
aqueous NaHCO3: sat. aqueous Na2S2O3 (1 x 25 mL), and brine (1 x 25 mL), 
then dried over MgSO4, filtered, and condensed. The resultant yellow oil 
was purified via flash column chromatography (silica gel, hexanes/acetone 
85/15) to yield bicyclic aldehyde 169 as a crystalline white solid (0.95 g, 73% 
yield).  
 
169: Rf = 0.48 (silica gel, hexanes/Et2O 1/1); IR (film): max 2953, 1717, 
1457, 1223, 1143, 1097, 896 cm-1; 1H NMR (600 MHz, CDCl3) δ 9.88 (d, J = 4.0 Hz, 
1H), 5.03 (s, 1H), 4.59 (s, 1H), 3.69 (s, 3H), 2.98 (td, J = 14.9, 6.1 Hz, 1H), 2.53 – 
2.48 (m, 2H), 2.45 (ddd, J = 14.8, 4.5, 2.7 Hz, 1H), 2.07 – 1.93 (m, 3H), 1.62 – 1.55 
(m, 2H), 1.49 (dd, J = 11.7, 3.2 Hz, 1H), 1.38 (s, 3H), 1.21 (s, 3H); 13C NMR (150 MHz, 
CDCl3) δ 207.5, 203.2, 173.6, 143.1, 110.9, 66.1, 57.6, 56.4, 52.4, 38.9, 38.7, 36.9, 
36.7, 25.2, 21.4, 13.9; HRMS (ESI, m/z) calcd for C16H23O4 [M+H]+ 279.1596, 
found 279.1583. 
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A2 
 
Tert-butyl 3-iodoindole-1-carboxylate A2. KOH (2.39 g, 42.7 mmol, 
2.5 equiv.) was added to a solution of indole (2 g, 17.1 mmol, 1.0 equiv.) in 
anhydrous DMF (35 mL) at room temperature under air. A solution of I2 
(4.38 g, 17.2 mmol, 1.0 equiv.) in anhydrous DMF (5 mL) was added and the 
resultant solution was stirred at room temperature for 50 min. Upon 
completion, the solution was poured into ice water (400 mL), the precipitate 
was collected via filtration, washed with H2O (~30 mL), and dried via 
azeotropic distillation with PhMe. The resultant material was immediately 
used in the next step due to its instability. The resultant beige powder was 
dissolved in anhydrous CH2Cl2 (90 mL) at room temperature. Et3N (7.2 mL, 
51.3 mmol, 3.0 equiv.) was added and the solution was cooled to 0 oC. Then, 
Boc2O (7.9 mL, 34.2 mmol, 2.0 equiv.) was added, followed by a catalytic 
amount of DMAP (~ 10 mg). The solution was removed from the ice bath and 
stirred at room temperature overnight (16 h). The reaction was quenched 
with H2O (~150 mL), the aqueous layer was extracted with CH2Cl2 (3 x 75 mL), 
the combined organic layers were washed with H2O (1 x 100 mL), brine (1 x 
100 mL), dried over MgSO4, filtered, and condensed. The crude material was 
purified via flash column chromatography (silica gel, hexanes/EtOAc 19/1) 
to yield tert-butyl 3-iodoindole-1-carboxylate A2 as a dark brown oil (5.27 g, 
90% yield over two steps).  
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A2: Spectroscopic data was in agreement with the literature8; 1H NMR 
(600 MHz, CDCl3) δ 8.15 (d, J = 6.4 Hz, 1H), 7.75 (s, 1H), 7.42 (d, J = 8.0 Hz, 1H), 
7.39 (t, J = 7.8 Hz, 1H), 7.33 (t, J = 7.3 Hz, 1H), 1.69 (s, 9H); 13C NMR (150 MHz, 
CDCl3) δ 148.8, 134.9, 132.2, 130.2, 125.4, 123.4, 121.59, 115.2, 84.38, 65.6, 28.3. 
 
 
171 
 
Secondary Alcohol 171. Trace water was removed from tert-butyl 3-
iodoindole-1-carboxylate A2 (5.87 g, 17.1 mmol, 5.0 equiv.) via azeotropic 
distillation with PhMe. Then, it was dissolved in anhydrous THF (90 mL) and 
cooled to 0 oC. A solution of EtMgBr (3.0 M in Et2O, 5.6 mL, 16.9 mmol, 
4.95 equiv.) was added dropwise. The solution was stirred at 0 oC for 20 min, 
then it was removed from the ice bath and stirred at room temperature for 
35 min. During this time, a solution of aldehyde 169 (0.95 g, 3.42 mmol, 
1.0 equiv.) was prepared as follows: Trace water was removed from aldehyde 
169 via azeotropic distillation with PhMe. Then it was dissolved in THF 
(60 mL) and cooled to 0 oC. The solution of tert-butyl 3-iodoindole-1-
carboxylate A1 and EtMgBr was re-cooled to 0 oC, then cannulated dropwise 
into the solution containing aldehyde 169 over the course of 15 min at 0 oC. 
The resulting solution was allowed to stir at 0 oC for 30 min before being 
quenched with sat. NH4Cl (~100 mL). The aqueous layer was extracted with 
EtOAc (3 x 75 mL), and the combined organic layers were dried over MgSO4, 
filtered, and condensed. The orange-yellow oil was purified via flash column 
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chromatography (silica gel, hexanes/acetone 4/1) to yield secondary 
alcohol 171 as a pale-yellow powder (1.68 g, 99% yield). The diastereomers 
were not separated and were characterized together (approximate dr = 4:1). 
 
171: Rf = 0.45 (silica gel, hexanes/Et2O 1/1); IR (film): max 3535, 2982, 
2951, 1711, 1454, 1367, 1252, 1223, 1155, 735 cm-1; 1H NMR (600 MHz, CDCl3): 
Selected Peaks, Major Diastereomer δ 7.53 (s, 1H), 7.49 (d, J = 7.8 Hz, 1H), 5.51 
(t, J = 3.7 Hz, 1H), 5.28 (s, 1H), 5.06 (s, 1H), 3.01 (td, J = 14.7, 6.1 Hz, 1H), 2.41 
(ddd, J = 14.7, 4.5, 2.8 Hz, 1H), 1.24 (s, 3H). Minor Diastereomer: δ 7.57 (d, J = 
7.8 Hz, 1H), 7.46 (s, 1H), 5.40 (dd, J = 7.5, 3.4 Hz, 1H), 4.83 (s, 1H), 4.58 (s, 1H), 
2.83 (ddd, J = 13.8, 6.1, 2.8 Hz, 1H), 2.54 (d, J = 7.4 Hz, 1H), 1.20 (s, 3H); 13C NMR 
(150 MHz, CDCl3) Both Diastereomers: δ 208.9, 208.5, 173.9, 173.8, 149.8, 147.2, 
144.2, 135.7, 128.8, 125.6, 124.7, 124.5, 124.0, 123.8, 122.8, 122.7, 122.6, 119.5, 115.6, 
115.6, 111.7, 110.3, 83.9, 68.3, 66.6, 58.9, 58.3, 58.2, 58.2, 58.0, 57.6, 52.2, 52.2, 
42.0, 40.6, 39.9, 39.1, 38.9, 38.2, 37.4, 37.2, 28.3, 28.3, 26.5, 26.4, 21.6, 21.4, 14.6, 
13.7; HRMS (ESI, m/z) calcd for C29H37NO6Na [M+Na]+ 518.2519, found 
518.2521. 
 
 
175 
 
 Triene 175. Secondary alcohol 171 (25 mg, 50 µmol, 1.0 equiv.) was 
dissolved in 1 mL CH2Cl2 and cooled to 0 oC. TFA (8 µL, 100 µmol, 2.0 equiv.) 
was added dropwise, and the solution was stirred for 40 min at 0 oC. The 
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reaction was removed from the ice bath and allowed to warm to room 
temperature over 2h. The reaction was diluted with EtOAc and H2O, and the 
aqueous layer was extracted 3x with EtOAc. The combined organic layers 
were washed with brine, dried over MgSO4, filtered, and condensed. The 
resultant material was purified via flash column chromatography (silica gel, 
10% EtOAc/hexanes) to yield triene 175 as a clear oil (20 mg, 83% yield). 
 
175: Rf = 0.25 (silica gel, 10% ethyl acetate/hexanes); IR (film): max 1727, 
1453, 1370, 1224, 1155, 1082, 907, 732 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.07 (s, 
1H), 7.71 (s, 1H), 7.49 (d, J = 7.7 Hz, 1H), 7.29 (t, J = 7.8 Hz, 1H), 7.22 (t, J = 7.6 Hz, 
1H), 6.20 (s, 1H), 5.02 (s, 1H), 4.80 (s, 1H), 3.71 (s, 3H), 3.13 (td, J = 14.8, 5.8 Hz, 
1H), 2.69 – 2.54 (m, 2H), 2.25 – 2.00 (m, 5H), 1.74 (dd, J = 12.2, 3.3 Hz, 1H), 1.66 
(s, 10H), 1.40 (s, 3H), 1.21 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 208.3, 173.7, 152.1, 
145.2, 124.4, 123.3, 122.5, 119.2, 117.3, 115.3, 114.2, 109.8, 57.9, 56.2, 52.3, 41.7, 37.5, 
37.2, 36.8, 28.4, 25.6, 21.6, 18.6; HRMS (ESI, m/z) calcd for C29H36NO5 [M+H]+ 
478.2593, found 478.2574. 
 
 
176 
 
 Boc-Carbazole 176. Preparation 1. Triene 175 (17 mg, 36 µmol, 
1.0 equiv.) was dissolved in 600 µL PhMe and transferred to a pressure tube. 
The solution was heated to 140 oC for 2 h and 20 min before being 
condensed. The crude material was purified via flash column 
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chromatography (silica gel, 12% to 15% EtOAc/hexanes) to yield 
Boc-carbazole 176 as a pale-yellow oil (11.3 mg, 66% yield). 
 
 Boc-Carbazole 176. Preparation 2. Secondary alcohol 171 (260 mg, 
0.52 mmol, 1.0 equiv.) was dissolved in anhydrous CH2Cl2 (9 mL) and cooled 
to 0 oC (no effort was made to maintain an inert atmosphere). TFA (80μL, 
1.05 mmol, 2.0 equiv.) was added in one portion, and the solution was stirred 
at 0 oC for 20 min. The flask was removed from the ice bath and was allowed 
to warm to room temperature, and was stirred at room temperature for 
2.5 h. The solvent was removed under reduced pressure, then 
azeotropically distilled with PhMe, dissolved in anhydrous PhMe (9 mL), and 
heated to 140 oC for 2 h and 20 min. Upon completion, the reaction was 
condensed to yield a brown foam, which was purified by flash column 
chromatography (silica gel, hexanes/acetone 9/1) to yield 176 as a beige 
foam (168 mg, 68% yield).  
 
176: Rf = 0.22 (silica gel, hexanes/acetone 9/1); IR (film): max 2976, 
1723, 1456, 1359, 1226, 1156, 769 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.22 (d, J = 
8.4 Hz, 1H), 8.04 (s, 1H), 7.92 (d, J = 7.3 Hz, 1H), 7.87 (s, 1H), 7.42 (ddd, J = 8.4, 
7.3, 1.3 Hz, 1H), 7.32 (td, J = 7.5, 1.0 Hz, 1H), 3.73 (s, 3H), 3.24 – 3.16 (m, 2H), 
3.09 – 3.00 (m, 1H), 2.78 (ddd, J = 13.3, 6.3, 2.5 Hz, 1H), 2.64 (ddd, J = 14.7, 4.5, 
2.4 Hz, 1H), 2.29 – 2.21 (m, 2H), 1.95 – 1.85 (m, 2H), 1.75 (s, 9H), 1.50 (s, 3H), 1.41 
(s, 3H); 13C NMR (150 MHz, CDCl3) δ 208.1, 174.2, 151.3, 141.6, 138.8, 137.3, 134.7, 
126.9, 125.9, 124.5, 123.1, 119.4, 116.4, 116.4, 116.2, 84.0, 57.7, 54.2, 52.4, 39.8, 38.4, 
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37.7, 32.9, 28.5, 23.4, 21.8, 21.1; HRMS (ESI, m/z) calcd for C29H33NO5Na 
[M+Na]+ 498.2256, found 498.2239. 
 
 
177 
 
Carbazole 177. Preparation 1. Boc-carbazole 173 (11.3 mg, 24 μmol, 
1.0 equiv.) was dissolved in 400 μL CH2Cl2. TFA (18 μL, 240 μmol, 10.0 equiv.) 
was added, and the solution was heated to 45 oC for 2.5 h. The solution was 
condensed and the resultant material was purified via flash column 
chromatography (silica gel, 15% acetone/hexanes) to yield carbazole 177 as 
a white foam (5.5 mg, 61% yield). 
 
Carbazole 177. Preparation 2. Secondary alcohol 171 (1.42 g, 2.87 mmol, 
1.0 equiv.) was dissolved in anhydrous CH2Cl2 (48 mL) and cooled to 0 oC. 
TFA (440 μL, 5.74 mmol, 2.0 equiv.) was added dropwise, and the solution 
was allowed to stir at 0o C for 10 min, at which point it was removed from 
the ice bath and allowed to warm to room temperature. The solution was 
stirred at room temperature for 3 h, then it was condensed, azeotropically 
distilled with PhMe to remove trace TFA and H2O, dissolved in anhydrous 
PhMe (48 mL), transferred to a pressure tube, heated to 135 oC, and stirred 
for 2 h. The solution was allowed to cool to room temperature, then TFA 
(2.2 mL, 28.7 mmol, 10.0 equiv.) was added dropwise, the solution was 
heated to 45 oC, and the mixture was stirred for 2.5 h. The solution was 
condensed and the resultant brown oil was purified by flash column 
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chromatography (silica gel, acetone/hexanes 4/1) to yield carbazole 177 as 
a brown foam (561 mg, 52% yield).  
 
177: Rf = 0.63 (silica gel, hexanes/EtOAc 2/1); IR (film): max 3410, 2956, 
1705, 1467, 1322, 1239, 1097, 735 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.00 (d, J = 
7.8 Hz, 1H), 7.98 (s, 1H), 7.87 (s, 1H), 7.37 (d, J = 3.5 Hz, 1H), 7.20 (dt, J = 8.0, 
3.8 Hz, 1H), 7.11 (s, 1H), 3.73 (s, 3H), 3.25 – 3.12 (m, 2H), 3.08 – 2.99 (m, 1H), 
2.82 (ddd, J = 13.3, 6.3, 2.5 Hz, 1H), 2.64 (ddd, J = 14.7, 4.6, 2.4 Hz, 1H), 2.31 – 
2.19 (m, 2H), 1.94 (td, J = 14.0, 4.5 Hz, 1H), 1.89 (dd, J = 11.4, 2.7 Hz, 1H), 1.50 (s, 
3H), 1.43 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 208.4, 174.3, 140.2, 138.5, 138.3, 
133.6, 125.8, 123.5, 122.4, 120.1, 119.4, 116.9, 110.7, 110.0, 57.7, 54.5, 52.3, 40.1, 
38.4, 37.8, 32.7, 23.6, 21.8, 21.2; HRMS (ESI, m/z) calcd for C24H26NO3 [M+H]+ 
376.1913, found 376.1913. 
 
 
178 
 
Alcohol 178. Carbazole 177 (100 mg, 0.27 mmol, 1.0 equiv.) was 
azeotropically distilled with PhMe to remove trace H2O, then dissolved in 
anhydrous MeOH (6 mL) and cooled to 0 oC. NaBH4 (31 mg, 0.80 mmol, 
3.0 equiv.) was added in one portion, and the reaction was stirred for 3 h. 
Upon completion, the reaction was quenched with with H2O (~10 mL), then 
diluted with EtOAc (~10 mL). The aqueous phase was extracted with EtOAc 
(3 x 10 mL), and the combined organic layers were dried over MgSO4, 
filtered, and condensed. The resultant oil was purified by flash column 
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chromatography (silica gel, EtOAc/hexanes 3/7) to yield alcohol 178 as a 
pink foam (72 mg, 72% yield).  
 
178: Rf = 0.42 (silica gel, hexanes/EtOAc 7/3); IR (film): max 3410, 2951, 
1701, 1467, 1236, 1027, 735 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.02 (d, J = 7.8 Hz, 
1H), 7.97 (s, 1H), 7.92 (s, 1H), 7.38 (t, J = 7.4 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.21 
(t, J = 7.6 Hz, 1H), 7.00 (s, 1H), 3.72 (s, 3H), 3.65 (d, J = 11.9 Hz, 1H), 3.24 (td, J = 
11.9, 4.4 Hz, 1H), 3.10 (dd, J = 16.6, 4.3 Hz, 1H), 3.05 – 2.95 (m, 1H), 2.56 (dt, J = 
13.3, 3.6 Hz, 1H), 2.34 – 2.20 (m, 2H), 2.11 – 2.01 (m, 2H), 1.64 (td, J = 13.6, 4.1 Hz, 
1H), 1.56 (s, 3H), 1.18 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 178.7, 140.2, 139.6, 
138.3, 133.7, 125.6, 123.6, 122.3, 120.1, 119.3, 117.2, 110.6, 109.8, 78.3, 53.0, 51.4, 
49.2, 39.1, 38.5, 33.2, 29.4, 23.9, 23.8, 21.5; HRMS (ESI, m/z) calcd for 
C24H28NO3 [M+H]+ 378.2069, found 378.2057. 
 
 
Oridamycin A (26) 
 
Oridamycin A (26). Alcohol 178 (50 mg, 0.135 mmol, 1.0 equiv.) was 
dissolved in DMSO (3 mL) and solid NaCN (132 mg, 2.7 mmol, 20.0 equiv.) 
was added in one portion (no effort was made to maintain an inert 
atmosphere). The resulting solution was heated to 120 oC and stirred for 2 h 
and 40 min before it was allowed to cool to room temperature. The amber 
solution was diluted with EtOAc (~20 mL), washed with a solution of 5:3 
brine:1M HCl (4 x 15 mL) (Beware! Forms HCN, highly toxic! Keep in fume 
hood!), dried over MgSO4, filtered, and condensed. The resultant amber 
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solid was found to be pure Oridamycin A (26) (42 mg, 86% yield) and no 
further purification was necessary.  
 
Oridamycin A (26): IR (film): max 3411, 2962, 1693, 1611, 1466, 1321, 1243, 
1026, 937, 737 cm-1; 1H NMR (600 MHz, CD3OD) δ 7.98 – 7.94 (m, 2H), 7.34 (d, 
J = 8.1 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H), 7.08 (t, J = 7.6 Hz, 1H), 7.05 (s, 1H), 3.24 
(dd, J = 12.2, 4.6 Hz, 1H), 3.07 (ddd, J = 16.9, 5.5, 1.9 Hz, 1H), 3.00 – 2.92 (m, 1H), 
2.58 (dt, J = 13.2, 3.6 Hz, 1H), 2.32 (dq, J = 13.6, 3.6 Hz, 1H), 2.26 – 2.19 (m, 1H), 
2.13 (dt, J = 12.9, 5.4 Hz, 1H), 1.96 – 1.90 (m, 1H), 1.59 (dt, J = 13.6, 3.9 Hz, 1H), 
1.52 (d, 12.3 Hz, 1H), 1.49 (s, 3H), 1.27 (s, 3H); 13C NMR (150 MHz, CD3OD) δ 181.0, 
142.0, 140.3, 140.1, 134.5, 126.1, 124.6, 123.2, 120.6, 119.3, 117.5, 111.4, 110.7, 79.1, 
54.1, 48.7, 40.0, 39.6, 34.0, 30.3, 24.8, 24.6, 22.5; HRMS (ESI, m/z) calcd for 
C23H25NO3Na [M+Na]+ 386.1732, found 386.1724. 
 
 
186 
 
 Oxime 186. Boc-carbazole 176 (70 mg, 150 µmol, 1.0 equiv.) was 
dissolved in 1 mL pyridine, and NH2OH•HCl (14 mg, 200 µmol, 1.35 equiv.) 
was added. The solution was heated to 80 oC and stirred for 40 min before 
being cooled to room temperature and diluted with EtOAc. The solution was 
washed 3x with 20% aqueous AcOH, sat. aqueous NaHCO3, brine, dried over 
MgSO4, filtered, and condensed. The resultant material was purified via 
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flash column chromatography (silica gel, 20% EtOAc/hexanes) to yield 
oxime 186 as a yellow oil (58 mg, 78% yield). 
 
186: Rf = 0.27 (silica gel, 20% ethyl acetate/hexanes); IR (film): max 
3462, 3272, 2977, 1720, 1358, 1325, 1225, 1153, 941, 766, 733 cm-1; 1H NMR 
(600 MHz, CDCl3) δ 8.22 (d, J = 8.3 Hz, 1H), 8.01 (s, 1H), 7.92 (d, J = 7.3 Hz, 1H), 
7.86 (s, 1H), 7.45 – 7.39 (m, 2H), 7.32 (t, J = 7.5 Hz, 1H), 3.72 (s, 3H), 3.59 (ddd, 
J = 15.0, 4.7, 2.5 Hz, 1H), 3.16 (dd, J = 16.8, 4.7 Hz, 1H), 3.07 – 2.98 (m, 1H), 2.61 
(ddd, J = 13.1, 5.5, 2.6 Hz, 1H), 2.43 (td, J = 14.8, 5.4 Hz, 1H), 2.31 (dd, J = 13.8, 
6.2 Hz, 1H), 2.21 – 2.10 (m, 1H), 1.80 (dd, J = 12.2, 1.9 Hz, 1H), 1.75 (s, 9H), 1.65 
(td, J = 13.5, 4.8 Hz, 1H), 1.57 (s, 3H), 1.28 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 
175.6, 161.5, 151.3, 142.4, 138.8, 137.2, 135.0, 126.8, 126.1, 124.4, 123.0, 119.4, 116.4, 
116.3, 83.9, 54.1, 52.3, 50.8, 38.6, 38.6, 33.0, 28.5, 23.4, 22.4, 21.4, 19.8; HRMS 
(ESI, m/z) calcd for C29H35N2O5 [M+H]+ 491.2546, found 491.2547. 
 
 
A3 
 
 Oxime A3. Carbazole 177 (50 mg, 130 µmol, 1.0 equiv.) was dissolved 
in 500 µL pyridine, to which NH2OH•HCl (13 mg, 180 µmol, 1.35 equiv.) was 
added. The solution was heated to 80 oC and stirred for 45 min before being 
cooled to room temperature and diluted with EtOAc. The solution was 
washed 3x with 20% aqueous AcOH, 3x with sat. aqueous NaHCO3, dried 
153 
 
over MgSO4, filtered, and condensed. The resultant material was purified via 
flash column chromatography (silica gel, 30% acetone/hexanes) to yield 
oxime A3 as a beige powder (43 mg, 85% yield).  
A3: Rf = 0.27 (silica gel, 30% ethyl acetate/hexanes); IR (film): max 
3405, 2951, 1719, 1465, 1320, 1239, 1106, 906, 729 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 8.00 (d, J = 7.8 Hz, 1H), 7.97 (s, 1H), 7.83 (s, 1H), 7.38 – 7.35 (m, 2H), 
7.24 (s, 1H), 7.21 – 7.17 (m, 1H), 7.09 (s, 1H), 3.71 (s, 3H), 3.58 (ddd, J = 15.0, 4.7, 
2.6 Hz, 1H), 3.14 (dd, J = 16.6, 5.2 Hz, 1H), 3.06 – 2.98 (m, 1H), 2.65 (ddd, J = 
13.1, 5.5, 2.6 Hz, 1H), 2.44 (td, J = 14.8, 5.4 Hz, 1H), 2.31 (ddt, J = 13.7, 6.3, 1.8 Hz, 
1H), 2.22 – 2.15 (m, 1H), 1.82 (dd, J = 12.2, 1.9 Hz, 1H), 1.67 (td, J = 13.7, 4.7 Hz, 
1H), 1.57 (s, 3H), 1.30 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 175.7, 161.7, 140.2, 
139.1, 138.4, 133.9, 125.7, 123.6, 122.4, 120.1, 119.4, 117.0, 110.6, 109.9, 54.3, 52.2, 
50.8, 38.9, 38.7, 32.8, 23.6, 22.5, 21.5, 19.9; HRMS (ESI, m/z) calcd for 
C24H27N2O3 [M+H]+ 391.2022, found 391.2022. 
 
 
A4 
 
 Tosyl-Carbazole A4. Carbazole 177 (30 mg, 80 µmol, 1.0 equiv.) was 
dissolved in 800 µL DMF and degassed with Ar for 10 min. NaH (60% 
dispersion in mineral oil, 3.5 mg, 90 µmol, 1.1 equiv.) was added and the 
solution was stirred at room temperature for 1 h. p-TsCl (30 mg, 160 µmol, 
2.0 equiv.) was added, and the solution was heated to 50 oC and stirred for 
6 h. The solution was removed from heat, diluted with EtOAc, and quenched 
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with sat. aqueous NH4Cl. The aqueous layer was extracted 3x with EtOAc, 
and the combined organic layers were washed 3x with brine, dried over 
MgSO4, filtered and condensed. The resultant material was purified using 
PTLC (silica gel, 0.5mm thickness, 5% acetone, 45% hexanes, 50% PhMe) to 
yield tosyl-carbazole A4 as a clear oil (16 mg, 38% yield). 
 
A4: Rf = 0.27 (silica gel, 25% ethyl acetate/hexanes); IR (film): max 
2952, 1713, 1451, 1368, 1171, 1092, 995, 812, 747, 658 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 8.25 (d, J = 8.3 Hz, 1H), 8.00 (s, 1H), 7.83 (d, J = 7.7 Hz, 1H), 7.79 (s, 1H), 
7.72 – 7.68 (m, 2H), 7.46 – 7.41 (m, 1H), 7.32 (td, J = 7.5, 1.0 Hz, 1H), 7.12 (d, J = 
8.0 Hz, 2H), 3.73 (s, 3H), 3.22 (dt, J = 16.7, 3.5 Hz, 1H), 3.17 (td, J = 14.7, 6.3 Hz, 
1H), 3.10 – 3.01 (m, 1H), 2.71 (ddd, J = 13.2, 6.2, 2.5 Hz, 1H), 2.62 (ddd, J = 14.7, 
4.6, 2.4 Hz, 1H), 2.28 (s, 3H), 2.27 – 2.21 (m, 2H), 1.90 – 1.84 (m, 1H), 1.49 (s, 3H), 
1.38 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 207.9, 174.1, 144.9, 142.5, 138.7, 137.1, 
135.3, 135.3, 129.8, 127.2, 126.7, 126.5, 124.9, 123.9, 119.7, 116.7, 115.2, 115.0, 57.7, 
54.0, 52.4, 39.7, 38.4, 37.6, 32.9, 23.4, 21.7, 21.7, 21.1; HRMS (ESI, m/z) calcd for 
C31H32NO5S [M+H]+ 530.2001, found 530.1992. 
 
 
187 
 
 O-Methyloxime 187. Tosyl-carbazole A4 (29 mg, 50 µmol, 1.0 equiv.) 
was dissolved in 250 µL pyridine. MeONH2•HCl (7 mg, 80 µmol, 1.5 equiv.) 
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was added, and the solution was stirred at room temperature for 21 h. The 
solution was diluted with EtOAc and added to 20% aqueous AcOH. The 
organic layer was washed 3x with 20% aqueous AcOH, 3x with sat. aqueous 
NaHCO3, dried over MgSO4, filtered and condensed. The resultant material 
was purified via flash column chromatography (silica gel, 
20% EtOAc/hexanes) to yield O-methyloxime 187 as a pale-yellow oil 
(29 mg, 95% yield). 
 
187: Rf = 0.25 (silica gel, 20% ethyl acetate/hexanes); IR (film): max 
3421, 2936, 1727, 1453, 1370, 1238, 1173, 1115, 1049, 907, 732, 666, 582 cm-1; 1H 
NMR (600 MHz, CDCl3) δ 8.28 (d, J = 8.3 Hz, 1H), 8.00 (s, 1H), 7.86 (d, J = 7.6 Hz, 
1H), 7.79 (s, 1H), 7.72 (d, J = 8.5 Hz, 2H), 7.48 – 7.42 (m, 1H), 7.34 (td, J = 7.5, 
1.0 Hz, 1H), 7.14 (d, J = 8.0 Hz, 2H), 3.89 (s, 3H), 3.73 (s, 3H), 3.48 (dq, J = 15.0, 
4.6, 2.5 Hz, 1H), 3.22 (dd, J = 16.8, 5.2 Hz, 1H), 3.11 – 3.01 (m, 1H), 2.72 (s, 0H), 
2.53 (dq, J = 13.0, 5.4, 2.6 Hz, 1H), 2.48 – 2.32 (m, 2H), 2.30 (s, 3H), 2.22 – 2.12 
(m, 1H), 1.80 (dd, J = 12.3, 1.8 Hz, 1H), 1.60 (s, 4H), 1.26 (s, 3H); 13C NMR 
(150 MHz, CDCl3) δ 175.8, 159.6, 144.9, 143.4, 138.7, 136.9, 135.6, 135.3, 129.8, 
127.1, 126.7, 124.8, 123.9, 119.7, 116.8, 115.2, 114.8, 61.6, 54.0, 52.2, 50.6, 38.7, 38.6, 
33.0, 23.3, 22.4, 21.7, 21.4, 20.5; HRMS (ESI, m/z) calcd for C32H35N2O5S 
[M+H]+ 559.2267, found 559.2250. 
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189 
 
 Acetoxymethyl 189. O-Methyloxime 187 (9.4 mg, 17 µmol, 1.0 equiv.) 
was dissolved in 200 µL of 1:1 AcOH: Ac2O at room temperature. PhI(OAc)2 
(11 mg, 34 µmol, 2.0 equiv.) and Pd(OAc)2 (376 µg, 1.68 µmol, 10 mol%) were 
added, and the solution was heated to 80 oC for 4 h. The solution was cooled, 
diluted with EtOAc, washed 2x with sat. aq. NaHCO3, brine, dried over 
MgSO4, filtered, and condensed. The resultant crude material was purified 
via PTLC (silica gel, 25% EtOAc/hexanes) to yield acetoxymethyl 189 as a 
white foam (3.9 mg, 37% yield). 
 
189: Rf = 0.29 (silica gel, 25% ethyl acetate/hexanes); IR (film): max 
3414, 2945, 1731, 1368, 1225, 1171, 1045, 908, 729, 664 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 8.25 (d, J = 8.4 Hz, 1H), 7.98 (s, 1H), 7.85 (d, J = 7.6 Hz, 1H), 7.80 (s, 1H), 
7.71 (d, J = 8.3 Hz, 2H), 7.47 – 7.41 (m, 1H), 7.32 (t, J = 7.5 Hz, 1H), 7.13 (d, J = 
8.2 Hz, 2H), 4.66 (d, J = 10.7 Hz, 1H), 4.55 (d, J = 10.7 Hz, 1H), 3.84 (s, 3H), 3.74 
(s, 3H), 3.28 – 3.21 (m, 1H), 3.17 (dd, J = 17.0, 5.4 Hz, 1H), 3.08 – 3.00 (m, 1H), 
2.59 – 2.49 (m, 2H), 2.28 (s, 3H), 2.18 – 2.10 (m, 2H), 2.06 – 1.97 (m, 4H), 1.67 – 
1.58 (m, 1H), 1.27 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 172.5, 170.8, 156.0, 144.9, 
143.0, 138.6, 137.0, 135.3, 135.2, 129.8, 127.2, 126.7, 126.5, 124.8, 123.9, 119.7, 116.7, 
115.1, 114.9, 65.7, 62.0, 54.4, 52.4, 46.8, 38.1, 36.7, 32.3, 23.5, 21.7, 21.2, 21.2, 20.8; 
HRMS (ESI, m/z) calcd for C34H37N2O7S [M+H]+ 617.2321, found 617.2298. 
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190 
 
 O-Methyloxime 190.  Boc-carbazole 176 (168 mg, 0.35 mmol, 
1.0 equiv.) was dissolved in anhydrous pyridine (6 mL), to which 
MeONH2•HCl (73 mg, 0.88 mmol, 2.5 equiv.) was added in one portion. The 
reaction was heated to 70 oC and stirred at that temperature for 3.5 h (no 
effort was made to maintain an inert atmosphere). Upon completion, the 
mixture was diluted with EtOAc (~25 mL), washed with sat. NH4Cl (4 x 
15 mL), washed with 1M HCl (1 x 15 mL), dried over MgSO4, filtered, and 
condensed. The resulting yellow oil was purified by flash chromatography 
(silica gel, hexanes/acetone 19/1) to yield O-methyloxime 190 as a yellow 
foam (160 mg, 90% yield). 
 
190: Rf = 0.40 (silica gel, hexanes/acetone 9/1); IR (film): max 2976, 
1725, 1490, 1359, 1228, 1158, 1049, 769, 736 cm-1; 1H NMR (600 MHz, CDCl3) δ 
8.22 (d, J = 8.3 Hz, 1H), 8.01 (s, 1H), 7.91 (d, J = 7.5 Hz, 1H), 7.84 (s, 1H), 7.41 (ddd, 
J = 8.5, 7.3, 1.3 Hz, 1H), 7.31 (td, J = 7.5, 1.0 Hz, 1H), 3.87 (s, 3H), 3.71 (s, 3H), 3.48 
(ddd, J = 15.0, 4.7, 2.5 Hz, 1H), 3.15 (dd, J = 16.9, 4.3 Hz, 1H), 3.02 (ddd, J = 17.4, 
12.6, 6.2 Hz, 1H), 2.57 (ddd, J = 13.0, 5.5, 2.6 Hz, 1H), 2.40 (td, J = 14.8, 5.3 Hz, 
1H), 2.31 (dd, J = 13.8, 6.1 Hz, 1H), 2.14 (qd, J = 12.9, 5.3 Hz, 1H), 1.79 (dd, J = 12.3, 
1.8 Hz, 1H), 1.75 (s, 10H), 1.68 – 1.61 (m, 1H), 1.58 (s, 3H), 1.26 (s, 3H); 13C NMR 
(150 MHz, CDCl3) δ 175.8, 159.8, 151.3, 142.5, 138.8, 137.1, 135.0, 126.8, 126.1, 
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124.4, 123.0, 119.4, 116.4, 116.3, 116.2, 83.9, 61.6, 54.2, 52.2, 50.6, 38.7, 38.6, 33.0, 
28.6, 28.5, 23.4, 22.4, 21.4, 20.5; HRMS (ESI, m/z) calcd for C30H37N2O5 [M+H]+ 
505.2702, found 505.2706. 
 
 
192 
 
 Acetoxymethyl 192. O-Methyloxime 190 (152 mg, 0.3 mmol, 1.0 equiv) 
was dissolved in 1:1 Ac2O: AcOH (3 mL). PhI(OAc)2 (193 mg, 0.6 mmol, 
2.0 equiv.) and Pd(OAc)2 (7 mg, 0.03 mmol, 0.1 equiv.) were added 
sequentially and the contents were heated to 70 oC and stirred at that 
temperature for 16 h (no effort was made to maintain an inert atmosphere). 
Upon completion, the mixture was diluted with EtOAc (~30 mL), washed 
with sat. aqueous NaHCO3 (3 x 20 mL), dried over MgSO4, filtered, and 
condensed. The resultant brown oil was purified by flash chromatography 
(silica gel, hexanes/acetone 20/3) to yield acetoxymethyl 192 as a yellow oil 
(116 mg, 69% yield).  
 
192: Rf = 0.42 (silica gel, hexanes/acetone 4/1); IR (film): max 2973, 
1727, 1491, 1360, 1227, 1154, 1051, 769, 736 cm-1; 1H NMR (600 MHz, CDCl3) δ 
8.23 (d, J = 8.3 Hz, 1H), 8.02 (s, 1H), 7.93 (d, J = 7.6 Hz, 1H), 7.88 (s, 1H), 7.42 (t, 
J = 7.4 Hz, 1H), 7.32 (t, J = 7.2 Hz, 1H), 4.67 (d, J = 10.7 Hz, 1H), 4.56 (d, J = 
10.7 Hz, 1H), 3.85 (s, 3H), 3.74 (s, 3H), 3.32 – 3.24 (m, 1H), 3.14 (dd, J = 16.9, 
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5.4 Hz, 1H), 3.03 (ddd, J = 17.4, 12.3, 6.4 Hz, 1H), 2.62 – 2.52 (m, 2H), 2.18 (d, J = 
11.5 Hz, 1H), 2.12 (dd, J = 13.3, 6.2 Hz, 1H), 2.05 – 1.96 (m, 4H), 1.75 (s, 9H), 1.69 
– 1.61 (m, 1H), 1.30 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 172.5, 170.7, 156.1, 151.3, 
142.2, 138.9, 137.2, 134.7, 126.9, 126.0, 124.4, 123.1, 119.4, 116.4, 116.4, 116.2, 83.9, 
65.7, 62.0, 54.4, 52.4, 46.9, 38.0, 36.8, 32.4, 28.5, 23.5, 21.2, 21.1, 20.8; HRMS 
(ESI, m/z) calcd for C32H39N2O7 [M+H]+ 563.2757, found 563.2762. 
 
 
193 
 
 Diol 193. Acetoxymethyl 192 (20 mg, 0.036 mmol, 1.0 equiv.) was 
dissolved in acetone (540 µL) and aq. 1M HCl (180 µL) was added (no effort 
was made to maintain an inert atmosphere). The contents were heated to 
80 oC and maintained at that temperature for 13 h. Upon completion, the 
reaction mixture was diluted with CH2Cl2 (10 mL), washed with H2O (1 x 5 mL) 
and sat. aq. NaHCO3 (1 x 5 mL), dried over Na2SO4, filtered, and condensed. 
The crude material was immediately taken up in MeOH (720 µL) and cooled 
to 0 oC. NaBH4 (4 mg, 0.11 mmol, 3.0 equiv.) was added, and the solution was 
stirred at 0 oC for 40 min. The reaction was diluted with EtOAc (500 µL), 
quenched by addition of aq. 1M HCl (500 µL), and stirred at room 
temperature for 15 min to quench excess reagent. Additional H2O (5 mL) and 
EtOAc (5 mL) were added, the aqueous was extracted with EtOAc (2 x 5 mL), 
the combined organic layers were washed with sat. aqueous NaHCO3 (2 x 
5 mL), dried over Na2SO4, filtered, and condensed. The resultant material 
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was purified via flash column chromatography (silica gel, hexanes/acetone 
5/2) to yield diol 193 as a brown foam (4.0 mg, 25% yield).  
 
193: Rf = 0.35 (silica gel, hexanes/acetone 3/2); IR (film): 3408, 2926, 
1706, 1492, 1240, 1071, 735 max  cm-1; 1H NMR (600 MHz, CDCl3) δ 7.99 (d, J = 
7.7 Hz, 1H), 7.95 (s, 1H), 7.83 (s, 1H), 7.37 (d, J = 3.9 Hz, 2H), 7.20 (dq, J = 8.0, 
4.4 Hz, 1H), 7.07 (s, 1H), 4.38 (t, J = 10.6 Hz, 1H), 3.96 (d, J = 10.4 Hz, 1H), 3.84 – 
3.81 (m, 2H), 3.80 (s, 4H), 3.69 (td, J = 12.0, 4.6 Hz, 1H), 3.09 (dd, J = 16.5, 5.3 Hz, 
1H), 3.05 – 2.95 (m, 1H), 2.59 (dt, J = 13.4, 3.6 Hz, 1H), 2.35 (qd, J = 13.2, 3.9 Hz, 
1H), 2.14 (dd, J = 14.0, 6.0 Hz, 1H), 2.08 – 1.99 (m, 2H), 1.70 – 1.63 (m, 2H), 1.22 
(s, 3H); 13C NMR (150 MHz, CDCl3) δ 176.4, 140.2, 139.2, 138.3, 133.5, 125.7, 123.6, 
122.4, 120.1, 119.4, 117.1, 110.6, 109.8, 79.6, 72.0, 53.4, 51.9, 47.5, 38.8, 38.3, 32.7, 
29.4, 24.2, 21.3; HRMS (ESI, m/z) calcd for C24H28NO4 [M+H]+ 394.2018, found 
394.2006. 
 
 
Oridamycin B (27) 
 
 Oridamycin B (27). Diol 193 (1.3 mg, 3.3 µmol, 1.0 equiv.) was dissolved 
in DMSO (70 µL) and solid NaCN (3.2 mg, 70 µmol, 21 equiv.) was added in 
one portion (no effort was made to maintain an inert atmosphere). The 
reaction was heated to 120 oC and was stirred at that temperature for 2 h. 
Upon completion, the amber solution was diluted with EtOAc (~20 mL), 
washed with a solution of 5:3 brine:1M HCl (4 x 15 mL) (Beware! Forms HCN, 
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highly toxic! Keep in fume hood!), dried over Na2SO4, filtered, and 
condensed. The crude material was purified by semi-preparative HPLC 
(7 injections, Varian Microsorb 300-5 C18 column, 5µm, 250 x 4.6 mm) using 
MeCN/H2O (30/70 to 80/20, 0.6 mL/min) as eluent to give pure 
oridamycin B (27), as a white powder (tR = 10.39 min, 0.30 mg, 24% yield). 
NOTE: While the 1H NMR spectrum of purified 27 corroborated the 
proposed structure (splitting, J values, relative chemical shifts, etc.), notable 
differences were found in the chemical shift of several protons relative to 
the isolated material. However, it was found that upon treatment with 
excess TFA the 1H NMR spectrum matched that of the natural isolate, and 
the tabulated data from both spectra are provided below. 
 
 Oridamycin B (27): IR (film): 3391, 2931, 2856, 1695, 1607, 1494, 1340, 
1266, 1026, 740 max  cm-1; 1H NMR (600 MHz, CD3OD) δ 7.97 (s, 1H), 7.96 (d, J 
= 7.9 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.27 (dt, J = 7.6, 1.3 Hz, 1H), 7.07 (dt, J = 
7.6, 1.2 Hz, 1H), 7.05 (s, 1H), 4.04 (d, J = 10.9 Hz, 1H), 3.95 (d, J = 10.9 Hz, 1H), 
3.61 (dd, J = 12.1, 4.7 Hz, 1H), 3.06 – 2.99 (m, 2H), 2.55 (dt, J = 13.0, 3.6 Hz, 1H), 
2.45 (dq, J = 12.5, 3.9 Hz, 1H), 2.27 – 2.22 (m, 2H), 1.95 – 1.88 (m, 1H), 1.84 – 1.78 
(m, 1H), 1.55 (td, J = 13.4, 3.7 Hz, 1H), 1.36 (s, 3H), 1.34 – 1.27 (m, 1H); 13C NMR 
(150 MHz, CD3OD) δ 180.6,A 142.0, 141.2, 140.0, 135.2, 125.9, 124.7, 123.0, 120.5, 
119.2, 117.6, 111.3, 110.6, 73.1, 64.7, 56.1, 46.9, 40.3, 39.5, 34.0, 30.8, 25.7, 22.6; 
HRMS (ESI, m/z) calcd for C23H25NO4 [M-H]- 378.1705, found 378.1723. 
A Assigned from HMBC data. 
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Oridamycin B (27): with TFA (excess): 1H NMR (600 MHz, CD3OD) δ 7.97 
(s, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.28 (dt, J = 7.7, 1.2 Hz, 
1H), 7.08 (d, J = 7.7 Hz, 1H), 7.07 (s, 1H), 4.11 (d, J = 10.9 Hz, 1H), 3.93 (d, J = 
10.9 Hz, 1H), 3.77 (dd, J = 12.2, 4.5, 1H), 3.05 (m, 2H), 2.62 (dt, J = 13.5, 3.6, 1H), 
2.43 (dq, J = 13.2, 3.7, 1H), 2.23-2.17 (m, 1H), 2.08 (m, 1H), 1.99-1.92 (m, 2H), 1.62 
(dt, J = 13.7, 3.8, 1H), 1.32 (s, 3H). 
 
 
237 
 
Linear Acetate 237. Linear alcohol 154 (2.9 g, 10.4 mmol, 1.0 equiv.) was 
dissolved in 70 mL CH2Cl2 at room temperature. Pyridine (2.0 mL, 
25.0 mmol, 2.4 equiv.) was added, followed by Ac2O (1.47 mL, 15.6 mmol, 
1.5 equiv.). The solution was allowed to stir for 21 h at room temperature. 
DMAP (9 mg, 73 µmol, 0.7 mol%) was added, and the solution was allowed 
to stir for an additional 5 h. Upon completion, the reaction mixture was 
diluted with CH2Cl2, and quenched with sat. aqueous NaHCO3. The layers 
were separated and the organic layer was washed with H2O and brine, then 
dried over Na2SO4, filtered, and condensed. The resultant material was 
purified via flash column chromatography (silica gel, 15% EtOAc/hexanes) 
to yield linear acetate 237 as a pale-yellow oil (2.52 g, 75% yield). 
 
237: Rf = 0.58 (silica gel, 20% ethyl acetate/hexanes); IR (film): max 
2916, 1739, 1716, 1437, 1368, 1232, 1070, 1024 cm-1; 1H NMR (600 MHz, CDCl3) δ 
5.33 (t, J = 7.0 Hz, 1H), 5.10 (t, J = 6.3 Hz, 1H), 4.58 (d, J = 7.1 Hz, 2H), 3.73 (s, 
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3H), 3.54 (q, J = 7.2 Hz, 1H), 2.71 – 2.55 (m, 2H), 2.26 (t, J = 7.7 Hz, 2H), 2.14 – 
2.08 (m, 2H), 2.05 (s, 3H), 2.05 – 1.99 (m, 2H), 1.70 (s, 3H), 1.59 (s, 3H), 1.34 (d, 
J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 205.6, 171.3, 171.2, 142.1, 134.0, 124.6, 
118.6, 61.5, 52.9, 52.5, 40.3, 39.5, 33.4, 26.3, 21.2, 16.6, 16.2, 13.0; HRMS (ESI, 
m/z) calcd for C18H28O5Na [M+Na]+ 347.1834, found 347.1820. 
 
 
A5 
 
Bicyclic Acetate A5. Bicyclic alcohol 162 (150 mg, 540 µmol, 1.0 equiv.) 
was dissolved in 5.4 mL Ac2O/pyridine (1/1) and stirred at room 
temperature for 19 h. The mixture was diluted with EtOAc, and then added 
to sat. aqueous NaHCO3. The layers were separated and the organic layer 
was washed with sat. aqueous NaHCO3, H2O, and brine. The resultant 
solution was dried over MgSO4, filtered, and condensed. The resultant 
material was purified via flash column chromatography (silica gel, 
20% EtOAc/hexanes) to yield bicyclic acetate A5 as a pale-yellow oil 
(126 mg, 72% yield). 
 
A5: Rf = 0.32 (silica gel, 20% EtOAc/hexanes); IR (film): max 2952, 2855, 
1713, 1364, 1228, 1095, 1031, 891, 733 cm-1; 1H NMR (600 MHz, CDCl3) δ 4.95 (s, 
1H), 4.61 (s, 1H), 4.33 (dd, J = 11.4, 4.0 Hz, 1H), 4.25 (dd, J = 11.4, 8.5 Hz, 1H), 3.66 
(s, 3H), 2.96 (td, J = 14.8, 6.2 Hz, 1H), 2.52 – 2.43 (m, 2H), 2.12 (ddd, J = 13.4, 
6.3, 2.7 Hz, 1H), 2.09 – 2.04 (m, 1H), 2.02 (s, 3H), 2.01 – 1.90 (m, 2H), 1.68 (td, J 
= 14.1, 4.6 Hz, 1H), 1.62 – 1.57 (m, 1H), 1.55 (s, 1H), 1.37 (s, 3H), 0.88 (s, 3H); 13C 
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NMR (150 MHz, CDCl3) δ 200.5, 171.3, 169.1, 142.2, 133.8, 124.9, 118.6, 62.7, 61.5, 
54.0, 39.5, 37.1, 34.4, 26.3, 25.6, 21.2, 16.6, 16.2; HRMS (ESI, m/z) calcd for 
C18H26O5Na [M+Na]+ 345.1678, found 345.1665. 
 
 
A6 
 
 Linear Silyl Ether A6. Linear alcohol 154 (1.5 g, 5.3 mmol, 1.0 equiv.) 
was dissolved in 25 mL DMF. TBSCl (964 mg, 6.4 mmol, 1.2 equiv.) and 
imidazole (645 mg, 9.5 mmol, 1.8 equiv.) were added and the solution was 
stirred at room temperature for 17 h. The reaction was diluted with Et2O and 
H2O. The aqueous layer was extracted 3x with Et2O, and the combined 
organic layers were washed 3x with brine, dried over MgSO4, filtered, and 
condensed. The resultant material was purified via flash column 
chromatography (silica gel, 2% acetone/hexanes) to yield linear silyl ether 
A6 as a yellow oil (1.33 g, 63% yield). 
 
A6: Rf = 0.29 (silica gel, 5% ethyl acetate/hexanes); IR (film): max 2930, 
2855, 1752, 1716, 1462, 1254, 1200, 1064, 833, 772, 737 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 5.29 (t, J = 6.4 Hz, 1H), 5.11 (t, J = 7.0 Hz, 1H), 4.19 (d, J = 6.6 Hz, 2H), 
3.73 (s, 3H), 3.59 – 3.50 (m, 1H), 2.71 – 2.47 (m, 2H), 2.25 (t, J = 7.7 Hz, 2H), 2.09 
(q, J = 7.4 Hz, 2H), 2.03 – 1.95 (m, 2H), 1.61 (s, 3H), 1.59 (s, 3H), 1.34 (d, J = 7.1 Hz, 
3H), 0.90 (s, 9H), 0.07 (s, 6H);13C NMR (150 MHz, CDCl3) δ 205.6, 171.2, 136.8, 
133.7, 125.0, 124.7, 60.5, 52.8, 52.5, 40.3, 39.5, 33.4, 26.4, 26.2, 18.6, 16.5, 16.2, 
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13.0, -4.9; HRMS (ESI, m/z) calcd for C22H39O4Si [M–H]– 395.2618, found 
395.2622. 
 
 
211 
 
Bicyclic Silyl Ether 211. Bicyclic alcohol 162 (634 mg, 2.26 mmol, 
1.0 equiv.) was dissolved in 11 mL DMF. TBSCl (410 mg, 2.72 mmol, 1.2 equiv.) 
and imidazole (308 mg, 4.53 mmol, 2.0 equiv.) were added, and the solution 
as allowed to stir at room temperature for 48 h. The solution was diluted 
with Et2O and H2O. The aqueous layer was extracted 3x with Et2O, and the 
combined organic layers were washed 4x with brine, dried over MgSO4, 
filtered, and condensed. The resultant material was purified via flash 
column chromatography (silica gel, 5% EtOAc/hexanes) to yield bicyclic 
silyl ether 211 as a yellow oil (653 mg, 73% yield). 
 
211: Rf = 0.52 (silica gel, 10% ethyl acetate/hexanes); IR (film): max 
2952, 2930, 2855, 1739, 1713, 1451, 1250, 1095, 837, 776 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 4.89 (s, 1H), 4.66 (s, 1H), 3.83 (dd, J = 5.9, 1.9 Hz, 2H), 3.66 (s, 3H), 
2.96 (td, J = 14.7, 6.1 Hz, 1H), 2.47 – 2.39 (m, 2H), 2.20 (ddd, J = 13.6, 6.1, 2.7 Hz, 
1H), 2.02 – 1.96 (m, 1H), 1.93 – 1.88 (m, 2H), 1.83 (t, J = 5.3 Hz, 1H), 1.66 (td, J = 
14.2, 4.4 Hz, 1H), 1.59 – 1.56 (m, 1H), 1.55 (s, 3H), 1.36 (s, 3H), 0.89 (s, 3H), 0.86 
(s, 9H), 0.03 (s, 6H); 13C NMR (150 MHz, CDCl3) δ 208.8, 174.0, 146.4, 108.4, 
60.4, 57.8, 56.8, 52.2, 39.3, 39.2, 37.9, 37.4, 26.0, 26.0, 21.4, 18.3, 13.4, -5.3, -
5.3; HRMS (ESI, m/z) calcd for C22H37O4Si [M–H]– 393.2461, found 393.2457. 
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A7 
 
 Linear β-Hydroxy Ester A7. Linear acetate 237 (755 mg, 2.33 mmol, 
1.0 equiv.) was dissolved in 24 mL MeOH and cooled to -78 oC. NaBH4 
(106 mg, 2.80 mmol, 1.2 equiv.) was added and the solution was stirred for 
3.5 h before being diluted with EtOAc and H2O, followed by quenching with 
sat. aqueous NaHCO3. The aqueous layer was extracted 3x with EtOAc, and 
the combined organic layers were washed with sat. aqueous NaHCO3, brine, 
dried over MgSO4, filtered, and condensed. The resultant material was 
purified via flash column chromatography (silica gel, 20% EtOAc/hexanes) 
to yield linear β-hydroxy ester A7 as a pale-yellow oil (514 mg, 68% yield). 
 
A7: Rf = 0.45 (silica gel, 30% ethyl acetate/hexanes); IR (film): max 
3435, 2932, 1727, 1439, 1368, 1231, 1025, 914, 729 cm-1; 1H NMR (600 MHz, 
CDCl3) δ Major Diastereomer: 3.67 – 3.61 (m, 1H), 1.20 (d, J = 7.2 Hz, 3H), Minor 
Diastereomer: 3.86 (ddd, J = 8.4, 4.1 Hz, 1H), 1.19 (d, J = 7.2 Hz, 3H), Shared 
Peaks: 5.34 (t, J = 7.1 Hz, 1H), 5.14 (t, J = 6.8 Hz, 1H), 4.58 (d, J = 7.1 Hz, 2H), 3.71 
(s, 3H), 2.59 – 2.47 (m, 2H), 2.21 – 1.99 (m, 9H), 1.70 (s, 3H), 1.60 (s, 3H), 1.56 – 
1.44 (m, 1H); 13C NMR (150 MHz, CDCl3) δ 176.6, 176.5, 171.3, 142.2, 135.2, 135.1, 
124.5, 124.4, 118.6, 73.2, 71.6, 61.6, 51.9, 51.9, 45.4, 44.5, 39.6, 36.2, 35.8, 32.9, 
32.1, 26.3, 26.2, 21.2, 16.6, 16.1, 14.4, 11.0; HRMS (ESI, m/z) calcd for C18H30O5Na 
[M+Na]+ 349.1991, found 349.1996. 
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239 
 
 α-Chlorinated Product 239. Linear acetate 237 (50 mg, 150 µmol, 
1.0 equiv.) was dissolved in 16 mL PhMe, to which 2,4,6-tri-tert-
butylpyridine (148 mg, 600 µmol, 4.0 equiv.) and Cu(OTf)2 (163 mg, 45 µmol, 
3.0 equiv.) were added. The solution was freeze-pump-thawed 3x to remove 
trace O2. The reaction was cooled to -55 oC and V(O)Cl2(OTFE) was added 
(prepared according to the literature9). The solution was stirred and slowly 
allowed to warm to -25 oC over the course of 2.5 h, at which point the 
reaction was diluted with EtOAc and quenched with aqueous 1M HCl. The 
aqueous layer was extracted 2x with EtOAc, and the combined organic 
layers were washed with sat. aqueous NH4Cl, sat. aqueous NaHCO3, brine, 
dried over MgSO4, filtered, and condensed. The resultant material was 
purified via flash column chromatography (silica gel, 10% EtOAc/hexanes) 
to yield α-chlorinated product 239 as a clear oil (30 mg, 56% yield). 
 
239: Rf = 0.26 (silica gel, 10% ethyl acetate/hexanes); IR (film): max 
2923, 2855, 1735, 1447, 1372, 1232, 1117, 1027, 733 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 5.33 (t, J = 7.0 Hz, 1H), 5.13 (t, J = 7.0 Hz, 1H), 4.58 (d, J = 7.1 Hz, 2H), 
3.82 (s, 3H), 2.92 – 2.84 (m, 1H), 2.77 – 2.69 (m, 1H), 2.28 (t, J = 7.7 Hz, 2H), 2.11 
(q, J = 7.4 Hz, 2H), 2.07 – 2.02 (m, 5H), 1.83 (s, 3H), 1.70 (s, 3H), 1.61 (s, 3H); 13C 
NMR (150 MHz, CDCl3) δ 201.1, 171.3, 168.8, 142.1, 133.7, 124.9, 118.6, 70.9, 61.5, 
168 
 
53.90, 39.5, 36.5, 33.9, 26.3, 24.7, 21.2, 16.6, 16.2; HRMS (ESI, m/z) calcd for 
C18H27O6ClNa [M+Na]+ 381.1445, found 381.1440. 
 
 
A8 
 
 Linear α-Seleno Acetate A8. Linear acetate 237 (50 mg, 150 µmol, 
1.0 equiv.) was dissolved in 1.5 mL THF and cooled to -78 oC. t-BuOK (26 mg, 
230 µmol, 1.5 equiv.) was added and the solution was stirred at -78 oC for 
50 min. PhSeCl (44 mg, 230 µmol, 1.5 equiv.) was added, and the solution was 
stirred at -78 oC for 3.5 h. The reaction was diluted with EtOAc and 
quenched with sat. aqueous NH4Cl. The aqueous layer was extracted 3x with 
EtOAc, and the combined organic layers were dried over MgSO4, filtered, 
and condensed. The resultant material was purified via flash column 
chromatography (silica gel, 5% acetone/hexanes) to yield linear α-seleno 
acetate A8 as a clear oil (71 mg, 98% yield). 
 
A8: Rf = 0.24 (silica gel, 10% acetone/hexanes); IR (film): max 3450, 
2942, 1737, 1700, 1633, 1303, 1233, 1104, 917, 737, 692 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 7.57 – 7.51 (m, 2H), 7.27 – 7.24 (m, 3H), 5.30 (t, J = 7.1 Hz, 1H), 4.55 (qd, 
J = 12.5, 7.0 Hz, 2H), 3.67 (s, 3H), 3.10 – 2.98 (m, 3H), 2.52 – 2.43 (m, 1H), 2.31 
– 2.19 (m, 2H), 2.09 (ddd, J = 12.8, 9.2, 7.9 Hz, 1H), 2.05 (s, 3H), 1.97 (ddd, J = 
12.8, 8.8, 5.7 Hz, 1H), 1.72 (t, J = 1.6 Hz, 3H), 1.70 – 1.63 (m, 4H), 1.42 (s, 3H); 13C 
NMR (150 MHz, CDCl3) δ 171.2, 169.9, 169.8, 141.2, 134.0, 130.9, 129.4, 127.7, 
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119.6, 97.4, 92.0, 61.4, 55.3, 51.0, 38.0, 35.8, 31.2, 29.4, 22.0, 21.2, 16.4, 11.5; 
HRMS (ESI, m/z) calcd for C24H33O5Se [M+H]+ 481.1493, found 481.1482. 
 
 
290 
 
 Linear α-Bromo Alcohol 290. Linear alcohol 154 (250 mg, 890 µmol, 
1.0 equiv.) was dissolved in 18 mL THF and cooled to 0 oC. NaH (60 % 
dispersion in mineral oil, 35 mg, 890 µmol, 1.0 equiv.) was added and the 
solution was stirred for 2h at 0 oC. The solution was cooled to -78 oC and 
NBS (173 mg, 980 µmol, 1.1 equiv.) was added. The solution was stirred for 
1 h at -78 oC before being diluted with Et2O and quenched with sat. aqueous 
NaHCO3. The aqueous layer was extracted 3x with Et2O, and the combined 
organic layers were washed 2x with H2O, brine, dried over MgSO4, filtered, 
and condensed. The resultant material was used without further 
purification, yielding linear α-bromo alcohol 290 as a yellow oil (320 mg, 
99% yield).  
 
290: Rf = 0.29 (silica gel, 30% ethyl acetate/hexanes); IR (film): max 
3391, 2921, 1723, 1442, 1250, 1119, 994, 736 cm-1; 1H NMR (600 MHz, CDCl3) δ 
5.40 (t, J = 7.0 Hz, 1H), 5.14 (t, J = 6.7 Hz, 1H), 4.15 (d, J = 6.9 Hz, 2H), 3.82 (s, 
3H), 2.97 – 2.89 (m, 1H), 2.81 – 2.74 (m, 1H), 2.30 (t, J = 7.5 Hz, 2H), 2.11 (q, J = 
7.3 Hz, 2H), 2.06 – 2.01 (m, 2H), 1.99 (s, 4H), 1.67 (s, 3H), 1.61 (s, 3H); 13C NMR 
(150 MHz, CDCl3) δ 200.5, 169.1, 139.5, 133.6, 125.1, 123.8, 62.7, 59.6, 54.0, 39.4, 
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36.96, 34.3, 26.3, 25.6, 16.4, 16.2; HRMS (ESI, m/z) calcd for C16H25O4NaBr 
[M+Na]+ 383.0834, found 383.0846. 
 
 
263 
 
 Truncated Linear Alcohol 263. Allylic alcohol 262 (see Scheme 4.12 
[pg. 107], prepared according to the literature10, 3.57g, 24.8 mmol, 1.0 equiv.) 
was azeotropically distilled with PhMe to remove trace water, and was 
subsequently dissolved in 83 mL THF. The solution was cooled to -78 oC and 
MsCl (2.5 mL, 32.2 mmol, 1.3 equiv.) and Et3N (6.9 mL, 49.6 mmol, 2.0 equiv.) 
were added. The solution was slowly allowed to warm to -15 oC over 3 h. A 
solution of LiI (13.3 g, 99.2 mmol, 4.0 equiv.) in 50 mL THF was added, and 
the resultant solution was stirred for 50 min, slowly warming from -15 oC to 
-10 oC. The resultant solution was diluted with Et2O, quenched with sat. 
aqueous NaHCO3, extracted 3x with Et2O, washed with 10% aqueous 
NaHSO3, sat. aqueous NH4Cl, H2O, and brine. The combined organic layers 
were dried over MgSO4, filtered, and condensed to yield the corresponding 
allylic iodide (5.2 g, 83% yield). The resultant crude material was used 
directly in the next step.  
A suspension of NaH (60% dispersion in mineral oil, 4.1 g, 102.5 mmol, 
5.0 equiv.) in 256 mL THF was cooled to 0 oC, and neat methyl 2-methyl-3-
oxobutanoate 155 (13.3 g, 102.5 mmol, 5.0 equiv.) was slowly added and the 
solution was allowed to stir for 35 min. n-BuLi (2.28M/hexanes, 45 mL, 
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102.5 mmol, 5.0 equiv.) was slowly added at 0 oC and the solution was 
allowed to stir for 45 min before being cooled to -78 oC. A solution of the 
allylic iodide (5.2 g, 20.5 mmol, 1.0 equiv.) in 40 mL THF was slowly added 
and the solution was stirred for 45 min. The resultant solution was diluted 
with EtOAc, and quenched with H2O and sat. aqueous NH4Cl. The aqueous 
layer was extracted 3x with EtOAc, and the combined organic layers were 
washed with brine, dried over MgSO4, filtered, and condensed. The 
resultant crude material was purified via flash column chromatography 
(silica gel, 10% to 15% to 25% to 35% to 50% EtOAc/hexanes) to yield 
truncated linear alcohol 263 as a yellow oil (2.82 g, 64% yield). Truncated 
linear acetate 264 was also isolated as a yellow oil (500 mg, 10% yield). 
 
263: Rf = 0.19 (silica gel, 40% ethyl acetate/hexanes); IR (film): max 
3418, 2920, 1739, 1710, 1437, 1268, 1207, 1070, 999 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 5.40 (t, J = 6.9 Hz, 1H), 4.15 (d, J = 6.9 Hz, 2H), 3.74 (s, 3H), 3.55 (q, J 
= 7.2 Hz, 1H), 2.77 – 2.69 (m, 1H), 2.68 – 2.60 (m, 1H), 2.31 (d, J = 7.5 Hz, 2H), 
1.68 (s, 3H), 1.35 (d, J = 7.1 Hz, 3H);13C NMR (150 MHz, CDCl3) δ 205.2, 171.1, 
138.1, 124.2, 59.4, 52.9, 52.6, 39.7, 33.0, 16.6, 13.0; HRMS (ESI, m/z) calcd for 
C11H18O4Na [M+Na]+ 237.1103, found 237.1096. 
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264 
 
 Truncated Linear Acetate 264. Truncated linear alcohol 263 (1.44 g, 
5.6 mmol, 1.0 equiv.) was dissolved in 5.6 mL CH2Cl2 at room temperature. 
Ac2O (1.32 mL, 14 mmol, 2.5 equiv.) was added, followed by DMAP (17 mg, 
140 µmol, 2.5 mol%), and the solution was stirred at room temperature for 
1.25 h before MeOH was added. After stirring for an additional 10 min, the 
solution was added to H2O/hexanes, and the layers were separated. The 
organic layer was washed 2x with H2O, 2x with sat. aqueous NaHCO3, brine, 
dried over MgSO4, filtered, and condensed to yield truncated linear acetate 
264 as a pale-yellow oil (1.57 g, 91% yield). The resultant material was pure 
enough to be used in subsequent operations without purification.  
 
264: Rf = 0.26 (silica gel, 20% ethyl acetate/hexanes); IR (film): max 
3336, 2923, 1739, 1716, 1454, 1433, 1368, 1232, 1024, 610 cm-1; 1H NMR 
(600 MHz, CDCl3) δ 5.33 (t, J = 7.0 Hz, 1H), 4.57 (d, J = 7.1 Hz, 2H), 3.74 (s, 3H), 
3.54 (q, J = 7.0 Hz, 1H), 2.77 – 2.69 (m, 1H), 2.67 – 2.60 (m, 1H), 2.33 (t, J = 7.7 Hz, 
2H), 2.05 (s, 3H), 1.71 (s, 3H), 1.35 (d, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) 
δ 205.0, 171.2, 171.1, 140.6, 119.2, 61.3, 52.9, 52.6, 39.6, 33.0, 21.2, 16.8, 13.0; 
HRMS (ESI, m/z) calcd for C13H20O5Na [M+Na]+ 279.1208, found 279.1196. 
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A9 
 
Truncated α-Bromo Acetate A9. Truncated linear acetate 264 (1.57 g, 
6.13 mmol, 1.0 equiv.) was azeotropically distilled 2x with PhMe to remove 
trace H2O, dissolved in 125 mL THF, and cooled to 0 oC. NaH (60% dispersion 
in mineral oil, 270 mg, 6.74 mmol, 1.1 equiv.) was added, and the solution was 
stirred for 1.17 h at 0 oC. The solution was cooled to -78 oC and NBS (1.2 g, 
6.74 mmol, 1.1 equiv.) was added. The solution was stirred at -78 oC for 1 h 
before being diluted with EtOAc and quenched with aqueous. 1M HCl. The 
aqueous layer was exracted 3x with EtOAc, and the combined organic layers 
were washed with sat. aqueous NaHCO3, brine, and dried over MgSO4, 
filtered, and condensed. The resultant material was purified via flash 
column chromatography (silica gel, 15% EtOAc/hexanes) to yield truncated 
α-bromo acetate A9 as a pale-yellow oil (1.53 g, 75% yield). 
 
A9: Rf = 0.50 (silica gel, 20% ethyl acetate/hexanes); IR (film): max 
1728, 1443, 1367, 1230, 1118, 1073, 1022, 957, 736, 607 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 5.36 (t, J = 7.0 Hz, 1H), 4.58 (d, J = 7.0 Hz, 2H), 3.83 (s, 3H), 3.03 – 
2.94 (m, 1H), 2.88 – 2.79 (m, 1H), 2.37 (t, J = 7.7 Hz, 2H), 2.05 (s, 3H), 1.99 (s, 
3H), 1.72 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 200.2, 171.2, 169.0, 140.3, 119.4, 
62.4, 61.3, 54.0, 36.5, 34.1, 25.6, 21.2, 16.7; HRMS (ESI, m/z) calcd for 
C13H19O5NaBr [M+Na]+ 357.0314, found 357.0311. 
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 α-Bromo β-Hydroxy Ester 265. Truncated α-bromo acetate A9 
(270 mg, 810 µmol, 1.0 equiv.) was azeotropically distilled 2x with PhMe to 
remove trace H2O, and was then dissolved in 16 mL MeOH. The solution was 
cooled to -78 oC, and NaBH4 (61 mg, 1.61 mmol, 2.0 equiv.) was added. The 
solution was stirred for 50 min before being diluted with EtOAc and 
quenched with aqueous 1M HCl. The aqueous layer was extracted 3x with 
EtOAc, and the combined organic layers were washed with sat. aqueous 
NaHCO3, brine, dried over MgSO4, filtered, and condensed. The resultant 
material was purified via flash column chromatography (silica gel, 
15% EtOAc/hexanes) to yield α-bromo β-hydroxy ester 265 as a pale-yellow 
oil (130 mg, 48% yield). 
 
265: Rf = 0.23 (silica gel, 20% ethyl acetate/hexanes); IR (film): max 
3497, 2959, 2934, 1739, 1713, 1447, 1383, 1232, 1114, 1052, 1020, 737, 625 cm-1; 1H 
NMR (600 MHz, CDCl3) δ 5.42 (t, J = 7.2 Hz, 1H), 4.60 (dd, J = 7.1, 3.0 Hz, 2H), 
4.07 (ddd, J = 10.6, 6.1, 1.6 Hz, 1H), 3.83 (s, 3H), 2.53 (d, J = 6.0 Hz, 1H), 2.38 – 
2.31 (m, 1H), 2.20 – 2.14 (m, 1H), 2.06 (s, 3H), 2.04 – 1.98 (m, 1H), 1.87 (s, 3H), 
1.74 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 171.9, 171.3, 141.5, 119.3, 75.2, 63.1, 61.5, 
53.5, 36.4, 29.0, 22.0, 21.2, 16.6; HRMS (ESI, m/z) calcd for C13H21O5NaBr 
[M+Na]+ 359.0470, found 359.0458. 
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 Truncated β-Hydroxy Ester 269.  Preparation 1. α-Bromo β-hydroxy 
ester 265 (25 mg, 74 µmol, 1.0 equiv.) was azeotropically distilled 2x with 
PhMe to remove trace water, and was subsequently dissolved in 3.7 mL of 
CH2Cl2 and cooled to -45 oC under an O2 balloon. AlMe3 (2M/hexanes, 111 µL, 
222 µmol, 3.0 equiv.) was added and the solution was stirred for 35 min. 
Bu3SnH (36 µL, 133 µmol, 1.8 equiv.) was added, and syringe pump addition 
(0.08 mL/h) of Et3B (1M/hexanes, 148 µL, 148 µmol, 2.0 equiv.) was initiated. 
After stirring for 4 h, the solution was diluted with EtOAc, and quenched 
with H2O, aqueous 1M HCl, and solid potassium sodium tartrate 
tetrahydrate. The solution was allowed to stir for 30 min before sat. aqueous 
NaHCO3 was added until the layers were clear. The aqueous layer was 
extracted 3x with EtOAc, and the combined organic layers were washed 
with sat. aqueous NaHCO3, brine, dried over MgSO4, filtered, and 
condensed. The resultant crude material was purified via flash column 
chromatography (silica gel, 25% EtOAc/hexanes) to yield truncated 
β-hydroxy ester 269 as a clear oil (7.8 mg, 41% yield). 
 
Truncated β-Hydroxy Ester 269.  Preparation 2. Truncated linear 
acetate 264 (80 mg, 240 µmol, 1.0 equiv.) was dissolved in 5 mL MeOH and 
cooled to 0 oC. NaBH4 (18 mg, 480 µmol, 2.0 equiv.) was added, and the 
solution was stirred at 0 oC for 25 min before being diluted with EtOAc and 
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quenched with aqueous 1M HCl. The aqueous layer was extracted 3x with 
EtOAc, and the combined organic layers were washed with sat. aqueous 
NaHCO3, brine, dried over MgSO4, filtered, and condensed. The resultant 
material was purified via flash column chromatography (silical gel, gradient: 
20% to 25% EtOAc/hexanes) to yield truncated β-hydroxy ester 269 as a 
clear oil (57 mg, 70% yield). 
 
269: Rf = 0.29 (silica gel, 30% ethyl acetate/hexanes); IR (film): max 
3467, 2947, 1731, 1439, 1368, 1231, 1025 cm-1; 1H NMR (600 MHz, CDCl3) δ Major 
Diastereomer: 3.67 – 3.61 (m, 1H), 1.22 (d, J = 7.2 Hz, 3H), Minor Diastereomer: 
3.86 (ddd, J = 8.4, 4.0 Hz, 1H), 1.19 (d, J = 7.3 Hz, 1H), Shared Peaks: 5.37 (t, J = 
7.2 Hz, 1H), 4.58 (d, J = 7.1 Hz, 2H), 3.71 (s, 3H), 2.60 (d, J = 6.8 Hz, 1H), 2.58 – 
2.52 (m, 1H), 2.51 (d, J = 4.7 Hz, 0H), 2.30 – 2.22 (m, 1H), 2.17 – 2.06 (m, 1H), 
2.05 (s, 3H), 1.71 (s, 3H), 1.68 – 1.47 (m, 3H); 13C NMR (150 MHz, CDCl3) δ 176.6, 
176.5, 171.3, 142.0, 141.9, 118.9, 118.8, 73.1, 71.5, 61.5, 61.4, 52.0, 51.9, 45.3, 44.5, 
36.0, 35.6, 32.8, 31.8, 21.2, 16.6, 16.6, 14.5, 11.0; HRMS (ESI, m/z) calcd for 
C13H22O5Na [M+Na]+ 281.1365, found 281.1363. 
 
 
272 
 
 Truncated β-Keto Ester 272. Trans-2-methyl-2-butenal 270 (see 
Scheme 4.13 [pg. 109], 2 g, 23.8 mmol, 1.0 equiv.) was dissolved in 240 mL 
MeOH and cooled to -10 oC. NaBH4 (995 mg, 26.2 mmol, 1.1 equiv.) was added 
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and the solution was allowed to stir for 35 min. The reaction was diluted 
with CH2Cl2 and quenched with sat. aqueous NaHCO3. Brine was added, 
along with solid potassium sodium tartrate tetrahydrate and H2O. The 
solution was removed from the cold bath and allowed to stir for 30 min 
before the aqueous layer was extracted 3x with CH2Cl2. The combined 
organic layers were dried over MgSO4, filtered, and condensed to yield 
allylic alcohol 271 as a pale-yellow oil (1.84 g, 90% yield, spectroscopic data 
matched the literature). The crude material was used directly in the next 
step without further purification. 
 Allylic alcohol 271 (1.84 g, 21.4 mmol, 1.0 equiv.) was dissolved in 72 mL 
THF and cooled to -78 oC. MsCl (2.2 mL, 27.8 mmol, 1.3 equiv.) and Et3N 
(6.0 mL, 42.8 mmol, 2.0 equiv.) were added and the solution was slowly 
allowed to warm to -40 oC over the course of 3.5 h. A solution of LiI (11.5 g, 
85.6 mmol, 4.0 equiv.) in 36 mL THF was added, and the resultant solution 
was stirred for 1 h. The reaction was diluted with Et2O and quenched with 
sat. aqueous NaHCO3, H2O, and 10% aqueous NaHSO3. The aqueous layer 
was extracted 3x with Et2O, and the combined organic layers were washed 
with sat. aqueous NH4Cl, H2O, and brine. The organic layers were dried over 
MgSO4, filtered, and condensed (rotovap bath temperature = 0 oC) to yield 
the corresponding iodide, which was used without further purification in 
the next step.  
 A suspension of NaH (60% dispersion in mineral oil, 2.57 g, 64.2 mmol, 
3.0 equiv.) in 250 mL THF was cooled to 0 oC, and neat methyl 2-methyl-3-
oxobutanoate 155 (8.35 g, 64.2 mmol, 3.0 equiv.) was slowly added, and the 
resultant solution was allowed to stir for 30 min. n-BuLi (2.28M/hexanes, 
28 mL, 64.2 mmol, 3.0 equiv.) was slowly added, and the resultant solution 
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was allowed to stir for 35 min. A solution of the allylic iodide (assuming 
quantitative yield from previous step, 21.4 mmol, 1.0 equiv.) in 40 mL THF 
was added, and the reaction was removed from the cold bath and allowed 
to stir at room temperature for 2.5 h. The resultant solution was diluted 
with EtOAc and quenched with sat. aqueous NH4Cl, H2O, and 10% aqueous 
NaHSO3. The aqueous layer was extracted 3x with EtOAc, and the combined 
organic layers were washed with brine, dried over MgSO4, filtered, and 
condensed. The resultant crude material was purified via flash column 
chromatography (silica gel, 2.5% to 5% to 7.5% Et2O/hexanes) to yield 
truncated β-keto ester 272 as a pale-yellow oil (2.5 g, 59% yield over 2 steps). 
 
272: Rf = 0.44 (silica gel, 10% ethyl acetate/hexanes); IR (film): max 
2948, 1745, 1713, 1437, 1200, 1174, 1120, 1070 cm-1; 1H NMR (600 MHz, CDCl3) δ 
5.20 (q, J = 6.6 Hz, 1H), 3.73 (s, 3H), 3.54 (q, J = 7.1 Hz, 1H), 2.70 – 2.54 (m, 2H), 
2.26 (t, J = 7.7 Hz, 2H), 1.59 (s, 3H), 1.56 (s, 3H), 1.33 (d, J = 7.1 Hz, 3H); 13C NMR 
(150 MHz, CDCl3) δ 205.7, 171.2, 134.2, 119.4, 52.9, 52.5, 40.3, 33.4, 15.8, 13.5, 
13.0; HRMS (ESI, m/z) calcd for C11H17O3 [M–H]– 197.1178, found 197.1185. 
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 Truncated α-Bromo β-Keto Ester 273. Truncated β-keto ester 272 
(300 mg, 1.52 mmol, 1.0 equiv.) was azeotropically distilled 2x with PhMe to 
remove trace H2O, then dissolved in 30 mL MeOH and cooled to 0 oC. NaH 
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(60% dispersion in mineral oil, 67 mg, 1.67 mmol, 1.1 equiv.) was added and 
the solution was allowed to stir for 35 min at 0 oC. The solution was cooled 
to -78 oC, then NBS (297 mg, 1.67 mmol, 1.1 equiv.) was added and the solution 
was allowed to stir for 40 min at -78 oC. Upon completion, the solution was 
diluted with EtOAc and quenched with aqueous 1M HCl. The aqueous layer 
was extracted 3x with EtOAc, and the combined organic layers were washed 
with sat. aqueous NaHCO3, brine, dried over MgSO4, filtered, and 
condensed. The resultant material was purified via flash column 
chromatography (silica gel, gradient: 2% to 3% to 4% EtOAc/hexanes) to 
yield truncated α-bromo β-keto ester 273 as a clear oil (270 mg, 64% yield). 
NOTE: This compound is unstable at room temperature and should be 
stored in a freezer. 
 
273: Rf = 0.63 (silica gel, 10% ethyl acetate/hexanes); IR (film): max 
2959, 2920, 2862, 1760, 1724, 1443, 1268, 1117, 1074, 974, 737 cm-1; 1H NMR 
(600 MHz, CDCl3) δ 5.25 (q, J = 6.6 Hz, 1H), 3.82 (s, 3H), 2.97 – 2.89 (m, 1H), 
2.82 – 2.73 (m, 1H), 2.30 (t, J = 7.6 Hz, 2H), 1.99 (s, 4H), 1.61 (s, 3H), 1.57 (d, J = 
6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 200.6, 169.1, 134.0, 119.7, 62.8, 54.0, 
37.1, 34.4, 25.6, 15.8, 13.5; HRMS (ESI, m/z) calcd for C11H18O3Br [M+H]+ 
277.0439, found 277.0436. 
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274 
 
 Truncated α-Bromo β-Hydroxy Ester 274. Truncated α-bromo β-keto 
ester 273 (270 mg, 980 µmol, 1.0 equiv.) was dissolved in 20 mL MeOH and 
cooled to -78 oC. NaBH4 (75 mg, 1.96 mmol, 2.0 equiv.) was added and the 
solution was stirred at -78 oC for 40 min. Another portion of NaBH4 (37 mg, 
980 µmol, 1.0 equiv.) was added and the solution was stirred for 20 min 
at -78 oC. The reaction was diluted with EtOAc, and quenched with aqueous 
1M HCl. The aqueous layer was extracted 3x with EtOAc, and the combined 
organic layers were washed with sat. aqueous NaHCO3, brine, dried over 
MgSO4, filtered, and condensed. The resultant material was purified via 
flash column chromatography (silica gel, gradient: 5% to 
10% EtOAc/hexanes) to yield truncated α-bromo β-hydroxy ester 274 as a 
clear oil (190 mg, 70% yield). 
 
274: Rf = 0.32 (silica gel, 15% ethyl acetate/hexanes); IR (film): max 
3439, 2925, 1727, 1446, 1268, 1119, 1057, 910, 736 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 5.30 (q, J = 6.8 Hz, 1H), 4.07 (ddd, J = 10.5, 6.1, 1.6 Hz, 1H), 3.82 (s, 3H), 
2.47 (d, J = 6.2 Hz, 1H), 2.31 – 2.23 (m, 1H), 2.16 – 2.08 (m, 1H), 2.02 – 1.94 (m, 
1H), 1.86 (s, 3H), 1.63 (s, 3H), 1.59 (d, J = 6.7, 1.1 Hz, 3H), 1.53 – 1.44 (m, 1H); 13C 
NMR (150 MHz, CDCl3) δ 171.9, 135.1, 119.6, 75.4, 63.4, 53.4, 36.6, 29.3, 22.2, 
15.7, 13.5; HRMS (ESI, m/z) calcd for C11H20O3Br [M+H]+ 279.0596, found 
279.0586. 
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Bicyclic Lactone 282. Truncated α-Bromo β-Keto Ester 273 (58 mg, 
210 µmol, 1.0 equiv.) was dissolved in 2.1 mL CH2Cl2, and 2,6-lutidine (49 µL, 
420 µmol, 2.0 equiv.) and fac-Ir(ppy)3 (3.4 mg, 5.3 µmol, 2.5 mol%) were 
added at room temperature. Two strips of blue LEDs were turned on 
(purchased from Creative Lighting Solutions, creativelightings.com, 
Product Code: CL-FRS5050-12WP-12V, Model: Sapphire Blue LED Flex 
Strip) and the reaction was stirred for 1 h at room temperature. Upon 
completion, the solution was condensed and purified via PTLC (silica gel, 
25% EtOAc/hexanes) to yield bicyclic lactone 282 as a clear oil (3.8 mg, 10% 
yield). 
 
282: Rf = 0.39 (silica gel, 30% ethyl acetate/hexanes); IR (film): max 
2926, 1778, 1720, 1451, 1383, 1243, 1146, 1056, 927, 740 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 2.72 – 2.59 (m, 2H), 2.35 (qd, J = 13.9, 8.8, 1.4 Hz, 1H), 2.29 (q, J = 
7.0 Hz, 1H), 1.99 (ddd, J = 14.1, 10.4, 8.0 Hz, 1H), 1.49 (s, 3H), 1.22 (s, 3H), 1.03 
(d, J = 7.1 Hz, 3H).; 13C NMR (150 MHz, CDCl3) δ 201.5, 175.0, 84.4, 63.0, 48.6, 
36.5, 35.4, 21.3, 11.1, 10.6; HRMS (ESI, m/z) calcd for C10H14O3Na [M+Na]+ 
205.0841, found 205.0847. 
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 Linear α-Bromo Acetate 287. Linear acetate 237 (960 mg, 2.96 mmol, 
1.0 equiv.) was azeotropically distilled 2x with PhMe to remove trace H2O, 
dissolved in 60 mL THF, and cooled to -78 oC. NaH (60% dispersion in 
mineral oil, 130 mg, 3.26 mmol, 1.1 equiv.) was added, and the solution was 
removed from the cold bath and allowed to warm to room temperature over 
the course of 1.17 h. The solution was re-cooled to -78 oC and NBS (632 mg, 
3.55 mmol, 1.2 equiv.) was added. The solution was allowed to stir for 40 min 
at -78 oC before being diluted with EtOAc and quenched with a 1/1 solution 
of brine/aqueous 1M HCl. The aqueous layer was extracted 3x with EtOAc, 
and the combined organic layers were washed with sat. aqueous NaHCO3, 
brine, dried over MgSO4, filtered, and condensed. The resultant material 
was purified via flash column chromatography (silica gel, gradient: 5% to 
7.5% EtOAc/hexanes) to yield linear α-bromo acetate 287 as a pale-yellow 
oil (877 mg, 74 % yield). 
 
287: Rf = 0.26 (silica gel, 10% ethyl acetate/hexanes); IR (film): max 
2920, 2851, 1731, 1443, 1379, 1228, 1117, 1024, 737 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 5.33 (t, J = 7.1 Hz, 1H), 5.14 (t, J = 6.1 Hz, 1H), 4.58 (d, J = 7.1 Hz, 2H), 
3.82 (s, 3H), 2.98 – 2.88 (m, 1H), 2.83 – 2.74 (m, 1H), 2.30 (t, J = 7.7 Hz, 2H), 2.15 
– 2.08 (m, 2H), 2.07 – 2.03 (m, 5H), 1.99 (s, 3H), 1.70 (s, 3H), 1.61 (s, 3H); 13C 
NMR (150 MHz, CDCl3) δ 200.5, 171.3, 169.1, 142.2, 133.8, 124.9, 118.6, 62.7, 61.5, 
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54.0, 39.5, 37.1, 34.4, 26.3, 25.6, 21.2, 16.6, 16.2; HRMS (ESI, m/z) calcd for 
C18H27NaBrO5 [M+Na]+ 425.0940, found 425.0921. 
 
 
A10 
 
 N-Boc-3,4-Dimethyl-5-Isoxazolone A10. Methyl 2-methyl-3-
oxobutanoate 155 (500 mg, 3.85 mmol, 1.0 equiv.) was dissolved in 10 mL 
EtOH and 2.5 mL H2O. NaOAc (347 mg, 4.23 mmol, 1.1 equiv.) and NH2OH•HCl 
(296 mg, 4.23 mmol, 1.1 equiv.) were added and the reaction was heated to 
100 oC and stirred at that temperature for 1.5 h. The solution was diluted 
with CH2Cl2 and H2O, extracted 3x with CH2Cl2, dried over MgSO4, filtered, 
and condensed. The crude reaction products were purified via flash column 
chromatography (silica gel, 20% to 30% acetone/hexanes) to yield 3,4-
dimethyl-5-isozazolone as a yellow oil (characterization data not acquired, 
mixture of tautomers, 266 mg, 61% yield). 
 3,4-Dimethyl-5-isoxazolone (66 mg, 580 µmol, 1.0 equiv.) was 
dissolved in 3 mL CH2Cl2 and was cooled to 0 oC. Et3N (161 µL, 1.16 mmol, 
2.0 equiv.) and Boc2O (200 µL, 870 µmol, 1.5 equiv.) were added, and the 
solution was stirred at 0 oC for 50 min. The reaction was removed from the 
cold bath and allowed to stir at room temperature for 1.5 h. The reaction 
was quenched with sat. aqueous NH4Cl, extracted 3x with CH2Cl2, dried over 
MgSO4, filtered, and condensed. The crude reaction products were purified 
via flash column chromatography (silica gel, 10% acetone/hexanes) to yield 
Me
Me
BocN O
O
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N-Boc-3,4-dimethyl-5-isoxazolone A10 as an orange-yellow oil (78 mg, 
63% yield). 
 
A10: Rf = 0.36 (silica gel, 20% ethyl acetate/hexanes); IR (film): max 
3366, 2979, 2929, 1745, 1632, 1366, 1330, 1256, 1147, 947, 845, 725, 685, 
582 cm-1; 1H NMR (600 MHz, CDCl3) δ 2.44 (s, 3H), 1.82 (s, 3H), 1.57 (s, 9H); 13C 
NMR (150 MHz, CDCl3) δ 168.2, 154.0, 146.2, 101.7, 86.0, 28.2, 13.6, 6.7. 
 
 
A11 
 
Linear Boc-Isoxazolone A11. N-Boc-3,4-dimethyl-5-isozazolone A10 
(40 mg, 190 µL, 1.0 equiv.) was dissolved in 1.9 mL THF and 100 µL HMPA and 
cooled to -70 oC. KHMDS (0.5M/PhMe, 420 µL, 210 µmol, 1.1 equiv.) was 
added, and the solution was stirred at -70 oC for 20 min. Allylic bromide 158 
(52 mg, 190 µmol, 1.0 equiv.) was added as a solution in 400 µL THF, and the 
reaction was allowed to slowly warm to 0 oC over the course of 5.5 h. Upon 
completion, the solution was quenched with sat. aqueous NH4Cl, extracted 
3x with CH2Cl2, dried over MgSO4, filtered, and condensed. The resultant 
crude product mixture was purified via flash column chromatography (silica 
gel, 10% acetone/hexanes) to yield linear Boc-isoxazolone A11 as a clear oil 
(46 mg, 59% yield). 
 
Me
BocN O
O
MeMe
AcO
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A11: Rf = 0.38 (silica gel, 20% ethyl acetate/hexanes); IR (film): max 
2980,  2930, 1764, 1727, 1631, 1333, 1232, 1143, 1027, 844, 737 cm-1; 1H NMR 
(600 MHz, CDCl3) δ 5.33 (t, J = 7.2 Hz, 1H), 5.13 (t, J = 6.9 Hz, 1H), 4.58 (d, J = 
7.1 Hz, 2H), 2.98 – 2.90 (m, 2H), 2.26 (t, J = 7.7 Hz, 2H), 2.14 – 2.08 (m, 2H), 2.06 
– 2.01 (m, 5H), 1.80 (s, 3H), 1.69 (d, J = 2173.8 Hz, 3H), 1.66 (s, 3H); 13C NMR 
(150 MHz, CDCl3) δ 171.2, 168.3, 157.8, 145.8, 142.0, 133.4, 125.9, 118.6, 101.8, 
86.0, 61.5, 39.4, 37.5, 28.2, 28.2, 28.2, 26.4, 26.1, 21.2, 16.6, 16.1, 6.7. 
 
 
A12 
 
 
Linear Methyl Isoxazolone A12. Methyl 2-methyl-3-oxobutanoate 155 
(500 mg, 3.85 mmol, 1.0 equiv.) was dissolved in 7.7 mL AcOH. NaOAc 
(350 mg, 4.23 mmol, 1.1 equiv.) and MeNHOH•HCl (355 mg, 4.23 mmol, 
1.1 equiv.) were added and the solution was stirred at room temperature for 
1.5 h. The reaction was heated to 85 oC and stirred for 1 h before being 
diluted with CH2Cl2 and H2O, extracted 3x with CH2Cl2, dried over MgSO4, 
filtered, and condensed. The crude reaction mixture was purified via flash 
column chromatography (silica gel, 30% acetone/hexanes) to yield 3,4,5-
trimethyl-5-isoxazolone as a clear oil (1H NMR data matched the literature11, 
380 mg, 78% yield). 
3,4,5-Trimethyl-5-isoxazolone (100 mg, 790 µmol, 1.0 equiv.) was 
dissolved in 6 mL THF and 400 µL HMPA and was cooled to 0 oC. n-BuLi 
Me
MeN O
O
MeMe
AcO
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(2.37M/hexanes, 350 µL, 830 µmol, 1.05 equiv.) was added and the reaction 
was stirred for 25 min. A solution of allylic bromide 158 (216 mg, 790 µmol, 
1.0 equiv.) in 2 mL THF was added, and the solution was stirred at 0 oC for 
2.25 h. The reaction was quenched with sat. aqueous NH4Cl, diluted with 
Et2O and H2O, extracted 3x with CH2Cl2, dried over MgSO4, filtered, and 
condensed. The crude mixture was purified via flash column 
chromatography (silica gel, 20% acetone/hexanes) to yield linear methyl 
isoxazolone A12 as a pale-yellow liquid (174 mg, 69% yield). 
 
A12: Rf = 0.34 (silica gel, 50% ethyl acetate/hexanes); IR (film): max 
2923, 1731, 1631, 1441, 1379, 1232, 1120, 1024, 754 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 5.33 (t, J = 7.2 Hz, 1H), 5.15 (t, J = 7.0 Hz, 1H), 4.59 (d, J = 7.1 Hz, 2H), 
3.20 (s, 3H), 2.56 – 2.46 (m, 2H), 2.21 (d, J = 8.2 Hz, 2H), 2.16 – 2.09 (m, 2H), 
2.08 – 2.01 (m, 5H), 1.77 (s, 3H), 1.70 (s, 3H), 1.66 (s, 3H); 13C NMR (150 MHz, 
CDCl3) δ 172.1, 171.2, 165.6, 141.9, 133.0, 126.2, 118.8, 99.5, 61.5, 39.3, 38.8, 37.3, 
26.3, 24.6, 21.2, 16.6, 16.2, 7.0; HRMS (ESI, m/z) calcd for C18H28NO4 [M+H]+ 
322.2018, found 322.2018. 
 
 
A13 
 
Linear Acetonide A13. Tert-butyl 2-methyl-3-oxobutanoate (2.06 g, 
12 mmol, 1.0 equiv.) was dissolved in 3.4 mL Ac2O and 1.75 mL acetone and 
HO
Me Me
O
Me
O
O
Me Me
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cooled to 0 oC. Concentrated aqueous H2SO4 (700 µL, 12 mmol, 1.0 equiv.) 
was added dropwise and the solution was slowly allowed to warm to room 
temperature over the course of 15 h. The solution was diluted with CH2Cl2 
and H2O, extracted 5x with CH2Cl2, dried over Na2SO4, filtered, and 
condensed. The crude reaction products were purified via flash column 
chromatography (silica gel, 15% acetone/hexanes) to yield 2,2,5,6-
tetramethyl-4H-1,3-dioxin-4-one as an orange liquid (1H NMR data matched 
the literature12, 1.3 g, 69% yield). 
A solution consisting of i-Pr2NH (93 µL, 670 µmol, 1.05 equiv.) in 
2.5 mL THF was prepared and cooled to 0 oC. n-BuLi (2.37M/hexanes, 
280 µL, 670 µmol, 1.05 equiv.) was added and the solution was stirred for 
20 min. HMPA (300 µL) was added, followed by dropwise addition of a 
solution of 2,2,5,6-tetramethyl-4H-1,3-dioxin-4-one (100 mg, 640 µmol, 
1.0 equiv.) in 2 mL THF. The solution was stirred for 30 min before a solution 
of allylic bromide 158 (175 mg, 640 µmol, 1.0 equiv.) in 2 mL THF was slowly 
added. The reaction was stirred at 0 oC for 2.75 h before being quenched 
with sat. aqueous NH4Cl, diluted with Et2O and H2O, extracted 3x with 
CH2Cl2, dried over MgSO4, filtered, and condensed. The crude reaction 
mixture was purified via flash column chromatography (silica gel, 
10% acetone/hexanes) to yield linear acetonide A13 as a clear oil (76 mg, 
39% yield). 
 
A13: Rf = 0.38 (silica gel, 20% ethyl acetate/hexanes); IR (film): max 
2926, 1724, 1645, 1372, 1232, 1143, 1024 cm-1; 1H NMR (600 MHz, CDCl3) δ 5.34 
(t, J = 7.2 Hz, 1H), 5.14 (t, J = 6.6 Hz, 1H), 4.59 (d, J = 7.1 Hz, 2H), 2.40 – 2.33 (m, 
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2H), 2.19 (t, J = 7.8 Hz, 2H), 2.12 (q, J = 7.1 Hz, 2H), 2.08 – 2.02 (m, 5H), 1.82 (s, 
3H), 1.70 (s, 3H), 1.64 (s, 6H); 13C NMR (150 MHz, CDCl3) δ 171.2, 165.7, 163.0, 
142.0, 133.7, 125.3, 118.7, 104.8, 100.4, 61.5, 39.4, 35.9, 30.0, 26.3, 25.3, 21.2, 16.6, 
16.1, 10.3. 
 
Representative Photoredox-Catalyzed Cyclization 
 
Linear α-bromo alcohol 290 (26 mg, 72 µmol, 1.0 equiv.) was dissolved 
in 3.6 mL CH2Cl2 (no effort was made to exclude O2 or H2O). DABCO (16 mg, 
145 µmol, 2.0 equiv.) and fac-Ir(ppy)3 (240 µg, 360 nmol, 0.5 mol%) were 
added, and two strips of blue LEDs were turned on (purchased from 
Creative Lighting Solutions, creativelightings.com, Product Code: 
CL-FRS5050-12WP-12V, Model: Sapphire Blue LED Flex Strip). After 1.5 h the 
lights were turned off, the reaction was diluted with Et2O, several drops of 
aqueous 1M HCl were added (to precipitate DABCO), the solution was dried 
over MgSO4, filtered through celite, and condensed. The crude product 
mixture was analyzed using an internal standard (0.02M 1,3,5-
trimethoxybenzene in CDCl3) revealing bicyclic alcohol 162 (13.7% yield). 
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Appendix II. Comparison of Natural and Synthetic 
Oridamycin A and Oridamycin B 
 
 
1. 1H NMR of Natural Oridamycin A (26)1 
 
 
 
2. 1H NMR of Synthetic Oridamycin A (26) 
 
 
 
Figure A.1 Comparison of the 1H NMR (CD3OD) data of natural and 
synthetic oridamycin A (26). 
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1. 13C NMR of Natural Oridamycin A (26)1 
 
 
2. 13C NMR of Synthetic Oridamycin A (26) 
 
 
 
Figure A.2 Comparison of the 13C NMR (CD3OD) data of natural and 
synthetic oridamycin A (26). 
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Table A.1 Comparison of the 1H NMR (CD3OD) of natural and synthetic 
oridamycin A (26). 
 Natural Synthetic 
Assigned 
δH 
(ppm) 
integration, 
multiplicity, 
J (Hz) 
δH 
(ppm) 
integration, 
multiplicity, 
J (Hz) 
5 7.93 1H, d, 8.1 7.96 1H, d, 8.1 
10 7.93 1H, s 7.95 1H, s 
8 7.32 1H, d, 8.1 7.34 1H, d, 8.1 
7 7.25 1H, dt, 8.1, 1.4 7.28 1H, t, 7.6 
6 7.05 1H, dt, 8.1, 1.4 7.08 1H, t, 7.6 
21 7.03 1H, s 7.05 1H, s 
15 3.22 1H, dd, 12.2, 4.6 3.24 1H, dd, 12.2, 4.6 
19α 3.06 1H, ddd, 16.3, 5.4, 2.3 3.07 1H, ddd, 16.9, 5.5, 1.9 
19β 2.94 1H, ddd, 16.7, 21.7, 2.3 
3.00-
2.92 1H, m 
13α 2.57 1H, dt, 13.6, 3.6 2.58 1H, dt, 13.2, 3.6 
14α 2.30 1H, dq, 13.6, 3.6 2.32 1H, dq, 13.6, 3.6 
18β 2.23 1H, m 
2.26-
2.19 
1H, m 
18α 2.09 1H, dt, 12.7, 5.4 2.13 1H, dt, 12.9, 5.4 
14β 1.90 1H, dq, 13.6, 3.6 
1.96-
1.90 
1H, m 
13β 1.58 1H, dt, 13.6, 4.1 1.59 1H, dt, 13.6, 3.9 
17 1.51 1H, dd, 12.2, 2.3 1.52 1H, d, 12.3 
24 1.48 3H, s 1.49 3H, s 
22 1.26 3H, s 1.27 3H, s 
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Table A.2 Comparison of the 13C NMR (CD3OD) of natural and synthetic 
oridamycin A (26). 
 
 Natural Synthetic 
   
Assigned δC (ppm) δC (ppm) 
23 181.0 181.0 
9 142.0 142.0 
11 140.3 140.3 
2 140.1 140.1 
20 134.5 134.5 
8 126.1 126.1 
4 124.6 124.6 
3 123.2 123.2 
5 120.6 120.6 
6 119.3 119.3 
10 117.5 117.5 
21 111.4 111.4 
7 110.7 110.7 
15 79.1 79.1 
17 54.1 54.1 
16 48.7 48.7 
13 40.0 40.0 
12 39.6 39.6 
19 34.0 34.0 
14 30.3 30.3 
24 24.8 24.8 
22 24.6 24.6 
18 22.5 22.5 
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1. 1H NMR of Natural Oridamycin B (27) 
2. 1H NMR of Synthetic Oridamycin B (27) (with TFA) 
3. 1H NMR of Synthetic Oridamycin B (27) (without TFA) 
 
 
Figure A.3 Comparison of the 1H NMR (CD3OD) data of natural and 
synthetic oridamycin B (27). 
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1. 13C NMR of Natural Oridamycin B (27) 
 
 
 
2. 13C NMR of Synthetic Oridamycin B (27) (without TFA) 
 
 
 
Figure A.4 Comparison of the 13C NMR (CD3OD) data of natural and 
synthetic oridamycin B (27). 
 
 
 
 
 
 
 
 
197 
 
 
Table A.3 Comparison of the 1H NMR (CD3OD) of natural and synthetic 
oridamycin B (27) with TFA (excess). 
 
 Natural Synthetic (with TFA) 
Assigned δH 
(ppm) 
integration, 
multiplicity,  
J (Hz) 
δH 
(ppm) 
integration, 
multiplicity,  
J (Hz) 
5 7.95 1H, d, 7.9 7.96 1H, d, 8.0 
10 7.95 1H, s 7.97 1H, s 
8 7.33 1H, d, 7.9 7.35 1H, d, 8.0 
7 7.27 1H, dt, 7.9, 1.4 7.28 1H, dt, 7.7, 1.2 
6 7.06 1H, dt, 7.9, 1.4 7.08 1H, d, 7.7 
21 7.05 1H, s 7.07 1H, s 
24b 4.09 1H, d, 11.0 4.11 1H, d, 10.9 
24a 3.92 1H, d, 11.0 3.93 1H, d, 10.9 
15 3.73 1H, dd, 12.4, 4.8 3.77 1H, dd, 12.2, 4.5 
19α/β 3.04 2H, dd, 10.3, 4.1 3.05 2H, m 
13α 2.60 1H, dt, 13.0, 3.5 2.62 1H, dt, 13.5, 3.6 
14α 2.41 1H, dq, 13.0, 4.1 2.43 1H, dq, 13.2, 3.7 
18β 2.17 1H, m 
2.23-
2.17 1H, m 
18α 2.08 1H, m 2.08 1H, m 
14β 1.95 1H, m 
1.99-
1.92 2H, m 
17 1.92 1H, dd, 12.2, 2.3   
13β 1.59 1H, m 1.62 1H, dt, 13.7, 3.8 
22 1.31 3H, s 1.32 3H, s 
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Table A.4 Comparison of the 1H NMR (CD3OD) of natural and synthetic 
oridamycin B (27) without TFA. 
 
 Natural Synthetic (without TFA) 
Assigned δH 
(ppm) 
integration, 
multiplicity,  
J (Hz) 
δH 
(ppm) 
integration, 
multiplicity,  
J (Hz) 
5 7.95 1H, d, 7.9 7.96 1H, d, 7.9 
10 7.95 1H, s 7.97 1H, s 
8 7.33 1H, d, 7.9 7.33 1H, d, 8.0 
7 7.27 1H, dt, 7.9, 1.4 7.27 1H, dt, 7.6, 1.3 
6 7.06 1H, dt, 7.9, 1.4 7.07 1H, dt, 7.6, 1.2  
21 7.05 1H, s 7.05 1H, s 
24b 4.09 1H, d, 11.0 4.04 1H, d, 10.9 
24a 3.92 1H, d, 11.0 3.95 1H, d, 10.9 
15 3.73 1H, dd, 12.4, 4.8 3.61 1H, dd, 12.1, 4.7 
19α/β 3.04 2H, dd, 10.3, 4.1 3.02 2H, m 
13α 2.60 1H, dt, 13.0, 3.5 2.55 1H, dt, 13.0, 3.6 
14α 2.41 1H, dq, 13.0, 4.1 2.45 1H, dq, 12.5, 3.9 
18β 2.17 1H, m 
2.27-
2.22 
2H, m 
18α 2.08 1H, m   
14β 1.95 1H, m 
1.95-
1.88 1H, m 
17 1.92 1H, dd, 12.2, 2.3 
1.84-
1.78 1H, m 
13β 1.59 1H, m 1.55 1H, dt, 13.4, 3.7 
22 1.31 3H, s 1.36 3H, s 
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Table A.5 Comparison of the 13C NMR (CD3OD) of natural and synthetic 
oridamycin B (27) without TFA. 
 
Natural Synthetic 
Assigned δC (ppm) δC (ppm) 
23 179.2 180.6 
9 141.9 142.0 
11 140.5 141.2 
2 140.0 140.0 
20 134.5 135.2 
8 125.9 125.9 
4 124.5 124.7 
3 123.2 123.0 
5 120.4 120.5 
6 119.2 119.2 
10 117.2 117.6 
7 111.3 111.3 
21 110.5 110.6 
15 73.3 73.1 
24 64.4 64.7 
16 55.5 56.1 
17 46.3 46.9 
13 39.7 40.3 
12 39.2 39.5 
19 33.3 34.0 
14 29.8 30.8 
22 25.0 25.7 
18 22.1 22.6 
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Appendix III. 1H and 13C NMR Spectra 
 
1H NMR and 13C NMR spectra were recorded on a Bruker Avance DRX-600 
MHz at ambient temperature unless otherwise stated. Chemical shifts are 
reported in parts per million relative to residual solvent CDCl3 (1H, 7.26 ppm, 
13C, 77.16 ppm) or CD3OD (1H, 3.31 ppm, 13C, 49.00 ppm). 
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